3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors

ABSTRACT

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

CROSS-REFERENCE TO RELATED APPLICATIONS

This Application claims priority to U.S. Provisional Patent ApplicationsNos. 60/799,604, filed May 11, 2006, and 60/871,148, filed Dec. 21,2006, which are hereby incorporated by reference in their entireties.

FIELD OF THE INVENTION

The present invention is directed to compounds useful as CETPinhibitors, compositions containing them, and methods of using them, forexample, for the treatment of disorders and conditions modulated bycholesteryl ester transfer protein (CETP).

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

The research and development of the invention described below was notfederally sponsored.

BACKGROUND OF THE INVENTION

Cholesterol homeostasis is maintained by dietary intake, biosynthesis,metabolism to bile acids, absorption and a process known as reversecholesterol transport (RCT). Cholesterol is transported in the blood bylipoproteins, which contain different apolipoproteins that arerecognized by different receptors on the liver and cells such asmacrophages. RCT is involved in the movement of cholesterol fromperipheral tissues to the liver for excretion. This pathway mayrepresent up to 70% of the flux of cholesterol to the liver. Inherent inthis process is the remodeling of the lipoprotein particles. A keyplayer in RCT is the cholesteryl ester transfer protein (CETP), aglycoprotein that mediates the transfer of cholesteryl ester from thecardioprotective High Density Lipoprotein (HDL) particles to thepro-atherogenic LDL (Low Density Lipoprotein), VLDL (Very Low DensityLipoprotein) and IDL (Intermediate Density Lipoprotein).

CETP is a glycoprotein with a molecular weight of about 74 kDa and aprimary sequence containing 476 amino acids. Although the amino acidsequence would suggest the protein to be highly hydrophobic, most of thehydrophobic residues reside mainly on the interior, as the protein issoluble in water (Hesler et al., J. Biol. Chem., 262:2275-2282, 1987).This hydrophobic pocket allows for the binding of neutral lipids(Au-Young and Fielding, Proc. Natl. Acad. Sci., 89:4094-4098, 1992).Using the crystallographic structure of a related protein, BPI(bactericidal/permeability increasing protein) with about 20% homologyto CETP, a model of CETP was published by Bruce et al., Curr. Opin.Struct. Biol., 8:426-434, 1998. The C-terminal residues were predictedto form an amphipathic helix that covers the opening of an N-terminalpocket. Lipid transfer is thought to occur through a disordering of thelipids in the lipoprotein surface followed by flipping open of thehydrophobic pocket with entry of the neutral lipid.

CETP facilitates exchange and net transfer of neutral lipids, mainlycholesteryl esters and triglycerides between plasma lipoproteins.Phospholipids can also be transferred to a lesser degree. CETPinhibitors have emerged with the potential to increase HDL cholesterol(HDL-C) to levels exceeding those of the currently available therapies.

In normal human plasma, the CETP concentration is around 1-3 μg/ml;however, in patients with hypercholesterolemia, or mixed hyperlipidemiaswith hypertriglyceridemia, the CETP concentrations have been reported tobe 2-3 fold higher (Marcel et al., Journal of Clinical Investigation,85:10-17, 1990, and McPherson et al., Arteriosclerosis and Thrombosis: AJournal of Vascular Biology, 11 (4):797-804, 1991). Plasma CETP activityis modulated by a variety of factors including: plasma CETPconcentration, plasma levels of lipoprotein acceptors and donors, plasmatriglyceride levels, physical exercise, alcohol and smoking. CirculatingCETP is associated with HDL, VLDL and LDL particles (Nishida et al.,Journal of Biological Chemistry, 268(22):16352-60, 1993). Most seems tobe associated with HDL and only about 1% is reported to be present infree form.

In patients with Type IIa hypercholesterolemia (familialhypercholesterolemia, LDL-C>160 mg/dL), elevated levels of CETP havebeen reported as well as increased transfer of cholesteryl ester fromHDL to VLDL and LDL (Guerin et al., Arteriosclerosis and Thrombosis: AJournal of Vascular Biology, 14(5):679-85, 1994, and Guerin et al.,Arteriosclerosis and Thrombosis: A Journal of Vascular Biology,14(2):199-206, 1994) thereby generating the smaller more dense LDLparticles, which are considered to be atherogenic. Type IVhypertriglyceridemia is characterized by elevated levels of VLDL andVLDL remnants with plasma triglycerides measuring >150 mg/dL. Associatedwith these elevations are reduced levels of HDL and apoA-I. This may bedue to an increase in the CETP-mediated transfer of cholesterol estersto VLDL. This results in the formation of large VLDL1 subfractions,which are the preferential precursors of small dense proatherogenic LDLparticles (Packard and Shepard, Arterscler. Thromb. Vasc. Biol.,17:3542-3556, 1997). Type IIB is a mixed hyperlipidemia characterized bysimultaneous elevations in both plasma cholesterol and triglycerideswith increases in VLDL and LDL and decreases in HDL. The LDL particlesare shifted to the small dense LDL 4 and 5 subfractions. Plasma CETPconcentrations are elevated and a higher rate of transfer activity hasalso been reported (Guerin et al., European Journal of ClinicalInvestigation, 26(6):485-94, 1996). In the case of secondarydyslipidemias such as those found in diabetes, there are also reports ofelevated CETP activity particularly in the presence ofhypertriglyceridemia (Guerin et al, Arteriosclerosis, Thrombosis andVascular Biology, 20(1):189-97, 2001).

The first studies with CETP inhibitors were done in rabbits, whichexpress high levels of CETP and are highly susceptible toatherosclerosis when fed a high cholesterol diet. Anti-senseoligonucleotides, antibodies, vaccines and small molecule inhibitorshave been tested (Sugano et al., Journal of Biological Chemistry,273(9):5033-6, 1996; Rittershaus et al., Arteriosclerosis, Thrombosisand Vascular Biology, 20(9):2106-2112, 2000; Whitlock et al., Journal ofClinical Investigation, 84(1):129-37, 1989; and Okamoto et al., Nature,406:203-207, 2000). These studies showed that inhibition of CETPincreased plasma HDL-C levels and particle size as well as decreasingaortic cholesterol content and lesion development. Administration of thesmall molecule inhibitor JTT-705, which irreversibly inactivated CETP bybinding to a crucial cysteine residue (Cys13), to rabbits at a dose of30 mg/kg inhibited CETP activity, increased HDL-C (+90%), reducednon-HDL-C cholesterol and lesion size (−50% and −70%, respectively,Okamoto et al., Nature, 406:203-207, 2000). However, in another studywhere rabbits had severe hypercholesterolemia, JTT-705 was notefficacious in preventing lesion development (Huang et al., Clin. Sci.,103(6):587-594, 2002). Interestingly there were significant elevationsof plasma triglycerides in this study with JTT-705 treatment. In laterclinical studies, JTT-705 was found to raise HDL-C, modestly lower LDL-Cand not alter triglyceride levels (DeGrooth et al., Circulation,105(18):2159-2165, 2002). A more potent CETP inhibitor, Torcetrapib, hasshown positive results in Phase II trials, particularly in combinationwith Atorvastatin (Brousseau et al., New England Journal of Medicine,350(15):1505-1515, 2004). The references cited herein are herebyincorporated by reference in their entireties.

There is a continuing need for new CETP inhibitors. There is a furtherneed for new CETP inhibitors that increase HDL-C, increase the ratio ofHDL-C/total cholesterol, increase the ratio of HCL-C/LDL-C, and/or lowerLDL-C and/or lower non-HDL-C cholesterol.

It is an object of the present invention to provide compounds that areCETP inhibitors. It is also an object of the invention to provide amethod of treating or ameliorating a condition mediated by CETP. It is afurther object of the invention to provide a useful pharmaceuticalcomposition comprising a compound of the present invention useful as aCETP inhibitor.

SUMMARY OF THE INVENTION

In one aspect, the present invention is directed to a compound ofFormula (I):

wherein:

-   -   L is a covalent bond or O;    -   X is O or S;    -   Q is C₆₋₁₀ aryl or 5- or 6-membered heteroaryl;    -   n is 0 to 3;    -   m is 0 to 3;    -   R₁ is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,        C₃₋₁₀cycloalkyl, 5- or 6-membered heteroaryl, wherein each of        C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀cycloalkyl, 5-        or 6-membered heteroaryl may be optionally substituted;    -   or R₁ is phenyl optionally substituted with 1 or 2 members        selected from R_(a) and R_(b), wherein R_(a) and R_(b) are        independently selected from the group consisting of optionally        substituted C₁₋₄ alkyl, halogenated C₁₋₄alkyl, optionally        substituted C₂₋₄ alkenyl, optionally substituted C₂₋₄ alkynyl,        optionally substituted C₁₋₄ alkoxy, halogenatedC₁₋₄alkoxy,        optionally substituted C₁₋₄ alkylthio, halo, cyano, and hydroxy,        or        -   R_(a) and R_(b) together with the carbon atoms of the phenyl            ring to which they are attached form an optionally            substituted 5- or 6-membered heterocyclyl fused to the            phenyl ring;    -   each R₂ is independently selected from halo, hydroxy, cyano,        C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, C₁₋₄ alkyl, halogenated        C₁₋₄alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl and —C(O)H;    -   each R₃ is independently selected from C₁₋₄ alkyl, halogenated        C₁₋₄alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, C₁₋₄ alkoxy, halo, cyano,        and hydroxy;    -   R₄ is C₁₋₁₀ alkyl optionally substituted with 1-3 members        independently selected from halo, oxo, hydroxy,        halogenatedC₁₋₄alkyl, C₁₋₄ alkoxy, C₃₋₈ cycloalkyl, CN,        tert-butyldimethylsilyloxy, optionally substituted heterocyclyl        and —NR_(c)R_(d), wherein R_(c) and R_(d) are independently        selected from H, optionally substituted C₁₋₃ alkyl,        —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl; or        -   R₄ is C₁₋₆alkyl substituted with heteroaryl or phenyl            substituted with 1 to 3 members independently selected from            halo, hydroxy, C₁₋₃alkyl, halogenatedC₁₋₃alkyl, C₁₋₄alkoxy,            or halogenatedC₁₋₄alkoxy;            and enantiomers, diastereomers, tautomers, solvates, or            pharmaceutically acceptable salts thereof.

In another aspect, the present invention is directed to pharmaceuticalcompositions containing one or more compounds of Formula (I),enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof as described herein admixed with apharmaceutically acceptable carrier, excipient or diluent, wherein thecompositions can be used to treat a condition directly or indirectlymediated by CETP.

In yet another aspect, the present invention is directed to a method oftreating or preventing a disease or condition in a mammal which diseaseor condition is affected by the modulation of CETP, which methodcomprises administering to a mammal in need of such treatment orprevention a therapeutically effective amount of one or more compoundsof Formula (I), enantiomers, diastereomers, tautomers, solvates, orpharmaceutically acceptable salts thereof as described herein.

In a further aspect, the present invention is directed to a method fortreating or preventing a disease or condition selected fromatherosclerosis, peripheral vascular disease, dyslipidemia (includinghypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, andhypo-HDL-cholesterolemia), hyper-LDL-cholesterolemiahyperbetaliproteinemia, hypoalphalipoproteinemia, hypertriglyceridemia,familial-hypercholesterolemia, cardiovascular disorders, angina,ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusioninjury, angioplastic restenosis, hypertension, vascular complications ofdiabetes, obesity and Metabolic Syndrome, said method comprising thestep of administering to a mammal in need of such treatment atherapeutically effective amount of a compound of Formula (I), or anenantiomer, diastereomer, tautomer, solvate, or pharmaceuticallyacceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following underlined terms are intended to have thefollowing meanings unless otherwise noted:

The term “substituted” refers to a radical in which one or more hydrogenatoms are each independently replaced with the same or differentsubstituent(s).

With reference to substituents, the term “independently” means that whenmore than one of such substituent is possible, such substituents may bethe same or different from each other.

“C_(a-b)” (where a and b are integers) refers to a radical containingfrom a to b carbon atoms inclusive. For example, C₁₋₃ denotes a radicalcontaining 1, 2 or 3 carbon atoms.

“Alkyl” whether used alone or as part of a substituent group refers tostraight and branched carbon chains having 1 to 10 carbon atoms or anynumber within this range. Typical alkyl groups include, but are notlimited to, methyl, ethyl, propyl, and butyl. In preferred embodiments,the alkyl group is C₁₋₈ alkyl, with C₁₋₃alkyl being particularlypreferred. The term “alkoxy” refers to an —Oalkyl substituent group,wherein alkyl is defined supra. Similarly, the terms “alkenyl” and“alkynyl” refer to straight and branched carbon chains having 2 to 10carbon atoms or any number within this range, wherein an alkenyl chainhas at least one double bond in the chain and an alkynyl chain has atleast one triple bond in the chain.

The term “cycloalkyl” refers to saturated or partially unsaturated,monocyclic or polycyclic hydrocarbon rings of from 3 to 20 carbon atommembers (preferably from 3 to 14 carbon atom members). Examples of suchrings include, but are not limited to, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl or adamantyl.

In certain embodiments, wherein the alkyl, alkenyl, alkynyl, alkoxy,and/or cycloalkyl as defined herein can be optionally substituted, suchalkyl, alkenyl, alkynyl, alkoxy, and cycloalkyl can be substituted withone, two or three groups independently selected from halo (F, Cl, Br, orI), oxo, cyano, amino, alkoxy, cycloalkyl, carboxy, hydroxy,heterocyclyl, and halogenatedalkyl; and/or one group selected fromoptionally substituted aryl and optionally substituted heteroaryl.

“Halogenated alkyl” refers to a saturated branched or straight chainalkyl radical derived by removal of at least 1 hydrogen atom from theparent alkyl and substituting it with a halogen; the parent alkyl chaincontains from 1 to 10 carbon atoms with 1 or more hydrogen atomssubstituted with halogen atoms up to and including substitution of allhydrogen atoms with halogen. Preferred halogenated alkyl groups arefluorinated alkyls, including trifluoromethyl substituted alkyls andperfluorinated alkyls; more preferred fluorinated alkyls includetrifluoromethyl, perfluoroethyl, 1,1,2,2-tetrafluoroethyl,2,2,2-trifluoroethyl, perfluoropropyl, 1,1,2,2,3,3-Hexafluoro-propyl,3,3,3-trifluoroprop-1-yl, 3,3,3-trifluoroprop-2-yl; a particularlypreferred fluorinated alkyls are trifluoromethyl and1,1,2,2-tetrafluoroethyl.

“Halogenated alkoxy” refers to a radical derived from a halogenatedalkyl radical attached to an oxygen atom having one open valence forattachment to a parent structure. Preferred halogenated alkoxy groupsare fluorinated alkoxy groups, including trifluoromethoxy and1,1,2,2-tetrafluoro-ethoxy.

“Alkylthio” refers to an alkyl group as defined herein attached throughone or more sulfur (S) atoms. For example, an alkylthio group caninclude —S—C₁₋₆alkyl optionally substituted with, for example, one, two,or three groups selected from, halo (F, Cl, Br, or I), amino, alkoxy,carboxy, and hydroxy.

“Oxo” whether used alone or as part of a substituent group refers to anO═ to either a carbon or a sulfur atom. For example, phthalimide andsaccharin are examples of compounds with oxo substituents.

The term “aryl” refers to an unsaturated monocyclic or polycyclic ring,preferably an aromatic monocyclic ring of 6 carbon members or to anunsaturated, aromatic polycyclic ring of from 10 to 14 carbon members.Preferred aryl groups for the practice of this invention are phenyl andnaphthalenyl. In certain embodiments, the aryl ring is a C₆₋₁₀aryl. “Ph”when used herein refers to phenyl. In certain embodiments, wherein thearyl is optionally substituted, the aryl can be substituted with one,two or three groups independently selected from optionally substitutedalkyl, halogenated alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, halo, —CHO, cyano, amino, optionally substitutedalkoxy, halogenated alkoxy, carboxy, hydroxy, and optionally substitutedheterocyclyl.

The term “arylalkyl” means an alkyl group substituted with an aryl group(e.g., benzyl, phenylethyl, naphthylmethyl). Similarly, the term“arylalkoxy” indicates an alkoxy group substituted with an aryl group(e.g., benzyloxy). In particularly preferred embodiments, the alkylmoiety of the arylalkyl group is (C₁₋₃) and the aryl moiety is (C₆₋₁₀).

“Heterocyclyl” or “heterocycle” is a 3- to 8-member, preferably 5-7membered saturated, or partially saturated single or fused ring systemwhich consists of carbon atoms and from 1 to 6 heteroatoms selected fromN, O and S. The heterocyclyl group may be attached at any heteroatom orcarbon atom which results in the creation of a stable structure. Exampleof heterocyclyl groups include, but are not limited to, 2-imidazoline,imidazolidine; morpholine, oxazoline, 1,3-dioxolane, 2-pyrroline,3-pyrroline, pyrrolidine, pyridone, pyrimidone, piperazine, piperidine,indoline, tetrahydrofuran, 2-pyrroline, 3-pyrroline, 2-imidazoline,2-pyrazoline, indolinone. A “heterocyclyl” can be a partiallyunsaturated ring such as 2-pyrroline, 3-pyrroline, 2-imidazoline,2-pyrazoline, or indolinone. In certain embodiments, wherein the“heterocyclyl” or “heterocycle” is optionally substituted, the“heterocyclyl” or “heterocycle” can be substituted with, one, two orthree groups independently selected from C₁₋₆alkyl,halogenatedC₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, hydroxy, —CN,and/or one group selected from aryl, heteroaryl, heterocyclyl, —SO₃H,—C(O)OH, —C(O)O—C₁₋₄alkyl, C(O)NR′R″, —OR′, —SR′, —C(O)R′, —N(R′)(R″),—S(O)₂—R′, and —S(O)₂—N(R′)(R″), wherein R′ and R″ are independentlyselected from H, C₁₋₆-alkyl, aryl, and heteroaryl.

“Heteroaryl” refers to a monovalent heteroaromatic radical derived bythe removal of one hydrogen atom from a single atom of a parentheteroaromatic ring system. Preferably, the term “heteroaryl” refers toan aromatic ring of 5 or 6 members wherein the ring consists of carbonatoms and has at least one heteroatom member. Suitable heteroatomsinclude nitrogen, oxygen or sulfur. In the case of 5 membered rings, theheteroaryl ring contains one member of nitrogen, oxygen or sulfur and,in addition, may contain up to three additional nitrogens. In the caseof 6 membered rings, the heteroaryl ring may contain from one to threenitrogen atoms. For the case wherein the 6 membered ring has threenitrogens, at most two nitrogen atoms are adjacent. The term heteroarylincludes a heteroaryl ring fused to a benzene ring (benzo fusedheteroaryl), a 5 or 6 membered heteroaryl ring (containing one of O, Sor N and, optionally, one additional nitrogen), a 5 to 7 memberedcycloalkyl ring or a 5 to 7 membered heterocyclic ring. For suchcompounds in which the heteroaryl ring is fused to a moiety as describedabove, the point of attachment is through the heteroaryl ring portion ofthe compound. Examples of heteroaryl groups include, and are not limitedto, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, tetrazolyl,imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl,thiadiazolyl, pyranyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl;fused heteroaryl groups include indolyl, isoindolyl, indolinyl,isoindolinyl, indolizinyl, benzofuryl, benzothienyl, indazolyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzisoxazolyl,benzothiadiazolyl, benzotriazolyl, purinyl, quinolizinyl, quinoxalinyl,quinolinyl, isoquinolinyl or quinazolinyl. Preferred are thienyl,oxazolyl, thiazolyl, isoxazolyl, pyridinyl, and pyridazinyl. In certainembodiments, wherein the heteroaryl is optionally substituted, theheteroaryl can be optionally substituted with one, two or three groupsindependently selected from alkyl, halogenatedalkyl, alkenyl, alkynyl,halo, —CHO, cyano, amino, optionally substituted alkoxy,halogenatedalkoxy, carboxy, hydroxy, and heterocyclyl.

The term “composition” is intended to encompass a product comprising thespecified ingredients in the specified amounts, as well as any productwhich results, directly or indirectly, from combinations of thespecified ingredients in the specified amounts.

The term “subject” as used herein, refers to an animal, preferably amammal, most preferably a human, who is the object of treatment,observation or experiment.

The term “therapeutically effective amount” as used herein, means thatamount of active compound or pharmaceutical agent that elicits thebiological or medicinal response in a tissue system, animal or humanthat is being sought by a researcher, veterinarian, medical doctor orother clinician, which includes alleviation of the symptoms of thedisease or disorder being treated.

Whenever the term “alkyl” or “aryl” or either of their prefix rootsappear in a name of a substituent (e.g., arylalkyl, alkylamino) it shallbe interpreted as including those limitations given above for “alkyl”and “aryl.” Designated numbers of carbon atoms (e.g., C₁-C₆) shall referindependently to the number of carbon atoms in an alkyl moiety or to thealkyl portion of a larger substituent in which alkyl appears as itsprefix root. For alkyl, and alkoxy substituents the designated number ofcarbon atoms includes all of the independent member included in therange specified individually and all the combination of ranges within inthe range specified. For example C₁₋₆ alkyl would include methyl, ethyl,propyl, butyl, pentyl and hexyl individually as well as sub-combinationsthereof (e.g. C₁₋₂, C₁₋₃, C₁₋₄, C₁₋₅, C₂₋₆, C₃₋₆, C₄₋₆, C₅₋₆, C₂₋₅,etc.).

The term “halogen” or “halo” refers to fluorine, chlorine, bromine andiodine. Substituents that are substituted with multiple halogens aresubstituted in a manner that provides compounds, which are stable.

Throughout this disclosure, unless otherwise indicated, the terminalportion of the designated side chain is described first, followed by theadjacent functionality toward the point of attachment. Thus, forexample, a “phenylC₁₋₆alkylaminocarbonylC₁₋₆alkyl” substituent refers toa group of the formula

The present invention is directed to compositions comprising a compoundof Formula (I) for uses as CETP inhibitors:

wherein:

-   -   L is a covalent bond or O;    -   X is O or S;    -   Q is C₆₋₁₀ aryl or 5- or 6-membered heteroaryl;    -   n is 0 to 3;    -   m is 0 to 3;    -   R₁ is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,        C₃₋₁₀cycloalkyl, 5- or 6-membered heteroaryl, wherein each of        C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀cycloalkyl, 5-        or 6-membered heteroaryl may be optionally substituted;    -   or R₁ is phenyl optionally substituted with 1 or 2 members        selected from R_(a) and R_(b), wherein R_(a) and R_(b) are        independently selected from the group consisting of optionally        substituted C₁₋₄ alkyl, halogenated C₁₋₄alkyl, optionally        substituted C₂₋₄ alkenyl, optionally substituted C₂₋₄ alkynyl,        optionally substituted C₁₋₄ alkoxy, halogenatedC₁₋₄alkoxy,        optionally substituted C₁₋₄ alkylthio, halo, cyano, and hydroxy,        or        -   R_(a) and R_(b) together with the carbon atoms of the phenyl            ring to which they are attached form an optionally            substituted 5- or 6-membered heterocyclyl fused to the            phenyl ring;    -   each R₂ is independently selected from halo, hydroxy, cyano,        C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, C₁₋₄ alkyl, halogenated        C₁₋₄alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl and —C(O)H;    -   each R₃ is independently selected from C₁₋₄ alkyl, halogenated        C₁₋₄alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, C₁₋₄ alkoxy, halo, cyano,        and hydroxy;    -   R₄ is C₁₋₁₀ alkyl optionally substituted with 1-3 members        independently selected from halo, oxo, hydroxy,        halogenatedC₁₋₄alkyl, C₁₋₄ alkoxy, C₃₋₈ cycloalkyl, CN,        tert-butyldimethylsilyloxy, optionally substituted heterocyclyl        and —NR_(c)R_(d), wherein R_(c) and R_(d) are independently        selected from H, optionally substituted C₁₋₃ alkyl,        —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl; or        -   R₄ is C₁₋₆alkyl substituted with heteroaryl or phenyl            substituted with 1 to 3 members independently selected from            halo, hydroxy, C₁₋₃alkyl, halogenatedC₁₋₃alkyl, C₁₋₄alkoxy,            or halogenatedC₁₋₄alkoxy;            and enantiomers, diastereomers, tautomers, solvates, or            pharmaceutically acceptable salts thereof.

Particularly, the present invention features a compound of Formula (I)wherein m is 0.

Particularly, the present invention features a compound of Formula (I)wherein n is 1 or 2.

Particularly, the present invention features a compound of Formula (I)wherein L is a covalent bond.

Particularly, the present invention features a compound of Formula (I)wherein Q is phenyl.

Particularly, the present invention features a compound of Formula (I)wherein Q is thienyl or pyridinyl.

Particularly, the present invention features a compound of Formula (I)wherein X is O.

Particularly, the present invention features a compound of Formula (I)wherein R₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl,C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, halo, cyano, hydroxy, halogenatedC₁₋₄alkylthio, or an optionally substituted five membered heterocyclylring fused to the phenyl ring forming a bicyclic ring system.

Particularly, the present invention features a compound of Formula (I)wherein R₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl,C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, halo, cyano, or hydroxy.

Particularly, the present invention features a compound of Formula (I)wherein R₁ is phenyl substituted with halogenated C₁₋₄alkyl orhalogenated C₁₋₄alkoxy, preferably R₁ is phenyl substituted with—OCF₂CF₂H, —CF₃, or —OCF₃.

Particularly, the present invention features a compound of Formula (I)wherein R₁ is C₁₋₆ alkyl substituted with hydroxy, C₁₋₄alkoxy, oxo,halo, or cyano.

Particularly, the present invention features a compound of Formula (I)wherein R₁ is furanyl or thienyl optionally substituted with C₁₋₃alkyl,C₁₋₃alkoxy, hydroxy, or cyano.

Particularly, the present invention features a compound of Formula (I)wherein n is 1, 2, or 3 and each R₂ is independently selected from halo,halogenated C₁₋₄alkyl, and halogenated C₁₋₄alkoxy, preferably R₂ is—OCF₂CF₂H, —OCF₃ or F.

Particularly, the present invention features a compound of Formula (I)wherein n is 1 and R₂ is halogenated C₁₋₄alkoxy, preferably R₂ is—OCF₂CF₂H.

Particularly, the present invention features a compound of Formula (I)wherein R₄ is C₁₋₅ alkyl optionally substituted with 1 or 2 members eachindependently selected from halo, oxo, hydroxy, halogenatedC₁₋₄alkyl,and optionally substituted heterocyclyl; preferably R₄ is C₁₋₃ alkylsubstituted with 2 members each independently selected from halo,hydroxy, and halogenatedC₁₋₃alkyl.

In particular, the present invention is directed to a compound ofFormula (I) wherein

-   -   X is O;    -   Q is phenyl;    -   m is 0;    -   n is 1, 2, or 3;    -   L is a covalent bond;    -   R₁ is phenyl optionally substituted with C₁₋₄ alkyl,        halogenatedC₁₋₄alkyl,        -   C₁₋₄alkoxy, halogenatedC₁₋₄ alkoxy, or cyano;    -   Each R₂ is independently selected from halo, hydroxy, cyano,        C₁₋₄ alkoxy, halogenatedC₁₋₄ alkoxy, C₁₋₄alkyl,        halogenatedC₁₋₄alkyl, and —C(O)H; and    -   R₄ is C₁₋₆ alkyl substituted with 1-3 members independently        selected from halo, hydroxy, oxo, halogenatedC₁₋₄alkyl,        C₁₋₄alkoxy, and halogenatedC₁₋₄alkoxy.

In particular, the present invention is directed to a compound ofFormula (I) wherein

-   -   Q is phenyl;    -   n is 1;    -   m is 0; and    -   L is a covalent bond.

In particular, the present invention is directed to a compound ofFormula (I) as shown above, wherein (n) is 1; (m) is 0; and the Q-R₂group is

In particular, the present invention is directed to a compound ofFormula (I) as shown above, wherein (m) is 0; and R₁ is

In particular, the present invention is directed to a compound ofFormula (I) as shown above wherein (m) is 0, and R₄ is

In particular, the present invention is directed to a compound ofFormula (I) wherein

-   -   X is O;    -   Q is phenyl;    -   m is 0;    -   n is 1 or 2;    -   L is a covalent bond;    -   R₁ is C₁₋₅alkyl substituted with oxo, hydroxy, or C₁₋₃alkoxy,        thienyl optionally substituted with C₁₋₃alkyl or C₁₋₃alkoxy,        furanyl, or phenyl optionally substituted with        halogenatedC₁₋₄alkyl, halogenatedC₁₋₄alkoxy, C₁₋₄alkoxy, or        halo;    -   Each R₂ is independently selected from halo, C₁₋₄alkyl,        halogenatedC₁₋₄alkyl, halogenatedC₁₋₄alkoxy, and C₁₋₄alkoxy; and    -   R₄ is C₁₋₅ alkyl optionally substituted with 1-3 members        independently selected from —OH, halogenatedC₁₋₃alkyl, and        C₁₋₄alkoxy.

In particular, the present invention is directed to a compound ofFormula (I) wherein

-   -   X is O;    -   Q is phenyl;    -   m is 0;    -   n is 1 or 2;    -   L is a covalent bond;    -   R₁ is C₁₋₅alkyl substituted with oxo, hydroxy, or C₁₋₃alkoxy,        thienyl optionally substituted with C₁₋₃alkyl or C₁₋₃alkoxy,        furanyl, or phenyl optionally substituted with —OCF₂CF₂H, —CF₃,        —F, —OCH₃, —Cl, or —OCF₃;

Each R₂ is independently selected from —OCF₃, —CF₃, and —F; and R₄ isC₁₋₅ alkyl optionally substituted with 1-3 members independentlyselected from —OH, halogenatedC₁₋₃alkyl, and C₁₋₄alkoxy.

In particular, the present invention is directed to a compound ofFormula (I) wherein

-   -   Q is thienyl or pyridinyl;    -   X is O;    -   m is 0;    -   n is 0;    -   L is a covalent bond;    -   R₁ is C₁₋₅alkyl substituted with oxo, hydroxy, or C₁₋₃alkoxy,        thienyl optionally substituted with C₁₋₃alkyl or C₁₋₃alkoxy,        furanyl, or phenyl optionally substituted with        halogenatedC₁₋₄alkyl, halogenatedC₁₋₄alkoxy, C₁₋₄alkoxy, or        halo; and    -   R₄ is C₁₋₅ alkyl optionally substituted with 1-3 members        independently selected from —OH, halogenatedC₁₋₃alkyl, and        C₁₋₄alkoxy.

In particular, the present invention is directed to a compound ofFormula (I) as shown above wherein:

-   -   (a) X is O;    -   (b) X is S;    -   (c) R₁ is C₁₋₆alkyl substituted with hydroxy, oxo, or        C₁₋₃alkoxy;    -   (d) R₁ is thienyl optionally substituted with C₁₋₃alkyl or        C₁₋₃alkoxy;    -   (e) R₁ is phenyl optionally substituted with 1 or 2 members        selected from R_(a) and R_(b), wherein        -   R_(a) and R_(b) are independently selected from the group            consisting of C₁₋₄ alkyl, halogenatedC₁₋₄ alkyl, C₁₋₄            alkoxy, halogenated C₁₋₄ alkoxy, phenylC₁₋₃alkoxy, —S—CF₃,            halo, cyano, and hydroxy, or R_(a) and R_(b) together with            the carbon atoms they are attached to form 5- or 6-membered            heterocyclyl fused to the phenyl ring;        -   preferably R₁ is phenyl,

-   -   (f) R₁ is optionally substituted 5- or 6-membered heteroaryl,        preferably,

-   -   (g) L is a covalent bond;    -   (h) Q is C₆₋₁₀ aryl, and preferably Q is phenyl;    -   (i) Q is 5- or 6-membered heteroaryl; preferably thienyl,        oxazolyl, thiazolyl, isoxazolyl, pyridinyl, and pyridazinyl; and        more preferably thienyl and pyridinyl;    -   (j) each R₂ is independently selected from halo, hydroxy, cyano,        C₁₋₄ alkoxy, halogenatedC₁₋₄ alkoxy, C₁₋₄alkyl,        halogenatedC₁₋₄alkyl, and —C(O)H; preferably —CH₃, —CH₂CH₃,        —C(O)H, —O—CH₃, —O—CF₃, —O—CH(CH₃)₂, —CH(CH₃)₂, CN, OH, F, Cl,        and —CF₃; more preferably —O—CF₃, F, and —CF₃;    -   (k) n is 1, 2, or 3;    -   (l) m is 0;    -   (m) R₄ is —C(O)O—C₁₋₄alkyl, preferably —C(O)O—CH₃ or        —C(O)O—CH₂CH₃;    -   (n) R₄ is C₁₋₅ alkyl optionally substituted with 1-3 members        independently selected from halo, oxo, hydroxy,        halogenatedC₁₋₃alkyl, C₁₋₄ alkoxy, tert-butyldimethylsilyloxy,        C₃₋₈ cycloalkyl, CN, heterocyclyl, and —NR_(c)R_(d), wherein        -   R_(c) and R_(d) are independently selected from H,            —S(O)₂—C₁₋₄alkyl, C₁₋₃ alkyl, —C(O)—C₁₋₃ alkyl, and            —C(O)O—C₁₋₃ alkyl,            more preferably R₄ is C₁₋₅ alkyl optionally substituted with            1-2 members independently selected from oxo, F, —CF₃,            hydroxy, tert-butyldimethylsilyloxy, —NH₂, —N(CH₃)₂, —O—CH₃,            —CH₂CH₃,

more preferably R₄ is C₁₋₃ alkyl substituted with OH and —CF₃, morepreferably

and enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof; or any possible combinations of examples(a)-(n) above.

More particularly, the present invention is directed to a compound ofFormula (I) as shown above wherein:

-   -   m is 0;    -   n is 1, 2, or 3;    -   R₁ is —CH₂—CH═CH₂, —CH₂CH₂CH₂OH, —CH₂CH₂CH₂—O—CH₃, or        —CH═C(O)—C(CH₃)₃, Ph,

-   -   Each R₂ is independently selected from —O—CF₃, F, or —CF₃; and    -   R₄ is —C(O)O—CH₃, —C(O)O—CH₂CH₃, or C₁₋₅ alkyl optionally        substituted with 1-2 members independently selected from oxo,    -   F, —CF₃, hydroxy, NH₂, —N(CH₃)₂, —O—CH₃,

and enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.

In one aspect, the present invention is directed to a compound ofFormula (Ia):

wherein:

-   -   X is O or S;    -   L is a covalent bond or O;    -   Q is phenyl, naphthalenyl, or a heteroaryl selected from the        group consisting of thienyl, oxazolyl, thiazolyl, isoxazolyl,        pyridinyl, and pyridazinyl;    -   n is 0 to 3;    -   m is 0 to 3;    -   R₁ is C₁₋₁₀ alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl,        or a 5- or 6-membered heteroaryl; wherein said C₁₋₁₀ alkyl,        C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, or 5- or 6-membered        heteroaryl is optionally substituted with 1 to 3 substituents        independently selected from halo, cyano, hydroxy, oxo,        C₁₋₃alkyl, and C₁₋₃alkoxy;    -   or R₁ is phenyl optionally substituted with 1 to 2 members        selected from R_(a) and R_(b), wherein R_(a) and R_(b) are        independently selected from the group consisting of C₁₋₄ alkyl,        halogenatedC₁₋₄alkyl, phenylC₁₋₄alkyl, C₁₋₄ alkoxy, halogenated        C₁₋₄ alkoxy, phenylC₁₋₄ alkoxy, C₁₋₄ alkylthio,        halogenatedC₁₋₄alkylthio, halo, cyano, and hydroxy, or        -   R_(a) and R_(b) together with the carbon atoms of the phenyl            ring to which they are attached form a 5- or 6-membered            heterocyclyl fused to the phenyl ring; said heterocyclyl            optionally substituted with 1 or 2 members independently            selected from halo, C₁₋₃alkyl, cyano, and hydroxy;    -   each R₂ is independently selected from the group consisting of        halo, hydroxy, cyano, C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, C₁₋₄        alkyl, halogenatedC₁₋₄ alkyl, and —C(O)H;    -   each R₃ is independently selected from the group consisting of        C₁₋₄ alkyl, C₁₋₄ alkoxy, halo, cyano, and hydroxy;    -   R₄ is C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl,        wherein said C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or        phenylC₁₋₃alkyl is optionally substituted with 1-3 members        independently selected from the group consisting of oxo,        hydroxy, C₁₋₄ alkoxy, halogenatedC₁₋₄ alkoxy, C₃₋₈ cycloalkyl,        cyano, tert-butyldimethylsilyloxy, heterocyclyl optionally        substituted with 1 or 2 C₁₋₃alkyl groups, and —NR_(c)R_(d),        wherein        -   R_(c) and R_(d) are independently selected from H,            optionally substituted C₁₋₃ alkyl, —C(O)C₁₋₃alkyl,            —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl;            and enantiomers, diastereomers, tautomers, solvates, or            pharmaceutically acceptable salts thereof.

Particularly, the present invention features a compound of Formula (Ia)wherein X is O.

Particularly, the present invention features a compound of Formula (Ia)wherein m is 0.

Particularly, the present invention features a compound of Formula (Ia)wherein n is 1 or 2.

Particularly, the present invention features a compound of Formula (Ia)wherein L is a covalent bond.

Particularly, the present invention features a compound of Formula (Ia)wherein Q is phenyl.

Particularly, the present invention features a compound of Formula (Ia)wherein Q is thienyl or pyridinyl.

Particularly, the present invention features a compound of Formula (Ia)wherein R₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl,C₁₋₄ alkoxy, halogenatedC₁₋₄alkoxy, halo, cyano, or hydroxy.

Particularly, the present invention features a compound of Formula (Ia)wherein R₁ is phenyl substituted with halogenated C₁₋₄alkyl orhalogenatedC₁₋₄alkoxy, preferably R₁ is phenyl substituted with—OCF₂CF₂H, —CF₃, or —OCF₃.

Particularly, the present invention features a compound of Formula (Ia)wherein R₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl,C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, halo, cyano, hydroxy, halogenatedC₁₋₄alkylthio, or an optionally substituted five membered heterocyclylring fused to the phenyl ring forming a bicyclic ring system.

Particularly, the present invention features a compound of Formula (Ia)wherein R₁ is C₁₋₆ alkyl substituted with hydroxy, C₁₋₄alkoxy, oxo,halo, or cyano.

Particularly, the present invention features a compound of Formula (Ia)wherein R₁ is furanyl or thienyl optionally substituted with C₁₋₃alkyl,C₁₋₃alkoxy, hydroxy, or cyano.

Particularly, the present invention features a compound of Formula (Ia)wherein n is 1 and R₂ is halo, halogenated C₁₋₄alkyl, or halogenatedC₁₋₄alkoxy, preferably R₂ is —OCF₂CF₂H or —OCF₃.

Particularly, the present invention features a compound of Formula (Ia)wherein n is 1, 2, or 3 and each R₂ is independently selected from halo,halogenated C₁₋₄alkyl, and halogenated C₁₋₄alkoxy; preferably R₂ is—OCF₂CF₂H, —OCF₃ or F.

Particularly, the present invention features a compound of Formula (Ia)wherein n is 1 and R₂ is halogenated C₁₋₄alkoxy, preferably R₂ is—OCF₂CF₂H.

Particularly, the present invention features a compound of Formula (Ia)wherein R₄ is C₁₋₅ alkyl substituted with 1 or 2 members eachindependently selected from oxo, hydroxy, C₁₋₄alkoxy, cyano, andheterocyclyl; preferably R₄ is C₁₋₃ alkyl substituted with hydroxy,C₁₋₄alkoxy, or cyano.

Particularly, the present invention features a compound of Formula (Ia)wherein R₄ is C₁₋₅ alkyl substituted with —NR_(c)R_(d), wherein

R_(c) and R_(d) are independently selected from H, optionallysubstituted C₁₋₃ alkyl, —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and—SO₂C₁₋₃alkyl.

Particularly, the present invention features a compound of Formula (Ia)wherein R₄ is halogenatedC₁₋₄ alkyl substituted with oxo, hydroxy,C₁₋₄alkoxy, or cyano; preferably R₄ is fluorinatedC₁₋₃ alkyl substitutedwith hydroxy.

Particularly, the present invention features a compound of Formula (Ia)wherein R₄ is phenylC₁₋₃ alkyl wherein the phenyl group is substitutedwith hydroxy, C₁₋₄alkoxy, cyano, or halogenatedC₁₋₄ alkoxy, preferablyR₄ is phenylC₁₋₃ alkyl wherein the phenyl group is substituted withhalogenatedC₁₋₄alkoxy.

In particular, the present invention is directed to a compound ofFormula (Ia) wherein

-   -   X is O;    -   Q is phenyl;    -   m is 0;    -   n is 1 or 2;    -   L is a covalent bond;    -   R₁ is phenyl optionally substituted with C₁₋₄ alkyl,        halogenatedC₁₋₄alkyl,        -   C₁₋₄alkoxy, halogenatedC₁₋₄ alkoxy, or cyano;    -   Each R₂ is independently selected from halo, hydroxy, cyano,        C₁₋₄ alkoxy, halogenatedC₁₋₄ alkoxy, C₁₋₄alkyl,        halogenatedC₁₋₄alkyl, and —C(O)H; and    -   R₄ is C₁₋₅ alkyl substituted with 1 to 2 members independently        selected from hydroxy, C₁₋₄alkoxy, oxo, halogenatedC₁₋₄alkoxy,        C₃₋₈cycloalkyl, cyano; or R₄ is halogenatedC₁₋₄ alkyl        substituted with hydroxy, C₁₋₄alkoxy, oxo, or cyano.

In particular, the present invention is directed to a compound ofFormula (Ia) wherein

-   -   X is O;    -   m is 0; and    -   L is a covalent bond.

In particular, the present invention is directed to a compound ofFormula (Ia) as shown above, wherein (n) is 1; (m) is 0; and the Q-R₂group is

In particular, the present invention is directed to a compound ofFormula (Ia) as shown above, wherein (m) is 0; and R₁ is

In particular, the present invention is directed to a compound ofFormula (Ia) as shown above wherein (m) is 0, and R₄ is

In particular, the present invention is directed to a compound ofFormula (Ia) wherein

-   -   X is O;    -   Q is phenyl;    -   m is 0;    -   n is 1 or 2;    -   L is a covalent bond;    -   R₁ is C₁₋₅alkyl substituted with oxo, hydroxy or C₁₋₃alkoxy;        thienyl optionally substituted with C₁₋₃alkyl or C₁₋₃alkoxy;        furanyl; or phenyl optionally substituted with —OCF₂CF₂H, —CF₃,        —F, —OCH₃, —Cl, or —OCF₃;    -   Each R₂ is independently selected from —OCF₃, —CF₃, —F; and    -   R₄ is C₁₋₆alkyl optionally substituted with 1 to 2 members        independently selected from —OH and —OCH₃; or R₄ is        halogenatedC₁₋₄ alkyl substituted with hydroxy, C₁₋₄alkoxy, oxo,        or cyano.

In particular, the present invention is directed to a compound ofFormula (Ia) wherein

-   -   X is O;    -   Q is thienyl or pyridinyl;    -   m is 0;    -   n is 0;    -   L is a covalent bond;    -   R₁ is phenyl optionally substituted with C₁₋₄ alkyl,        halogenatedC₁₋₄alkyl, C₁₋₄alkoxy, halogenatedC₁₋₄ alkoxy, halo,        or cyano; and    -   R₄ is C₁₋₅ alkyl substituted with 1 to 2 members independently        selected from hydroxy, C₁₋₄alkoxy, oxo, halogenatedC₁₋₄alkoxy,        heterocyclyl, C₃₋₈cycloalkyl, and cyano; or R₄ is        halogenatedC₁₋₄ alkyl substituted with hydroxy, C₁₋₄alkoxy, oxo,        or cyano.

In particular, the present invention is directed to a compound ofFormula (Ia) as shown above wherein:

-   -   (a) X is O;    -   (b) X is S;    -   (c) R₁ is C₁₋₆alkyl substituted with hydroxy, oxo, or        C₁₋₃alkoxy;    -   (d) R₁ is thienyl optionally substituted with C₁₋₃alkyl or        C₁₋₃alkoxy;    -   (e) R₁ is phenyl optionally substituted with 1 or 2 members        selected from R_(a) and R_(b), wherein        -   R_(a) and R_(b) are independently selected from the group            consisting of C₁₋₄ alkyl, halogenatedC₁₋₄ alkyl, C₁₋₄            alkoxy, halogenated C₁₋₄ alkoxy, phenylC₁₋₃alkoxy, —S—CF₃,            halo, cyano, and hydroxy, or R_(a) and R_(b) together with            the carbon atoms they are attached to form 5- or 6-membered            heterocyclyl fused to the phenyl ring; preferably R₁ is            phenyl,

-   -   (f) R₁ is optionally substituted 5- or 6-membered heteroaryl,        preferably,

-   -   (g) L is a covalent bond;    -   (h) Q is phenyl;    -   (i) Q is thienyl, oxazolyl, thiazolyl, isoxazolyl, pyridinyl,        and pyridazinyl; and more preferably thienyl and pyridinyl;    -   (j) each R₂ is independently selected from halo, hydroxy, cyano,        C₁₋₄ alkoxy, halogenatedC₁₋₄alkoxy, C₁₋₄alkyl,        halogenatedC₁₋₄alkyl, and —C(O)H; preferably —CH₃, —CH₂CH₃,        —C(O)H, —O—CH₃, —O—CF₃, —O—CH(CH₃)₂, —CH(CH₃)₂, CN, OH, F, Cl,        and —CF₃; more preferably —O—CF₃, F, and —CF₃;    -   (k) n is 1, 2, or 3;    -   (l) m is 0;    -   (m) R₄ is —C(O)O—C₁₋₄alkyl, preferably —C(O)O—CH₃ or        —C(O)O—CH₂CH₃;    -   (n) R₄ is C₁₋₅ alkyl optionally substituted with 1 or 2 members        independently selected from oxo, hydroxy, C₁₋₄ alkoxy, C₃₋₈        cycloalkyl, CN, heterocyclyl, and —NR_(c)R_(d), wherein        -   R_(c) and R_(d) are independently selected from H,            —S(O)₂—C₁₋₄alkyl, C₁₋₃ alkyl, —C(O)—C₁₋₃ alkyl, and            —C(O)O—C₁₋₃ alkyl,    -   (o) R₄ is C₁₋₅ alkyl optionally substituted with 1 or 2 members        independently selected from oxo, hydroxy, —NH₂, —N(CH₃)₂,

-   -   (p) R₄ is halogenated C₁₋₄ alkyl optionally substituted with        oxo, hydroxy, C₁₋₄ alkoxy, or cyano; preferably R₄ is        fluorinatedC₁₋₃alkyl    -   substituted with hydroxy; more preferably R₄ is

and enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof; or any possible combinations of examples(a)-(p) above.

More particularly, the present invention is directed to a compound ofFormula (Ia) as shown above wherein:

-   -   m is 0;    -   n is 1, 2, or 3;    -   R₁ is —CH₂—CH═CH₂, —CH₂CH₂CH₂OH, —CH₂CH₂CH₂—O—CH₃, or        —CH═C(O)—C(CH₃)₃, Ph,

-   -   Each R₂ is independently selected from —O—CF₃, F, or —CF₃; and    -   R₄ is —C(O)O—CH₃, —C(O)O—CH₂CH₃, or C₁₋₅ alkyl optionally        substituted with 1-2 members independently selected from oxo,        hydroxy, NH₂, —N(CH₃)₂, —O—CH₃,

In particular, the present invention is further directed to a compoundof Formula (Ia) wherein

-   -   (a) X is O;    -   (b) m is 0;    -   (c) n is 1, 2, or 3;    -   (d) m and n are both 0;    -   (e) m is 0 and n is 1;    -   (f) m is 0 and n is 2;    -   (g) L is a bond;    -   (h) L is O;    -   (i) R₁ is

-   -   (j) R₁ is

-   -   (k) R₁ is

-   -   (l) R₁ is

-   -   (m) R₁ is

-   -   (n) R₁ is —CH₂CH₃

-   -    or phenyl;    -   (o) R₁ is —CH₂CH₂CH₂OH;    -   (p) R₁ is

-   -   (q) R₁ is

-   -   (r) Q is phenyl or naphthalenyl;    -   (s) Q is phenyl;    -   (t) Q is a selected from the group consisting of thienyl,        thiazolyl, oxazolyl, isoxazolyl, pyridinyl, and pyridizinyl;    -   (u) Q is

-   -   (v) n is 1 and Q is

-   -   (w) n is 1 and Q is

-   -   (x) n is 2 and Q is

-   -   (y) n is 2 and Q is

-   -   (z) n is 3 and Q is

-   -   (aa) R₂ is —O—CF₃;    -   (bb) R₂ is —CF₃    -   (cc) R₂ is F;    -   (dd) R₂ is —CH₃, —CH₂CH₃, or —CH(CH₃)₂;    -   (ee) R₂ is —C(O)H, CN, OH,    -   (ff) R₂ is —O—CH(CH₃)₂, F, Cl, or —CF₃;    -   (gg) R₂ is —O—CH₃, —O—CF₃, or —O—CH(CH₃)₂;    -   (hh) R₄ is C₁₋₅alkyl substituted with 1 or 2 members        independently selected from oxo, hydroxy, —O—CH₃, and —O—CH₂CH₃    -   (ii) R₄ is C₁₋₅alkyl substituted with substituted heterocyclyl        selected from

-   -   (jj) R₄ is C₁₋₅alkyl substituted with

-   -   (kk) R₄ is halogenatedC₁₋₄ alkyl substituted with oxo, hydroxy,        or —O—CH₃;    -   (ll) R₄ is —CH₂CH(OH)CF₃;    -   (mm) R₄ is —CH₂CH₃, or —CH₂CH₂ CH₃;    -   (nn) R₄ is —CH₂CH(OH)CH₂C₁ or R₄ is —CH₂CH(OH)CF₃;    -   (oo) R₄ is —CH₂CH(OH)CH(CH₃)₂ or R₄ is —CH₂CH(OH)CH₂OCH₃;    -   (pp) m is 0, n is 1, and L is a bond;    -   (qq) m is 0, n is 2, and L is a bond;    -   (rr) m is 0, n is 3, and L is a bond    -   (ss) m is 0, n is 1, L is a bond, and R₁ is

-   -   (tt) m is 0, n is 1, L is a bond, Q is phenyl, and R₁ is

-   -   (uu) m is 0, n is 1, L is a bond, R₁ is

-   -    and Q is

-   -   (vv) m is 0, n is 1, L is a bond, R₁ is

-   -    and the Q-R₂ group is

-   -   (ww) m is 0, n is 1, 2, or 3, L is a bond, Q is phenyl, and R₁        is

-   -    and each R₂ is independently selected from F, —CF₃, and —O—CF₃;    -   (xx) m is 0, n is 2 or 3, L is a bond, Q is

-   -    and each R₂ is independently selected from —O—CF₃, —CF₃, or F;    -   (yy) m is 0, n is 1, L is a bond, Q is

-   -    and R₂ is —CH₃, —CH₂CH₃, —CH(CH₃)₂, —C(O)H, CN, OH,        —O—CH(CH₃)₂, F, Cl, —CF₃, —O—CH₃, —O—CF₃, or —O—CH(CH₃)₂; or        enantiomers, diastereomers, tautomers, solvates, or        pharmaceutically acceptable salts thereof; or any possible        combinations of (a)-(yy) above.

In another aspect, the present invention is further directed to acompound of Formula (Ib):

wherein:

-   -   R₁ is C₁₋₁₀ alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl,        or a 5- or 6-membered heteroaryl; wherein said C₁₋₁₀ alkyl,        C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, or 5- or 6-membered        heteroaryl is optionally substituted with halo, cyano, or        hydroxy, oxo, C₁₋₃alkyl, or C₁₋₃alkoxy;    -   or R₁ is phenyl optionally substituted with 1 to 2 members        selected from R_(a) and R_(b), wherein R_(a) and R_(b) are        independently selected from the group consisting of C₁₋₄ alkyl,        halogenatedC₁₋₄alkyl, phenylC₁₋₄alkyl, C₁₋₄ alkoxy, halogenated        C₁₋₄ alkoxy, phenylC₁₋₄ alkoxy, C₁₋₄ alkylthio,        halogenatedC₁₋₄alkylthio, halo, cyano, and hydroxy, or        -   R_(a) and R_(b) together with the carbon atoms of the phenyl            ring to which they are attached form a 5- or 6-membered            heterocyclyl fused to the phenyl ring; said heterocyclyl            optionally substituted with 1 or 2 members independently            selected from halo, C₁₋₃alkyl, cyano, and hydroxy;    -   each of R_(2a), R_(2b), and R_(2c) is independently absent or        selected from the group consisting of halo, hydroxy, cyano, C₁₋₄        alkoxy, halogenated C₁₋₄alkoxy, C₁₋₄ alkyl, halogenatedC₁₋₄        alkyl, and —C(O)H;    -   R₃ is absent or selected from the group consisting of C₁₋₄        alkyl, C₁₋₄ alkoxy, halo, cyano, and hydroxy;    -   R₄ is C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl,        wherein said C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or        phenylC₁₋₃alkyl is optionally substituted with 1-3 members        independently selected from the group consisting of oxo,        hydroxy, C₁₋₄ alkoxy, halogenatedC₁₋₄ alkoxy, C₃₋₈ cycloalkyl,        cyano, heterocyclyl, and —NR_(c)R_(d), wherein        -   R_(c) and R_(d) are independently selected from H,            optionally substituted C₁₋₃ alkyl, —C(O)C₁₋₃alkyl,            —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl;            and enantiomers, diastereomers, tautomers, solvates, or            pharmaceutically acceptable salts thereof.

Particularly, the present invention features a compound of Formula (Ib)wherein R₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl,C₁₋₄ alkoxy, halogenatedC₁₋₄alkoxy, halo, cyano, or hydroxy.

Particularly, the present invention features a compound of Formula (Ib)wherein R₁ is phenyl substituted with halogenated C₁₋₄alkyl orhalogenatedC₁₋₄alkoxy, preferably R₁ is phenyl substituted with—OCF₂CF₂H, —CF₃, or —OCF₃.

Particularly, the present invention features a compound of Formula (Ib)wherein R₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl,C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, halo, cyano, hydroxy, halogenatedC₁₋₄alkylthio, or an optionally substituted five membered heterocyclylring fused to the phenyl ring forming a bicyclic ring system.

Particularly, the present invention features a compound of Formula (Ib)wherein R₁ is C₁₋₆ alkyl substituted with hydroxy, C₁₋₃alkoxy, oxo,halo, or cyano.

Particularly, the present invention features a compound of Formula (Ib)wherein R₁ is furanyl or thienyl optionally substituted with C₁₋₃alkyl,C₁₋₃alkoxy, hydroxy, or cyano.

Particularly, the present invention features a compound of Formula (Ib)wherein R_(2a) and R_(2b) are both absent and R_(2c) is selected fromhalo, halogenated C₁₋₄alkyl, and halogenated C₁₋₄alkoxy, preferablyR_(2c) is —OCF₂CF₂H or —OCF₃.

Particularly, the present invention features a compound of Formula (Ib)wherein R_(2a), R_(2b), and R_(2c) are each independently absent orselected from halo, halogenated C₁₋₄alkyl, and halogenated C₁₋₄alkoxy,preferably R_(2a), R_(2b), and R_(2c) are independently absent,—OCF₂CF₂H, —OCF₃ or F.

Particularly, the present invention features a compound of Formula (Ib)wherein R₄ is C₁₋₅ alkyl substituted with 1 or 2 members eachindependently selected from oxo, hydroxy, C₁₋₄alkoxy, cyano, andheterocyclyl; preferably R₄ is C₁₋₃ alkyl substituted with hydroxy,C₁₋₄alkoxy, or cyano.

Particularly, the present invention features a compound of Formula (Ib)wherein R₄ is C₁₋₅ alkyl substituted with —NR_(c)R_(d), wherein R_(c)and R_(d) are independently selected from H, optionally substituted C₁₋₃alkyl, —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl.

Particularly, the present invention features a compound of Formula (Ib)wherein R₄ is halogenatedC₁₋₄ alkyl substituted with oxo, hydroxy,C₁₋₄alkoxy, or cyano; preferably R₄ is fluorinatedC₁₋₃ alkyl substitutedwith hydroxy.

Particularly, the present invention features a compound of Formula (Ib)wherein R₄ is phenylC₁₋₃ alkyl wherein the phenyl group is substitutedwith hydroxy, C₁₋₄alkoxy, cyano, or halogenatedC₁₋₄ alkoxy, preferablyR₄ is phenylC₁₋₃ alkyl wherein the phenyl group is substituted withhalogenatedC₁₋₄ alkoxy.

In particular, the present invention is directed to a compound ofFormula (Ib) wherein

-   -   R₁ is phenyl optionally substituted with C₁₋₄ alkyl,        halogenatedC₁₋₄alkyl,        -   C₁₋₄alkoxy, halogenatedC₁₋₄ alkoxy, or cyano;    -   Each R_(2a), R_(2b), and R_(2c) is independently absent or        selected from halo, hydroxy, cyano, C₁₋₄ alkoxy, halogenatedC₁₋₄        alkoxy, C₁₋₄alkyl, halogenatedC₁₋₄alkyl, and —C(O)H; and    -   R₄ is C₁₋₅ alkyl substituted with 1 to 2 members independently        selected from hydroxy, C₁₋₄alkoxy, oxo, halogenatedC₁₋₄alkoxy,        C₃₋₈cycloalkyl, cyano; or R₄ is halogenatedC₁₋₄ alkyl        substituted with hydroxy, C₁₋₄alkoxy, oxo, or cyano.

In particular, the present invention is directed to a compound ofFormula (Ib) as shown above wherein:

-   -   (a) R₁ is C₁₋₆alkyl substituted with hydroxy, oxo, or        C₁₋₃alkoxy;    -   (b) R₁ is thienyl optionally substituted with C₁₋₃alkyl or        C₁₋₃alkoxy;    -   (c) R₁ is phenyl optionally substituted with 1 or 2 members        selected from R_(a) and R_(b), wherein        -   R_(a) and R_(b) are independently selected from the group            consisting of C₁₋₄ alkyl, halogenatedC₁₋₄ alkyl, C₁₋₄            alkoxy, halogenated C₁₋₄ alkoxy, phenylC₁₋₃alkoxy, —S—CF₃,            halo, cyano, and hydroxy, or R_(a) and R_(b) together with            the carbon atoms they are attached to form 5- or 6-membered            heterocyclyl fused to the phenyl ring;    -   (d) R₁ is phenyl,

-   -   (e) R₁ is an optionally substituted 5- or 6-membered heteroaryl,        preferably,

-   -   (f) R_(2a), R_(2b), and R_(2c) are each independently absent or        selected from halo, hydroxy, cyano, C₁₋₄ alkoxy, halogenatedC₁₋₄        alkoxy, C₁₋₄alkyl, halogenatedC₁₋₄alkyl, and —C(O)H; preferably        absent or selected from —CH₃, —CH₂CH₃, —C(O)H, —O—CH₃, —O—CF₃,        —O—CH(CH₃)₂, —CH(CH₃)₂, CN, OH, F, Cl, and —CF₃; more preferably        absent or selected from —CF₃, F, and —CF₃;    -   (g) R₄ is —C(O)O—C₁₋₄alkyl, preferably —C(O)O—CH₃ or        —C(O)O—CH₂CH₃;    -   (h) R₄ is C₁₋₅ alkyl optionally substituted with 1 or 2 members        independently selected from oxo, hydroxy, C₁₋₄ alkoxy, C₃₋₈        cycloalkyl, CN, heterocyclyl, and —NR_(c)R_(d), wherein        -   R_(c) and R_(d) are independently selected from H,            —S(O)₂—C₁₋₄alkyl, C₁₋₃ alkyl, —C(O)—C₁₋₃ alkyl, and            —C(O)O—C₁₋₃ alkyl,    -   (i) R₄ is C₁₋₅ alkyl optionally substituted with 1 or 2 members        independently selected from oxo, hydroxy, —NH₂, —N(CH₃)₂,        —O—CH₃, —O—CH₂CH₃,

-   -   (j) R₄ is halogenated C₁₋₄ alkyl optionally substituted with        oxo, hydroxy, C₁₋₄ alkoxy, or cyano; preferably R₄ is        fluorinatedC₁₋₃alkyl    -   substituted with hydroxy; more preferably R₄ is

and enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof; or any possible combinations of examples(a)-above

In another aspect, the present invention is further directed to acompound of Formula (Ic):

wherein:

-   -   each R_(2a), R_(2b), and R_(2c) is independently absent or        selected from the group consisting of halo, hydroxy, cyano, C₁₋₄        alkoxy, halogenated C₁₋₄alkoxy, C₁₋₄ alkyl, halogenatedC₁₋₄        alkyl, and —C(O)H;    -   R₄ is C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl,        wherein said C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or        phenylC₁₋₃alkyl is optionally substituted with 1-3 members        independently selected from the group consisting of halo, oxo,        hydroxy, C₁₋₄ alkoxy, C₃₋₈ cycloalkyl, cyano, heterocyclyl,        heteroaryl, tert-butyldimethylsilyloxy, and —NR_(c)R_(d),        wherein        -   R_(c) and R_(d) are independently selected from H,            optionally substituted C₁₋₃ alkyl, —C(O)C₁₋₃alkyl,            —C(O)O—C₁₋₃ alkyl, and SO₂C₁₋₃alkyl;    -   R₅ is selected from the group consisting of C₁₋₄ alkyl,        halogenatedC₁₋₄alkyl, C₁₋₄ alkoxy, halogenated C₁₋₄ alkoxy, C₁₋₄        alkylthio, halo, cyano, and hydroxy;        and enantiomers, diastereomers, tautomers, solvates, or        pharmaceutically acceptable salts thereof.

In particular, the present invention is directed to a compound ofFormula (Ic) wherein R_(2a) is absent, halo, or halogenatedC₁₋₃alkyl;preferably R_(2a) is absent, F, or CF₃, more preferably R_(2a) isabsent.

In particular, the present invention is directed to a compound ofFormula (Ic) wherein R_(2b) is absent or halo; preferably R_(2b) isabsent or F; more preferably R_(2b) is absent.

In particular, the present invention is directed to a compound ofFormula (Ic) wherein R_(2c) is halo, hydroxy, cyano, C₁₋₄ alkoxy,halogenated C₁₋₄alkoxy, C₁₋₄ alkyl, or halogenatedC₁₋₄ alkyl; preferablyR_(2c) is halo, halogenatedC₁₋₄alkyl or halogenated C₁₋₄alkoxy; morepreferably, R_(2c) is —CF₃, —OCF₃ or F.

In particular, the present invention is directed to a compound ofFormula (Ic) wherein R₄ is C₁₋₅ alkyl substituted with 1 or 2 memberseach independently selected from oxo, hydroxy, C₁₋₄alkoxy, cyano, andheterocyclyl; preferably R₄ is C₁₋₃ alkyl substituted with hydroxy,C₁₋₄alkoxy, or cyano.

Particularly, the present invention features a compound of Formula (Ic)wherein R₄ is C₁₋₅ alkyl substituted with —NR_(c)R_(d), wherein R_(c)and R_(d) are independently selected from H, optionally substituted C₁₋₃alkyl, —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl.

Particularly, the present invention features a compound of Formula (Ic)wherein R₄ is halogenatedC₁₋₄ alkyl substituted with oxo, hydroxy,C₁₋₄alkoxy, or cyano; preferably R₄ is fluorinatedC₁₋₃ alkyl substitutedwith hydroxy.

Particularly, the present invention features a compound of Formula (Ic)wherein R₄ is phenylC₁₋₃ alkyl wherein the phenyl group is substitutedwith hydroxy, C₁₋₄alkoxy, cyano, or halogenatedC₁₋₄ alkoxy, preferablyphenylC₁₋₃ alkyl wherein the phenyl group is substituted withhalogenatedC₁₋₄ alkoxy.

In particular, the present invention is directed to a compound ofFormula (Ic) wherein R₄ is halogenatedC₁₋₄ alkyl substituted with oxo,hydroxy, C₁₋₄alkoxy, or cyano; preferably R₄ is fluorinatedC₁₋₃ alkylsubstituted with hydroxy; more R₄ is preferably

In particular, the present invention is directed to a compound ofFormula (Ic) wherein R₅ is halogenatedC₁₋₄alkyl, halogenated C₁₋₄alkoxy, or halo; preferably R₅ is —CF₃, —OCF₃ or —OCF₂CF₂H, morepreferably R₅ is —OCF₃ or —OCF₂CF₂H.

In particular, the present invention is directed to a compound selectedfrom the group consisting of:

-   1,1,1-Trifluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-a-(trifluoromethyl)-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-,    (3S,αR)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-,    (3R,αS)—;-   3-[3,8-Bis-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3,8-bis[3-(trifluoromethoxy)phenyl]-a-(trifluoromethyl)-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3,8-bis[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-,    (3S,αR)—;-   3-[3-(3-Benzyl-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   3-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   1,1,1-Trifluoro-3-[8-(3-trifluoromethoxy-phenyl)-3-(3-trifluoromethylsulfanyl    methyl-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[8-(3-trifluoromethoxy-phenyl)-3-(3-trifluoromethylsulfanyl-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   3-[3-(3-Ethoxy-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   3-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-one;-   3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic    acid methyl ester;-   3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic    acid ethyl ester;-   4-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethanol;-   4-(2-Methoxy-ethyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   4-[3-(tert-Butyl-dimethyl-silanyloxy)-propyl]-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   3-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-1-ol;-   4-(3-Methoxy-propyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   Dimethyl-{2-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-amine;-   4-(2-piperazin-1-yl-ethyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   4-(2-Morpholin-4-yl-ethyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   4-[2-(4-Methyl-piperazin-1-yl)-ethyl]-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   4-Methyl-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   4-Ethyl-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   4-Propyl-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-α-methyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,    (3S,αR)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-a-methyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,    (3S,αS)—;-   2-Propanone,    3-[(3S)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-1,1,1-trifluoro-;-   2-Propanone,    1-[(3S)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-;-   2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethylamine;-   N-{2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-acetamide;-   {2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-carbamic    acid methyl ester;-   Methyl-{2-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-carbamic    acid methyl ester;-   N-{2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-methanesulfonamide;-   N-Methyl-N-{2-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-methanesulfonamide;-   2H-1,4-Benzoxazine,    4-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-3,4-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,    (3S)—;-   2H-1,4-Benzoxazine,    4-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-3,4-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,    (3R)—;-   1,2-Propanediol,    3-[(3S)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-,    (2S)—;-   1,2-Propanediol,    3-[(3R)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-,    (2S)—;-   2-Methyl-1-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   3-[3-Allyl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   3-[4-(3,3,3-Trifluoro-2-hydroxy-propyl)-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazin-3-yl]-propan-1-ol;-   1,1,1-Trifluoro-3-[3-(3-methoxy-propyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-]propan-2-ol;-   3-[4-(3,3,3-Trifluoro-2-hydroxy-propyl)-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazin-3-yl]-propan-1-ol;-   1,1,1-Trifluoro-3-[3-(3-methoxy-propyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   3,3-Dimethyl-1-[4-(3,3,3-trifluoro-2-hydroxy-propyl)-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazin-3-yl]-butan-2-one;-   3-[3-(5-Ethyl-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   1,1,1-Trifluoro-3-[3-(3-methoxy-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[3-(5-methoxy-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   3-{8-(3,5-Difluoro-phenyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxazin-4-yl}-1,1,1-trifluoro-propan-2-ol;-   1,1,1-Trifluoro-3-{8-(3-fluoro-phenyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxazin-4-yl}-propan-2-ol;-   1-Fluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[8-(3-trifluoromethoxy-phenyl)-3-(3-trifluoromethyl-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   4H-1,4-Benzoxazine-4-ethanol,    8-(3,5-difluorophenyl)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-α-(trifluoromethyl)-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    8-(3,5-difluorophenyl)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-α-(trifluoromethyl)-,    (3S,αR)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-a-fluoromethyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,    (3S,αR)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-a-fluoromethyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,4,5-trifluoro-phenyl]-α-(trifluoromethyl)-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,4,5-trifluoro-phenyl]-α-(trifluoromethyl)-,    (3S,αR)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,5-bis(trifluoromethyl)phenyl]-α-(trifluoromethyl)-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,5-bis(trifluoromethyl)phenyl]-α-(trifluoromethyl)-,    (3S,αR)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,5-(difluoro)phenyl]-α-(trifluoromethyl)-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,5-(difluoro)phenyl]-α-(trifluoromethyl)-,    (3S,αR)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,4,5-(trifluoro)phenyl]-α-(trifluoromethyl)-,    (3S,αS)—;-   4H-1,4-Benzoxazine-4-ethanol,    2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,4,5-(trifluoro)phenyl]-α-(trifluoromethyl)-,    (3S,αR)—;-   3-Methyl-1-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-butan-2-ol;-   1,1,1-Trifluoro-3-[3-(3-methyl-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   3-[3-(3-Ethyl-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   1,1,1-Trifluoro-3-[3-furan-2-yl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[3-[2-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[3-phenyl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[3-(4-trifluoromethoxy-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[3-(3-methoxy-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   3-[3-(3-Chloro-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;-   1,1,1-Trifluoro-3-[3-thiophen-2-yl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[3-furan-3-yl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;-   1,1,1-Trifluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]thiazin-4-yl]-propan-2-ol;    and enantiomers, diastereomers, tautomers, solvates, or    pharmaceutically acceptable salts thereof.

In particular, the present invention is directed to a compound ofFormula (I), (Ia), (Ib) or (Ic) selected from the compounds shown inTable 1 below and enantiomers, diastereomers, tautomers, solvates, orpharmaceutically acceptable salts thereof.

More particularly, the present invention is directed to a compoundselected from:

and enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.

In particular, the present invention is directed to a compound of theformula:

or enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.

The compounds of the present invention may also be present in the formof pharmaceutically acceptable salts. For use in medicine, the salts ofthe compounds of this invention refer to non-toxic “pharmaceuticallyacceptable salts” (Ref. International J. Pharm., 1986, 33, 201-217; J.Pharm. Sci., 1997 (January), 66, 1, 1). Other salts well known to thosein the art may, however, be useful in the preparation of compoundsaccording to this invention or of their pharmaceutically acceptablesalts. Representative organic or inorganic acids include, but are notlimited to, hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric,nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic,maleic, fumaric, malic, tartaric, citric, benzoic, mandelic,methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic,2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic,salicylic, saccharinic or trifluoroacetic acid. Representative organicor inorganic bases include, but are not limited to, basic or cationicsalts such as benzathine, chloroprocaine, choline, diethanolamine,ethylenediamine, meglumine, procaine, aluminum, calcium, lithium,magnesium, potassium, sodium and zinc.

The present invention includes within its scope prodrugs of thecompounds of this invention. In general, such prodrugs will befunctional derivatives of the compounds that are readily convertible invivo into the required compound. Thus, in the methods of treatment ofthe present invention, the term “administering” shall encompass thetreatment of the various disorders described with the compoundspecifically disclosed or with a compound which may not be specificallydisclosed, but which converts to the specified compound in vivo afteradministration to the patient. Conventional procedures for the selectionand preparation of suitable prodrug derivatives are described, forexample, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.Representative hydroxy group prodrug forms include, but are not limitedto, C₁₋₄alkylethers, substituted C₁₋₄alkylethers, and C₁₋₄alkyl esters.

Another embodiment of the present invention is a composition comprisingthe dextrorotatory enantiomer of a compound of the present invention,wherein said composition is substantially free from the levorotatoryisomer of said compound. In the present context, substantially freemeans less than 25%, preferably less than 10%, more preferably less than5%, even more preferably less than 2% and even more preferably less than1% of the levorotatory isomer calculated as.

${\% \mspace{14mu} {levorotatory}} = {\frac{\left( {{mass}\mspace{14mu} {levorotatory}} \right)}{\left( {{mass}\mspace{14mu} {dextrorotatory}} \right) + \left( {{mass}\mspace{14mu} {levorotatory}} \right)} \times 100}$

Another embodiment of the present invention is a composition comprisingthe levorotatory enantiomer of a compound of the present inventionwherein said composition is substantially free from the dextrorotatoryisomer of said compound. In the present context, substantially free frommeans less than 25%, preferably less than 10%, more preferably less than5%, even more preferably less than 2% and even more preferably less than1% of the dextrorotatory isomer calculated as

${\% \mspace{14mu} {dextorotatory}} = {\frac{\left( {{mass}\mspace{14mu} {dextrorotatory}} \right)}{\left( {{mass}\mspace{14mu} {dextrorotatory}} \right) + \left( {{mass}\mspace{14mu} {levorotatory}} \right)} \times 100}$

Where the compounds according to this invention have at least one chiralcenter, they may accordingly exist as enantiomers. Where the compoundspossess two or more chiral centers, they may additionally exist asdiastereomers. It is to be understood that all such isomers and mixturesthereof are encompassed within the scope of the present invention.Furthermore, some of the crystalline forms for the compounds may existas polymorphs and as such are intended to be included in the presentinvention. In addition, some of the compounds may form solvates withwater (i.e., hydrates) or common organic solvents, and such solvates arealso intended to be encompassed within the scope of this invention.

Where the processes for the preparation of the compounds according tothe invention give rise to mixture of stereoisomers, these isomers maybe separated by conventional techniques such as preparativechromatography. The compounds may be prepared in racemic form, orindividual enantiomers may be prepared either by enantiospecificsynthesis or by resolution. The compounds may, for example, be resolvedinto their component enantiomers by standard techniques, such as theformation of diastereomeric pairs by salt formation with an opticallyactive acid, such as (−)-di-p-toluoyl-d-tartaric acid and/or(+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallizationand regeneration of the free base. The compounds may also be resolved byformation of diastereomeric esters or amides, followed bychromatographic separation and removal of the chiral auxiliary.Alternatively, the compounds may be resolved using a chiral HPLC column.

The term “protecting groups” refer to those moieties known in the artthat are used to mask functional groups; protecting groups may beremoved during subsequent synthetic transformations or by metabolic orother in vivo administration conditions. During any of the processes forpreparation of the compounds of the present invention, it may benecessary and/or desirable to protect sensitive or reactive groups onany of the molecules concerned. This may be achieved by means ofconventional protecting groups, such as those described in ProtectiveGroups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973;and T. W. Greene & P. G. M. Wuts, Protective Groups in OrganicSynthesis, Third Edition, John Wiley & Sons, 1999. The protecting groupsmay be removed at a convenient subsequent stage using methods known inthe art.

In another aspect, the present invention is directed to pharmaceuticalcompositions containing one or more compounds, salts or solvates of thepresent invention as described herein admixed with a pharmaceuticallyacceptable carrier, excipient or diluent, wherein the compositions canbe used to treat a condition directly or indirectly mediated by CETP.

Even though the compounds of the present invention (including theirenantiomers, diastereomers, tautomers, pharmaceutically acceptable saltsand pharmaceutically acceptable solvates) can be administered alone,they will generally be administered in admixture with a pharmaceuticalcarrier, excipient or diluent selected with regard to the intended routeof administration and standard pharmaceutical or veterinary practice.Thus, the present invention is directed to pharmaceutical and veterinarycompositions comprising compounds of the present invention and one ormore pharmaceutically acceptable carriers, excipients or diluents.

By way of example, in the pharmaceutical compositions of the presentinvention, the compounds of the present invention may be admixed withany suitable binder(s), lubricant(s), suspending agent(s), coatingagent(s), and/or solubilising agent(s).

Tablets or capsules of the compounds may be administered singly or twoor more at a time, as appropriate. It is also possible to administer thecompounds in sustained release formulations.

Alternatively, the compounds of the present invention can beadministered by inhalation or in the form of a suppository or pessary,or they may be applied topically in the form of a lotion, solution,cream, ointment or dusting powder. An alternative means of transdermaladministration is by use of a skin patch. For example, they can beincorporated into a cream consisting of an aqueous emulsion ofpolyethylene glycols or liquid paraffin. They can also be incorporated,at a concentration of between 1 and 10% by weight, into an ointmentconsisting of a white wax or white soft paraffin base together with suchstabilizers and preservatives as may be required.

For some applications, preferably the compositions are administeredorally in the form of tablets containing excipients such as starch orlactose, or in capsules or ovules either alone or in admixture withexcipients, or in the form of elixirs, solutions or suspensionscontaining flavoring or coloring agents.

The compositions (as well as the compounds alone) can also be injectedparenterally, for example intracavernosally, intravenously,intramuscularly or subcutaneously. In this case, the compositions willcomprise a suitable carrier or diluent.

For parenteral administration, the compositions may be administered inthe form of a sterile aqueous solution which may contain othersubstances, for example enough salts or monosaccharides to make thesolution isotonic with blood.

For buccal or sublingual administration the compositions may beadministered in the form of tablets or lozenges which can be formulatedin a conventional manner.

By way of further example, pharmaceutical compositions containing one ormore of the compounds of the invention described herein as the activeingredient can be prepared by intimately mixing the compound orcompounds with a pharmaceutical carrier according to conventionalpharmaceutical compounding techniques. The carrier may take a widevariety of forms depending upon the desired route of administration(e.g., oral, parenteral). Thus for liquid oral preparations such assuspensions, elixirs and solutions, suitable carriers and additivesinclude water, glycols, oils, alcohols, flavoring agents, preservatives,stabilizers, coloring agents and the like; for solid oral preparations,such as powders, capsules and tablets, suitable carriers and additivesinclude starches, sugars, diluents, granulating agents, lubricants,binders, disintegrating agents and the like. Solid oral preparations mayalso be coated with substances such as sugars or be enteric-coated so asto modulate the major site of absorption. For parenteral administration,the carrier will usually consist of sterile water and other ingredientsmay be added to increase solubility or preservation. Injectablesuspensions or solutions may also be prepared utilizing aqueous carriersalong with appropriate additives.

Advantageously, compounds of the present invention may be administeredin a single daily dose, or the total daily dosage may be administered individed doses of two, three or four times daily. Furthermore, compoundsfor the present invention can be administered in intranasal form viatopical use of suitable intranasal vehicles, or via transdermal skinpatches well known to those skilled in that art. To be administered inthe form of a transdermal delivery system, the dosage administrationwill, of course, be continuous rather than intermittent throughout thedosage regimen.

The instant pharmaceutical composition will generally contain a perdosage unit (e.g., tablet, capsule, powder, injection, teaspoonful andthe like) from about 0.001 to about 50 mg/kg. In one embodiment, theinstant pharmaceutical composition contains a per dosage unit of fromabout 0.01 to about 20 mg/kg of compound, and preferably from about 0.05to about 10 mg/kg. Methods are known in the art for determiningtherapeutically effective doses for the instant pharmaceuticalcomposition. The therapeutically effective amount for administering thepharmaceutical composition to a human, for example, can be determined bypersons skilled in the art by the use of established animal models.

A therapeutically effective amount for use of the instant compound of apharmaceutical composition thereof comprises a dose range of from about0.01 mg to about 1,000 mg, preferably from about 10 to about 800 mg, inparticular from about 25 mg to about 750 mg, or more particularly, adose range of from about 50 mg to about 400 mg of active ingredient in aregimen of about 1 to 4 times per day for an average (70 kg) human;although, it is apparent to one skilled in the art that thetherapeutically effective amount for active compounds of the inventionwill vary as will the conditions being treated.

For oral administration, a pharmaceutical composition is preferablyprovided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0,2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250, and 500 milligramsof the active ingredient for the symptomatic adjustment of the dosage tothe subject to be treated. In certain embodiments, an effective amountof the drug may be supplied at a dosage level of from about 0.01 mg/kgto about 100 mg/kg of body weight per day, or any range therein.Preferably, the range is from about 0.5 to about 50.0 mg/kg of bodyweight per day, or any range therein. More preferably, from about 1.0 toabout 5.0 mg/kg of body weight per day, or any range therein. Thecompounds may be administered on a regimen of 1 to 4 times per day.

It is also apparent to one skilled in the art that the therapeuticallyeffective dose for active compounds of the invention or a pharmaceuticalcomposition thereof will vary according to the desired effect.Therefore, optimal dosages to be administered may be readily determinedand will vary with the particular compound used, the mode ofadministration, the strength of the preparation, and the advancement ofthe disease condition. In addition, factors associated with theparticular subject being treated, including subject age, weight, dietand time of administration, will result in the need to adjust the doseto an appropriate therapeutic level. The above dosages are thusexemplary of the average case. There can, of course, be individualinstances where higher or lower dosage ranges are merited, and such arewithin the scope of this invention.

Compounds of the present invention may be administered in any of theforegoing compositions and dosage regimens or by means of thosecompositions and dosage regimens established in the art whenever use ofthe compounds of the invention as CETP inhibitors is required for asubject in need thereof.

The invention also provides a pharmaceutical or veterinary pack or kitcomprising one or more containers filled with one or more of theingredients of the pharmaceutical and veterinary compositions of theinvention. Optionally associated with such container(s) can be a noticein the form prescribed by a governmental agency regulating themanufacture, use or sale of pharmaceuticals or biological products,which notice reflects approval by the agency of manufacture, use or salefor human administration.

In certain embodiments, the present invention is further directed to aprocess for preparation of the compounds of the present invention.

As inhibitors of CETP, the compounds of the present invention are usefulin methods for treating, preventing, or inhibiting the progression of, adisease or condition in a mammal which disease or condition is affectedby the inhibition of CETP. Such methods comprise administering to amammal in need of such treatment or prevention a therapeuticallyeffective amount of a compound of the present invention, or apharmaceutically acceptable salt or solvate thereof as described herein.

The present invention is also directed to a method of treating orpreventing a disease or condition in a subject, particularly a mammalincluding human, which disease or condition is affected by themodulation of CETP. Therefore, in yet another aspect, the presentinvention is directed to a method of treating or preventing a disease orcondition in a subject which disease or condition is affected by themodulation of CETP, which method comprises administering to a subject inneed of such treatment or prevention a therapeutically effective amountof a compound of the present invention, pharmaceutically acceptable saltor solvate thereof as described herein.

In a further aspect, the present invention is directed to a method ofincreasing HDL-C (HDL cholesterol) in a subject, which method comprisesadministering to a subject in need thereof a therapeutically effectiveamount of a compound of the present invention, pharmaceuticallyacceptable salt or solvate thereof as described herein.

In a further aspect, the present invention is directed to a method ofincreasing the ratio of HDL-C/total cholesterol in a subject, whichmethod comprises administering to a subject in need thereof atherapeutically effective amount of a compound of the present invention,pharmaceutically acceptable salt or solvate thereof as described herein.

In a further aspect, the present invention is directed to a method ofincreasing the ratio of HDL-C/LDL-C in a subject, which method comprisesadministering to a subject in need thereof a therapeutically effectiveamount of a compound of the present invention, pharmaceuticallyacceptable salt or solvate thereof as described herein.

In a further aspect, the present invention is directed to a method oflowering either or both of LDL-C (LDL-cholesterol) and non-HDL-Ccholesterol in a subject, which method comprises administering to asubject in need thereof a therapeutically effective amount of a compoundof the present invention, pharmaceutically acceptable salt or solvatethereof as described herein.

Examples of the disease or condition intended to be within the scope ofthe present invention include, but are not limited to, atherosclerosis,peripheral vascular disease, dyslipidemia (includinghypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, andhypo-HDL-cholesterolemia), hyper-LDL-cholesterolemiahyperbetaliproteinemia, hypoalphalipoproteinemia,familial-hypercholesterolemia, cardiovascular disorders, angina,ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusioninjury, angioplastic restenosis, hypertension, vascular complications ofdiabetes, obesity and Metabolic Syndrome.

Preferably the compounds of the present invention are useful for thetreatment of dyslipidemia (including hypertriglyceridemia,hypercholesterolemia, mixed hyperlipidemia, andhypo-HDL-cholesterolemia) and atherosclerosis.

While the present invention comprises compositions comprising one ormore of the compounds of the present invention, the present inventionalso comprises compositions comprising intermediates used in themanufacture of compounds of the present invention.

The compounds of the present invention, pharmaceutically acceptablesalts or solvates thereof can also be useful in combination therapy withone or more additional compounds, said additional compound being, forexample, an HMG-CoA reductase inhibitor, an microsomal triglyceridetransfer protein (MTP)/Apo B secretion inhibitor, a PPAR activator, abile acid reuptake inhibitor, a cholesterol absorption inhibitor, acholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchangeresin, an antioxidant, an ACAT inhibitor, a bile acid sequestrant,and/or an “antihypertensive agent” (examples of an antihypertensiveagent include, a calcium channel blocker, an ACE inhibitor, an A-II(Angiotensin-II receptor) antagonist, a diuretic, a beta-adrenergicreceptor blocker, an alpha-adrenergic receptor blocker, or avasodilator).

The term “jointly effective amount” as used herein, means that amount ofeach active compound or pharmaceutical agent, alone or in combination,that elicits the biological or medicinal response in a tissue system,animal or human that is being sought by a researcher, veterinarian,medical doctor or other clinician, which includes alleviation of thesymptoms of the disease or disorder being treated. For prophylacticpurposes (i.e., inhibiting the onset or progression of a disorder), theterm “jointly effective amount” refers to that amount of each activecompound or pharmaceutical agent, alone or in combination, that treatsor inhibits in a subject the onset or progression of a disease orcondition as being sought by a researcher, veterinarian, medical doctoror other clinician. Thus in another aspect, the present inventionprovides combinations of two or more drugs wherein, for example, (a)each drug is administered in an independently therapeutically orprophylactically effective amount; (b) at least one drug in thecombination is administered in an amount that is sub-therapeutic orsub-prophylactic if administered alone, but is therapeutic orprophylactic when administered in combination with the second oradditional drugs according to the invention; or (c) both drugs areadministered in an amount that is sub-therapeutic or sub-prophylactic ifadministered alone, but are therapeutic or prophylactic whenadministered together.

In certain embodiments, this invention provides a method for treating orpreventing in a subject one or more diseases or conditions as describedherein, said method comprising

-   -   (a) administering to said subject a jointly effective amount of        a compound of Formula (I), (Ia), (Ib), or (Ic) or an enantiomer,        diastereomer, tautomer, or pharmaceutically acceptable salt        thereof as described herein; and    -   (b) administering to said subject a jointly effective amount of        an HMG-CoA reductase inhibitor, an microsomal triglyceride        transfer protein (MTP)/Apo B secretion inhibitor, a PPAR        activator, a bile acid reuptake inhibitor, a cholesterol        absorption inhibitor, a cholesterol synthesis inhibitor, a        fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT        inhibitor, a bile acid sequestrant, or an antihypertensive        agent.        said co-administration being in any order and the combined        jointly effective amounts providing the desired therapeutic or        prophylactic effect.

In certain embodiments, this invention provides a method for treating orpreventing in a subject one or more diseases or conditions as describedherein, said method comprising

-   -   (a) administering to said subject a jointly effective amount of        a compound of Formula (I), (Ia), (Ib) or (Ic) or an enantiomer,        diastereomer, tautomer, or pharmaceutically acceptable salt        thereof as described herein; and    -   (b) administering to said subject a jointly effective amount of        an HMG-CoA reductase inhibitor,        said co-administration being in any order and the combined        jointly effective amounts providing the desired therapeutic or        prophylactic effect.

Such administration encompasses co-administration of these therapeuticagents in a substantially simultaneous manner, such as in a singlecapsule having a fixed ratio of active ingredients or in multiple,separate capsules for each agent. In addition, such administration alsoencompasses use of each type of therapeutic agent in a sequentialmanner.

The HMG-CoA reductase inhibitor for use in the present invention may beany HMG-CoA reductase inhibitor which is preferably capable of lowerplasma concentrations of low-density lipoprotein, total cholesterol, orboth. In a preferred aspect, the HMG-CoA reductase inhibitor is from aclass of therapeutics commonly called statins. Examples of HMG-CoAreductase inhibitors that may be used include but are not limited tolovastatin (Mevacor®), simvastatin (Zocor®), pravastatin (Pravachol®),lactones of pravastatin, fluvastatin (Lescol®), lactones of fluvastatin,atorvastatin (Lipitor®), lactones of atorvastatin, cerivastatin (alsoknown as rivastatin and Baychol®), lactones of cerivastatin,rosuvastatin (Crestor®), lactones of rosuvastatin, itavastatin,nisvastatin, visastatin, atavastatin, bervastatin, compactin,dihydrocompactin, dalvastatin, fluindostatin, pitivastatin, mevastatin,and velostatin (also referred to as synvinolin), and pharmaceuticallyacceptable forms thereof. Preferably the HMG-CoA reductase inhibitor isselected from the group consisting of fluvastatin, lovastatin,pravastatin, atorvastatin, simvastatin, cerivastatin, rivastatin,mevastatin, velostatin, compactin, dalvastatin, fluindostatin,rosuvastatin, pitivastatin, dihydrocompactin, and pharmaceuticallyacceptable forms thereof.

In one embodiment the present invention provides a combination therapycomprising the use of a first amount of a compound of Formula (I), (Ia),(Ib) or (Ic) or an enantiomer, diastereomer, tautomer, orpharmaceutically acceptable salt thereof as described herein and asecond amount of an HMG CoA reductase inhibitor compound useful in theprophylaxis or treatment of hyperlipidemia, atherosclerosis, orhypercholesterolemia, wherein said first and second amounts togethercomprise an anti-hyperlipidemic condition effective amount, ananti-atherosclerotic condition effective amount, or ananti-hypercholesterolemic condition effective amount of the compounds.

General Synthetic Methods

Representative compounds of the present invention can be synthesized inaccordance with the general synthetic method described below as well asthe illustrative examples that follow. Since the schemes are anillustration, the invention should not be construed as being limited bythe chemical reactions and conditions expressed. The preparation of thevarious starting materials used in the schemes is well within the skillof persons versed in the art.

In accordance with General Scheme 1, wherein R₃ is C₁₋₄ alkyl, C₁₋₄alkoxy, halo, or cyano, and R₁, R₂, R₄, m, n, L, and Q are as describedherein, reduction of GA1 gives GA2. O-alkylation of GA2 withalpha-halo-ketone gives GA3. Reductive amination of GA3 gives GA4.Transition metal-catalyzed cross-coupling of GA4 gives GA5. Alkylationof GA5 with various electrophile gives compounds of Formula (Id). WhenR₃ is OH, one can first protect the OH of GA1 as OTBS-GA1, then followthe same sequences described above in General Scheme 1 to give compoundsof Formula (II),

Wherein R₃′ is OTBS and R₁, R₂, R₄, m, n, L, and Q are as describedherein, followed by removal of the TBS protection group to givecompounds of Formula (Ie):

In accordance with General Scheme 2, wherein R₃ is C₁₋₄ alkyl, C₁₋₄alkoxy, halo, or cyano, and R₁, R₂, R₄, m, n, L, and Q are as describedherein, reaction of GA1 with (CH₃)₂NCsCl followed by treatment with KOHgives GB2. Reduction of GB2 gives GB3. S-alkylation of GB3 withalpha-halo-ketone gives GB4. Reductive amination of GB4 gives GB5.Transition metal-catalyzed cross-coupling of GB5 gives GB6. Alkylationof GB6 with various electrophile gives compounds of Formula (If). WhenR₃ is OH, one can first protect the OH of GA1 as OTBS-GA1, then followedthe same sequences as just described above to give compounds of Formula(II),

wherein R₃′ is OTBS and R₁, R₂, R₄, m, n, L, and Q are as describedherein, followed by removal of the TBS protection group to givecompounds of Formula (Ig):

Compounds of the present invention that are chiral may be separated intotheir enantiomers by chromatography on a chiral stationary phase.Alternatively, the basic compounds of the present invention may beconverted to diastereomeric salts by mixture with a chiral acid andresolved into their enantiomers by fractional crystallization.

It is generally preferred that the respective product of each processstep be separated from other components of the reaction mixture andsubjected to purification before its use as a starting material in asubsequent step. Separation techniques typically include evaporation,extraction, precipitation and filtration. Purification techniquestypically include column chromatography (Still, W. C. et. al., J. Org.Chem. 1978, 43, 2921), thin-layer chromatography, crystallization anddistillation. The structures of the final products, intermediates andstarting materials are confirmed by spectroscopic, spectrometric andanalytical methods including nuclear magnetic resonance (NMR), massspectrometry (MS) and liquid chromatography (HPLC). In the descriptionsfor the preparation of compounds of this invention, ethyl ether,tetrahydrofuran and dioxane are common examples of an ethereal solvent;benzene, toluene, hexanes and heptanes are typical hydrocarbon solventsand dichloromethane and dichloroethane are representative halogenatedhydrocarbon solvents. In those cases where the product is isolated asthe acid addition salt the free base may be obtained by techniques knownto those skilled in the art. In those cases in which the product isisolated as an acid addition salt, the salt may contain one or moreequivalents of the acid. Enantiomers of the compounds of the presentinvention may be separated using chiral HPLC.

Abbreviations

-   -   Ac=CH₃C(O)—    -   Aq=aqueous    -   Cpd, Cmpd=compound    -   con=concentration    -   DCE=dichloroethane    -   DCM=dichloromethane    -   DIEA=diisopropylethyl amine    -   DMF=N,N-dimethylformamide    -   DMSO=dimethylsulfoxide    -   DPPF=diphenylphosphinoferrocene    -   Et=ethyl    -   EtOAc=ethyl acetate    -   h or hr=hour(s)    -   HATU=N-[(dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridine-3-yloxy)methylene]-N-methylmethanaminium        hexafluorophosphate    -   HDL=High Density Lipoprotein    -   HDL-C=high density lipoprotein cholesterol    -   IDL=Intermediate Density Lipoprotein    -   LAH=lithium aluminum hydride    -   LDL=Low Density Lipoprotein    -   LDL-C=Low Density Lipoprotein cholesterol    -   LiN(TMS)₂=Lithium bis(trimethylsilyl)amide    -   Me=methyl    -   min=minute(s)    -   NBS=N-bromosuccinimide    -   Ph=phenyl    -   PPA=polyphosphoric acid    -   psi=pascal per square inch    -   Rf=retention time    -   t-Boc=tert-butoxycarbonyl    -   TBSO=tert-butyldimethylsilyloxy    -   t-Bu=tert-butyl    -   TEA=triethylamine    -   TFA=trifluoroacetic acid    -   THF=tetrahydrofuran    -   TLC=(thin layer chromatography)    -   TMS=trimethylsilyl    -   TMSOTf=trimethylsilyl triflate    -   Tol=toluene    -   VLDL=Very Low Density Lipoprotein    -   Yb(OTf)₃=Ytterbium tristriflate

EXAMPLES Example 1

1,1,1-Trifluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol

To a mixture of 2-bromo-6-nitro-phenol (15.0 g, 68.8 mmol) in EtOH (200mL) at 60° C. was added a warm solution of Na₂S₂O₄ (50.0 g, 287 mmol) inwater (180 mL) dropwise. Upon the addition of Na₂S₂O₄ solution thereaction mixture turned to deep orange. After addition of about half ofthe Na₂S₂O₄ solution, the deep orange changed to light yellow. Thereaction mixture was allowed to cool to room temperature and EtOH wasremoved in vacuo. The residue was filtered, and the solid washed withwater and dried under vacuum. The filtrate was extracted with CH₂Cl₂.The combined organic layers were dried (Na₂SO₄) and concentrated. Thesolids were combined to give 11.1 g (86%) of Ala as a white crystallinematerial: ¹H NMR (300 MHz, CDCl₃) δ 6.87-6.83 (m, 1H), 6.66-6.63 (m,2H), 5.39 (brs, 1H), 3.85 (brs, 2H); MS (ES) m/z: 188 (M+H⁺).

To a solution of dichlorophenylmethyl sulfoxide (5.94 g, 28.4 mmol; K.C. Tin & T. Dust, Tetra. Lett. 1970, 4643) in THF (100 mL) at −78° C.was added LDA (1.8 M in THF, 20.5 mL, 36.9 mmol). The reaction mixturewas stirred at −78° C. for 15 min and then was added3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde (6.94 g, 31.3 mmol). Afterstirring at −78° C. for 45 min, EtMgBr (1.0 M solution in ^(t-)BuOMe, 60mL, 60 mmol) was added. The reaction mixture was stirred at −78° C. foranother 40 min, quenched with NH₄Cl aqueous solution and acidified with1 N HCl. The organic layer was separated and the aqueous layer wasextracted with CH₂Cl₂. The combined organic phases were dried (Na₂SO₄),concentrated and purified by column chromatography to give 4.13 g (49%)of A2a as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.89 (dd, J=7.6, 2.6Hz, 1H), 7.81 (s, 1H), 7.58-7.46 (m, 2H), 5.95 (tt, J=53.0, 2.7 Hz, 1H),4.68 (s, 2H); MS (ES) m/z: 293 (M+Na⁺).

A mixture of A1a (2.59 g, 13.8 mmol), A2a (4.10 g, 15.2 mmol) and Cs₂CO₃(4.49 g, 13.8 mmol) in CH₃CN (40 mL) was stirred at room temperature for2.5 h. The solid was filtered and washed with THF and CH₂Cl₂. Thefiltrate was concentrated and purified by column chromatography to give3.87 g (67%) of A2b as a brownish oil: ¹H NMR (300 MHz, CDCl₃) δ 7.84(s, 1H), 7.76 (d, J=7.8 Hz, 1H), 7.51 (t, J=8.0 Hz, 1H), 7.41-7.36 (m,3H), 6.93 (t, J=7.9 Hz, 1H), 5.95 (mt, J=53.0 Hz, 1H), 5.17 (s, 2H); MS(ES) m/z: 404 (M−H₂O).

To a mixture of A2b (2.77 g, 6.56 mmol) and NaB(OAc)₃H (2.78 g, 13.1mmol) in 1,2-dichloroethane (40 mL) was added trifluoroacetic acid(0.500 mL, 6.5 mmol). After stirring at room temperature for 45 min,NaHCO₃ saturated solution was added and the aqueous layer was extractedwith CH₂Cl₂. The combined organic phases were dried (Na₂SO₄),concentrated and purified by column chromatography to get 2.67 g (100%)of A2c as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.42 (t, J=8.2 Hz,1H), 7.31 (d, J=7.7 Hz, 1H), 7.26 (s, 1H), 7.22 (d, J=8.1 Hz, 1H), 6.96(d, J=7.8 Hz, 1H), 6.72-6.62 (m, 2H), 5.92 (bt, J=45.8 Hz, 1H), 4.55(bd, J=8.5 Hz, 1H), 4.42 (bd, J=10.7 Hz, 1H), 4.12 (brs, 1H), 4.07-4.02(m, 1H); MS (ES) m/z: 406 (M+H⁺).

A mixture of A2c (2.00 g, 4.93 mmol), 3-trifluoromethoxy-benzene boronicacid (2.03 g, 9.85 mmol) and 2 N K₂CO₃ (7.4 mL, 14.8 mmol) in1,4-dioxane (50 mL) was purged with N₂ for 15 min, and PdCl₂(PPh₃)₂ (210mg, 0.299 mmol) was added. The reaction mixture was purged with N₂ foranother 10 min and heated at 95° C. for 20 h. After cooling to roomtemperature, NH₄Cl aqueous solution was added and the mixture wasextracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄),concentrated and purified by column chromatography to give 2.09 g (87%)of A2d as a clear oil: ¹H NMR (300 MHz, CDCl₃) δ 7.49-7.14 (m, 8H), 6.89(t, J=7.7 Hz, 1H), 6.78-6.70 (m, 2H), 5.91 (tt, J=53.1, 2.8 Hz, 1H),4.58 (dd, J=8.2, 2.7 Hz, 1H), 4.32 (dd, J=10.6, 1.9 Hz, 1H), 4.14 (brs,1H), 3.99 (dd, J=10.6, 6.4 Hz, 1H); MS (ES) m/z: 488 (M+H⁺).

A mixture of A2d (38 mg, 0.078 mmol), 2-trifluoromethyl-oxirane (44 mg,0.39 mmol) and Yb(SO₃CF₃)₃ (5 mg, 0.008 mmol) in CH₂Cl₂ (0.35 mL) washeated at 50° C. for 18 h in a sealed tube. After cooling to roomtemperature, the crude mixture was purified by thin layer chromatography(20% EtOAc in hexane) to give 8 mg (17%) higher Rf compound 1 as a clearoil: ¹H NMR (300 MHz, CDCl₃) δ 7.44-7.35 (m, 4H), 7.22-7.12 (m, 4H),7.01 (t, J=7.9 Hz, 1H), 6.81-6.76 (m, 2H), 5.89 (tt, J=53.1, 2.7 Hz,1H), 4.86 (t, J=3.8 Hz, 1H), 4.40 (m, 1H), 4.27 (dd, J=11.0, 3.2 Hz,1H), 4.17 (dd, J=11.0, 4.7 Hz, 1H), 3.82 (d, J=15.6 Hz, 1H), 3.32 (dd,J=15.7, 9.6 Hz, 1H), 2.47 (brs, 1H); MS (ES) m/z: 600 (M+H⁺).

Example 2

Compound 2 was isolated as a lower Rf compound (26%, clear oil) in thesame reaction of synthesizing compound 1: ¹H NMR (300 MHz, CDCl₃) δ7.45-7.34 (m, 4H), 7.19-7.14 (m, 3H), 7.09 (s, 1H), 7.02 (t, J=7.9 Hz,1H), 6.89 (d, J=7.3 Hz, 1H), 6.78 (d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1,2.7 Hz, 1H), 4.55 (t, J=2.9 Hz, 1H), 4.34-4.20 (m, 3H), 3.70 (dd,J=15.7, 6.5 Hz, 1H), 3.56 (dd, J=15.7, 5.2 Hz, 1H), 2.30 (brs, 1H); MS(ES) m/z: 600 (M+H⁺).

Example 3

The racemic mixture A2d (1.5 g) was separated by chiral HPLC (column:Chiralcel OJ; eluent: isocratic mixture of 90% heptane and 10% ethanol)to give enantiomers C1a (first off HPLC, 0.63 g) and C1b (second offHPLC, 0.54 g). Spectrums of C1a are as follows: [α]²⁰ _(D) +34.4° (c=1,CHCl₃); 1H NMR (300 MHz, CDCl₃) δ 7.49-7.11 (m, 8H), 6.90 (t, J=7.7 Hz,1H), 6.78-6.71 (m, 2H), 5.91 (tt, J=53.1, 2.6 Hz, 1H), 4.58 (dd, J=8.3,2.6 Hz, 1H), 4.31 (dd, J=10.6, 2.3 Hz, 1H), 4.15 (brs, 1H), 3.99 (dd,J=10.6, 8.4 Hz, 1H); MS (ES) m/z: 488 (M+H⁺).

Spectrums of C1b are as following: [α]²⁰ _(D) −35.7° (c=1, CHCl₃); ¹HNMR (300 MHz, CDCl₃) δ 7.50-7.12 (m, 8H), 6.90 (t, J=7.7 Hz, 1H),6.79-6.70 (m, 2H), 5.90 (tt, J=53.1, 2.8 Hz, 1H), 4.59 (dd, J=8.2, 2.7Hz, 1H), 4.31 (dd, J=10.6, 1.9 Hz, 1H), 4.15 (brs, 1H), 3.99 (dd,J=10.6, 6.4 Hz, 1H); MS (ES) m/z: 488 (M+H⁺).

Replacing A2d with C1a and following the same procedure as in thepreparation of compound 1 and 2 gave compound 3 and 4. Spectrums ofcompound 3 are as follows: [α]²⁰ _(D) −69.6° (c=1, CHCl₃); ¹H NMR (300MHz, CDCl₃) δ 7.44-7.35 (m, 4H), 7.22-7.12 (m, 4H), 7.01 (t, J=7.9 Hz, 1H), 6.81-6.77 (m, 2H), 5.90 (tt, J=53.1, 2.7 Hz, 1H), 4.87 (t, J=3.8 Hz,1H), 4.40 (m, 1H), 4.28 (dd, J=11.0, 3.2 Hz, 1H), 4.18 (dd, J=11.0, 4.7Hz, 1H), 3.82 (d, J=15.6 Hz, 1H), 3.34 (dd, J=15.7, 9.6 Hz, 1H), 2.50(brs, 1H); MS (ES) m/z: 600 (M+H⁺). Anal. Calcd. For C₂₆H₁₉F₁₀NO₄: C,52.10; H, 3.19; N, 2.34. Found: C, 51.95; H, 2.82; N, 2.34.

Example 4

Spectrums of compound 4 are as following: [α]²⁰ _(D) −80.8° (c=1,CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.32 (m, 4H), 7.19-7.10 (m, 3H),7.09 (s, 1H), 7.02 (t, J=7.9 Hz, 1H), 6.89 (d, J=8.1 Hz, 1H), 6.79 (d,J=7.6 Hz, 1H), 5.87 (tt, J=53.1, 2.6 Hz, 1H), 4.54 (s, 1H), 4.36-4.20(m, 3H), 3.70 (dd, J=15.8, 6.5 Hz, 1H), 3.56 (dd, J=15.7, 5.2 Hz, 1 H),2.30 (brs, 1H); MS (ES) m/z: 600 (M+H⁺).

Example 5

Replacing A2d with C1b and following the same procedure as in thepreparation of compound 1 and 2 gave compound 5 and 6. Spectrums ofcompound 5 are as following: [α]²⁰ _(D) +68.4° (c=1, CHCl₃); ¹H NMR (300MHz, CDCl₃) δ 7.44-7.35 (m, 4H), 7.22-7.12 (m, 4H), 7.01 (t, J=7.9 Hz,1H), 6.81-6.77 (m, 2H), 5.90 (tt, J=53.1, 2.7 Hz, 1H), 4.87 (t, J=3.8Hz, 1H), 4.40 (m, 1H), 4.28 (dd, J=11.0, 3.2 Hz, 1H), 4.18 (dd, J=11.0,4.7 Hz, 1H), 3.82 (d, J=15.6 Hz, 1H), 3.34 (dd, J=15.7, 9.6 Hz, 1H),2.50 (brs, 1H); MS (ES) m/z: 600 (M+H⁺).

Example 6

Spectrums of compound 6 are as following: [α]²⁰ _(D) +71° (c=0.33,CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.32 (m, 4H), 7.19-7.10 (m, 3 H),7.09 (s, 1H), 7.02 (t, J=7.9 Hz, 1H), 6.89 (d, J=8.1 Hz, 1H), 6.79 (d,J=7.6 Hz, 1H), 5.87 (tt, J=53.1, 2.6 Hz, 1H), 4.54 (s, 1H), 4.36-4.20(m, 3H), 3.70 (dd, J=15.8, 6.5 Hz, 1H), 3.56 (dd, J=15.7, 5.2 Hz, 1H),2.30 (brs, 1H); MS (ES) m/z: 600 (M+H⁺).

To a solution of C2a (6.94 g, 10.2 mmol; S. Atarashi, H. Tsurumi, T.Fujiwara and 1. Hayakawa, J. Heterocyclic Chem. 1991, 28, 329) indichloromethane (25 mL) at −78° C. was added a solution of A2b (2.06 g,4.88 mmol) in CH₂Cl₂ (11 mL) followed by TFA (0.37 mL, 4.88 mmol). Afterstirring at −78° C. for 2 h, NaHCO₃ saturated solution was added and theaqueous layer was extracted with CH₂Cl₂. The combined organic phaseswere dried (Na₂SO₄), concentrated and purified by column chromatographyto get 1.7 g (86%) of C2b as a yellow oil: [α]²⁰ _(D) +66.0° (c=1,CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.42 (t, J=8.2 Hz, 1H), 7.31 (d, J=7.7Hz, 1H), 7.26 (s, 1H), 7.22 (d, J=8.1 Hz, 1H), 6.96 (d, J=7.8 Hz, 1H),6.72-6.62 (m, 2H), 5.92 (bt, J=45.8 Hz, 1H), 4.55 (bd, J=8.5 Hz, 1H),4.42 (bd, J=10.7 Hz, 1H), 4.12 (brs, 1H), 4.07-4.02 (m, 1H); MS (ES)m/z: 406 (M+H⁺).

Replacing A2c with C2b and following the same procedure as in thepreparation of compound A2d gave compound C1a (89%): [α]²⁰ _(D) +33.5°(c=1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.49-7.14 (m, 8H), 6.89 (t,J=7.7 Hz, 1H), 6.78-6.70 (m, 2H), 5.91 (tt, J=53.1, 2.8 Hz, 1H), 4.58(dd, J=8.2, 2.7 Hz, 1H), 4.32 (dd, J=10.6, 1.9 Hz, 1H), 4.14 (brs, 1H),3.99 (dd, J=10.6, 6.4 Hz, 1H); MS (ES) m/z: 488 (M+H⁺).

Example 7

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with3-trifluoro-methoxy-benzaldehyde and following the same procedure as inthe preparation of compound A2a gave compound D1 (49%): ¹H NMR (300 MHz,CDCl₃) δ 7.89 (d, J=7.6 Hz, 1H), 7.82 (s, 1H), 7.60-7.46 (m, 2H), 4.68(s, 2H).

A mixture of 2-amino-6-bromo-phenol (255 mg, 1.36 mmol),m-trifluoromethoxy-phenyl boronic acid (560 mg, 2.72 mmol), K₂CO₃ (2.0M, 2.0 mL, 4.0 mmol) in 1,4-dioxane (8 mL) was degassed under N₂ for 10min, and PdCl₂(PPh₃)₂ (95 mg, 0.14 mmol) was added. The mixture waspurged with N₂ for another 10 min then heated at 100° C. for 17 h. Aftercooling to room temperature, the organic layer was separated and theaqueous layer was extracted with CH₂Cl₂. The combined organic layerswere dried (Na₂SO₄), concentrated and purified by column chromatographyto give 191 mg (52%) of D2 as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ7.54-7.40 (m, 2H), 7.35 (s, 1H), 7.24 (m, 1H), 6.88-6.77 (m, 2H),6.70-6.62 (m, 1H), 5.20 (brs, 1H), 3.78 (brs, 2H); MS (ES) m/z: 270(M+H⁺).

To a solution of phenol (145 mg, 0.539 mmol), acyl chloride (141 mg,0.591 mmol) and DMF (1.5 mL) was added K₂CO₃ (82 mg, 0.59 mmol). Afterstirring at room temperature for 2 h, the reaction mixture waspartitioned between Et₂O and water. The organic layer washed with waterand the aqueous layer was back extracted with Et₂O. The combined organicextracts were dried (Na₂SO₄), concentrated and purified by columnchromatography to give 100 mg (39%) of D3 as a yellow oil: ¹H NMR (300MHz, CDCl₃) δ 7.87 (s, 1H), 7.79 (d, J=7.9 Hz, 1H), 7.55-7.30 (m, 7H),7.28-7.19 (m, 1H), 7.13 (t, J=7.8 Hz, 1H), 5.03 (s, 2H); MS (ES) m/z:454 (M−H₂O+H⁺).

Replacing A2b with D3 and following the same procedure as in thepreparation of compound A2c gave compound D4 (88%): ¹H NMR (300 MHz,CDCl₃) δ 7.50-7.12 (m, 8H), 6.90 (t, J=7.7 Hz, 1H), 6.79-6.70 (m, 2H),4.57 (bd, J=8.2 Hz, 1H), 4.32 (m, 1H), 4.13 (brs, 1H), 3.98 (dd, J=10.7,8.3 Hz, 1H); MS (ES) m/z: 456 (M+H⁺).

Replacing A2d with D4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 7 (34%) andLower Rf compound 8 (eluent: 20% EtOAc in hexane). Spectrums of compound7 are as follows: ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.34 (m, 4H), 7.22-7.10(m, 4H), 7.01 (t, J=7.9 Hz, 1H), 6.81-6.76 (m, 2H), 4.87 (t, J=3.8 Hz,1H), 4.41 (m, 1H), 4.27 (dd, J=11.0, 3.1 Hz, 1H), 4.16 (dd, J=11.0, 4.6Hz, 1H), 3.83 (d, J=15.6 Hz, 1H), 3.31 (dd, J=15.7, 9.6 Hz, 1H), 2.46(d, J=3.5 Hz, 1H); MS (ES) m/z: 568 (M+H⁺).

Example 8

Spectrums of compound 8 (41%) are as follows: ¹H NMR (300 MHz, CDCl₃) δ7.40-7.31 (m, 4H), 7.20-6.99 (m, 5H), 6.89 (d, J=8.2 Hz, 1H), 6.78 (d,J=7.6 Hz, 1H), 4.55 (t, J=2.9 Hz, 1H), 4.36-4.20 (m, 3H), 3.70 (dd,J=15.7, 6.5 Hz, 1H), 3.55 (dd, J=15.7, 5.2 Hz, 1H), 2.29 (brs, 1H); MS(ES) m/z: 568 (M+H⁺).

Example 9

The racemic mixture D4 was separated by chiral HPLC (column: ChiralcelOJ; eluent: isocratic mixture of 90% heptane and 10% ethanol) to giveenantiomers E1 (first off HPLC column) and E2 (second off HPLC column).Spectrums of E1 are as following: [α]²⁰ _(D) +33.4° (c=1, CHCl₃); ¹H NMR(300 MHz, CDCl₃) δ 7.50-7.12 (m, 8H), 6.90 (t, J=7.7 Hz, 1H), 6.79-6.70(m, 2H), 4.57 (bd, J=8.2 Hz, 1H), 4.32 (m, 1H), 4.13 (brs, 1H), 3.98(dd, J=10.7, 8.3 Hz, 1H); MS (ES) m/z: 456 (M+H⁺).

Spectrums of E2 are as following: [α]²⁰ _(D) −29.0° (c=1, CHCl₃); ¹H NMR(300 MHz, CDCl₃) δ 7.50-7.12 (m, 8H), 6.90 (t, J=7.7 Hz, 1H), 6.79-6.70(m, 2H), 4.57 (bd, J=8.2 Hz, 1H), 4.32 (m, 1H), 4.13 (brs, 1H), 3.98(dd, J=10.7, 8.3 Hz, 1H); MS (ES) m/z: 456 (M+H⁺).

Replacing A2d with E1 and following the same procedure as in thepreparation of compound 1 and 2 gave compound 9 and 10. Spectrums ofcompound 9 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.34 (m,4H), 7.22-7.10 (m, 4H), 7.01 (t, J=7.9 Hz, 1H), 6.81-6.76 (m, 2H), 4.87(t, J=3.8 Hz, 1H), 4.41 (m, 1H), 4.27 (dd, J=11.0, 3.1 Hz, 1H), 4.16(dd, J=11.0, 4.6 Hz, 1H), 3.83 (d, J=15.6 Hz, 1H), 3.31 (dd, J=15.7, 9.6Hz, 1H), 2.46 (d, J=3.5 Hz, 1H); MS (ES) m/z: 568 (M+H⁺). Anal. Calcd.For C₂₅H₁₈F₉NO₄: C, 52.92; H, 3.20; N, 2.47. Found: C, 52.79; H, 3.00;N, 2.43.

Example 10

Spectrums of compound 10 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.40-7.31 (m, 4H), 7.20-6.99 (m, 5H), 6.89 (d, J=8.2 Hz, 1H), 6.78 (d,J=7.6 Hz, 1H), 4.55 (t, J=2.9 Hz, 1H), 4.36-4.20 (m, 3H), 3.70 (dd,J=15.7, 6.5 Hz, 1H), 3.55 (dd, J=15.7, 5.2 Hz, 1H), 2.29 (brs, 1H); MS(ES) m/z: 568 (M+H⁺).

Example 11

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with3-benzyl-benzaldehyde and following the same procedure as in thepreparation of compound A2a gave compound F1 (36%): ¹H NMR (300 MHz,CDCl₃) δ 7.60-7.50 (m, 2H), 7.48-7.32 (m, 6H), 7.25-7.20 (m, 1H), 5.12(s, 2H), 4.68 (s, 2H).

Replacing A2a with F1 and following the same procedure as in thepreparation of compound A2b gave compound F2 (70%): ¹H NMR (300 MHz,CDCl₃) δ 7.63 (s, 1H), 7.50-7.32 (m, 9H), 7.13 (bd, J=7.6 Hz, 1H), 6.91(t, J=7.9 Hz, 1H), 5.15 (s, 4H); MS (ES) m/z: 394 (M−H₂O).

Replacing A2b with F2 and following the same procedure as in thepreparation of compound A2c gave compound F3 (80%): ¹H NMR (300 MHz,CDCl₃) δ 7.45-7.22 (m, 6H), 7.02-6.89 (m, 4H), 6.66 (t, J=7.8 Hz, 1H),6.59 (d, J=8.0 Hz, 1H), 5.06 (s, 2H), 4.47 (bd, J=7.7 Hz, 1H), 4.41 (bd,J=10.6 Hz, 1H), 4.07-3.99 (m, 2H); MS (ES) m/z: 398 (M+2).

Replacing A2c with F3 and following the same procedure as in thepreparation of compound A2d gave compound F4 (89%): ¹H NMR (300 MHz,CDCl₃) δ 7.50-7.28 (m, 9H), 7.16 (d, J=8.1 Hz, 1H), 7.05 (s, 1H), 6.99(d, J=7.7 Hz, 1H), 6.95(dd, J=8.2, 2.5 Hz, 1H), 6.88 (t, J=7.7 Hz, 1H),6.74 (d, J=7.6 Hz, 1H), 6.70 (d, J=7.8 Hz, 1H), 5.07 (s, 2H), 4.52 (dd,J=8.5, 2.6 Hz, 1H), 4.30 (dd, J=10.6, 2.4 Hz, 1H), 4.11 (brs, 1H), 3.98(dd, J=10.3, 8.9 Hz, 1H); MS (ES) m/z: 478 (M+H⁺).

Replacing A2d with F4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 11 (45%) andlower Rf compound 12 (solvent for column: 20% EtOAc in hexane).Spectrums of compound 11 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.45-7.28 (m, 9H), 7.14 (d, J=7.8 Hz, 1H), 7.02-6.83 (m, 4H), 6.76 (m,2H), 5.06 (d, J=11.9 Hz, 1H), 5.00 (d, J=11.9 Hz, 1H), 4.75 (t, J=4.1Hz, 1H), 4.30-4.20 (m, 2H), 4.18-4.10 (m, 1H), 3.70 (d, J=15.5, 1 H),3.31 (dd, J=15.7, 9.6 Hz, 1H), 2.38 (brs, 1H); MS (ES) m/z: 590 (M+H⁺).

Example 12

Spectrums of compound 12 (45%) are as following: ¹H NMR (300 MHz, CDCl₃)δ 7.45-7.23 (m, 10H), 7.14 (d, J=7.9 Hz, 1H), 7.01 (t, J=7.9 Hz, 1H),6.92 (d, J=8.2 Hz, 1H), 6.80 (m, 3H), 5.04 (d, J=11.9 Hz, 1H), 4.96 (d,J=12.0 Hz, 1H), 4.45 (t, J=3.0 Hz, 1H), 4.22 (d, J=3.1 Hz, 2H), 4.12 (m,1H), 3.57 (m, 2H), 2.10 (brs, 1H); MS (ES) m/z: 590 (M+H⁺).

Example 13

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with2,2-difluoro-indan-5-carbaldehyde and following the same procedure as inthe preparation of compound A2a gave compound G1 (42%): ¹H NMR (300 MHz,CDCl₃) δ 7.78 (d, J=8.4 Hz, 1H), 7.71 (d, J=3.2 Hz, 1H), 7.18 (d, J=8.4Hz, 1H), 4.63 (s, 2H).

Replacing A2a with G1 and following the same procedure as in thepreparation of compound A2b gave compound G2 (39%): ¹H NMR (300 MHz,CDCl₃) δ 7.83 (s, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.39-7.34 (m, 2H), 7.15(d, J=8.4 Hz, 1H), 6.92 (d, J=7.9 Hz, 1H), 5.14 (s, 2H); MS (ES) m/z:368 (M−H₂O).

Replacing A2b with G2 and following the same procedure as in thepreparation of compound A2c gave compound G3 (94%): ¹H NMR (300 MHz,CDCl₃) δ 7.13-7.04 (m, 3H), 6.94 (d, J=7.9 Hz, 1H), 6.68 (t, J=7.9 Hz,1H), 6.61 (d, J=8.0 Hz, 1H), 4.50 (dd, J=8.1, 2.3 Hz, 1H), 4.36 (bd,J=10.8 Hz, 1H), 4.08 (brs, 1H), 3.99 (dd, J=10.7, 8.4 Hz, 1H); MS (ES)m/z: 370 (M).

Replacing A2c with G3 and following the same procedure as in thepreparation of compound A2d gave compound G4 (96%): ¹H NMR (300 MHz,CDCl₃) δ 7.50-7.39 (m, 3H), 7.20-7.10 (m, 3H), 7.06 (d, J=8.2 Hz, 1H),6.89 (t, J=7.8 Hz, 1H), 6.77 (d, J=7.6 Hz, 1H), 6.71 (d, J=7.8 Hz, 1H),4.55 (bd, J=5.7 Hz, 1H), 4.28 (dd, J=10.7, 2.1 Hz, 1H), 4.11 (brs, 1H),3.95 (dd, J=10.6, 8.3 Hz, 1H); MS (ES) m/z: 452 (M+H⁺).

Replacing A2d with G4 and following the same procedure as in thepreparation of compound 1 and 2 gave compound 13 and 14 (38%). Spectrumsof compound 13 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.42-7.32 (m,3H), 7.14 (d, J=7.6 Hz, 1H), 7.05-6.85 (m, 5H), 6.78 (d, J=7.6 Hz, 1H),4.52 (t, J=2.8 Hz, 1H), 4.25-4.13 (m, 3H), 3.69 (dd, J=15.7, 6.5 Hz,1H), 3.53 (dd, J=15.8, 5.2 Hz, 1H), 2.40 (brs, 1H); MS (ES) m/z: 564(M+H⁺).

Example 14

Spectrums of compound 14 (38%) are as following: ¹H NMR (300 MHz, CDCl₃)δ 7.45-7.34 (m, 3H), 7.15 (d, J=7.4 Hz, 1H), 7.07-6.96 (m, 4H),6.80-6.72 (m, 2H), 4.85 (t, J=3.8 Hz, 1H), 4.44 (bm, 1H), 4.25 (dd,J=10.9, 3.1 Hz, 1H), 4.12 (dd, J=11.0, 4.6 Hz, 1H), 3.82 (d, J=15.6 Hz,1H), 3.30 (dd, J=15.7, 9.7 Hz, 1H), 2.48 (d, J=3.1 Hz, 1H); MS (ES) m/z:564 (M+H⁺).

Example 15

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with3-trifluoromethylsulfanyl-benzaldehyde and following the same procedureas in the preparation of compound A2a gave compound H1 (53%): ¹H NMR(300 MHz, CDCl₃) δ 8.24 (s, 1H), 8.08 (m, 1H), 7.91 (d, J=7.8 Hz, 1H),7.59 (t, J=7.8 Hz, 1H), 4.69 (s, 2H).

Replacing A2a with H1 and following the same procedure as in thepreparation of compound A2b gave compound H2 (60%): ¹H NMR (300 MHz,CDCl₃) δ 8.22 (s, 1H), 8.01 (d, J=7.9 Hz, 1H), 7.80 (t, J=7.8 Hz, 1H),7.56 (t, J=7.8 Hz, 1H), 7.39 (m, 2H), 6.93 (t, J=7.9 Hz, 1H), 5.18 (s,2H); MS (ES) m/z: 388 (M−H₂O).

Replacing A2b with H2 and following the same procedure as in thepreparation of compound A2c gave compound H3 (94%): ¹H NMR (300 MHz,CDCl₃) δ 7.70-7.61 (m, 2H), 7.55-7.41 (m, 2H), 6.96 (dd, J=7.7, 1.7 Hz,1H), 6.72-6.60 (m, 2H), 4.56 (bd, J=8.3 Hz, 1H), 4.44-4.38 (m, 1H), 4.12(brs, 1H), 4.05 (dd, J=10.8, 2.5 Hz, 1H); MS (ES) m/z: 390 (M), 392(M+2).

Replacing A2c with H3 and following the same procedure as in thepreparation of compound A2d gave compound H4 (87%): ¹H NMR (300 MHz,CDCl₃) δ 7.70 (s, 1H), 7.64 (d, J=7.5 Hz, 1H), 7.54 (d, J=7.7 Hz, 1H),7.50-7.39 (m, 4H), 7.16 (d, J=8.1 Hz, 1H), 6.89 (t, J=7.7 Hz, 1H),6.80-6.71 (m, 2H), 4.60 (bd, J=6.5 Hz, 1H), 4.31 (d, J=10.7 Hz, 1H),4.15 (s, 1H), 4.00 (dd, J=10.7, 8.3 Hz, 1H); MS (ES) m/z: 472 (M+H⁺).

Replacing A2d with H4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 15 (43%) andlower Rf compound 16 (solvent for column: 20% EtOAc in hexane).Spectrums of compound 15 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.61 (d, J=6.9 Hz, 1H), 7.56 (s, 1H), 7.45-7.33 (m, 5H), 7.14 (d, J=7.1Hz, 1H), 7.02 (t, J=7.9 Hz, 1H), 6.81-6.76 (m, 2H), 4.88 (t, J=3.8 Hz,1H), 4.41 (m, 1H), 4.27 (dd, J=11.0, 3.2 Hz, 1H), 4.17 (t, J=11.0, 4.6Hz, 1H), 3.83 (t, J=15.7 Hz, 1H), 3.31 (dd, J=15.7, 9.6 Hz, 1H), 2.49(brs, 1H); MS (ES) m/z: 584 (M+H⁺).

Example 16

Spectrums of compound 16 (40%) are as following: ¹H NMR (300 MHz, CDCl₃)δ 7.60 (d, J=7.3 Hz, 1H), 7.52 (s, 1H), 7.44-7.31 (m, 5H), 7.14 (d,J=7.8 Hz, 1H), 7.03 (t, J=7.9 Hz, 1H), 6.90 (d, J=8.2 Hz, 1H), 6.79 (d,J=7.6 Hz, 1H), 4.57 (s, 1H), 4.36-4.19 (m, 3H), 3.70 (dd, J=14.6, 6.2Hz, 1H), 3.55 (dd, J=15.7, 5.2 Hz, 1H), 2.30 (brs, 1H); MS (ES) m/z: 584(M+H⁺).

Example 17

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with3-ethoxy-benzaldehyde and following the same procedure as in thepreparation of compound A2a gave compound I1 (40%): ¹H NMR (300 MHz,CDCl₃) δ 7.47 (m, 2H), 7.39 (t, J=7.9 Hz, 1H), 7.14 (m, 1H), 4.70 (s,2H), 4.09 (q, J=7.0 Hz, 2H), 1.44 (t, J=7.0 Hz, 3H).

Replacing A2a with I1 and following the same procedure as in thepreparation of compound A2b gave compound I2 (62%): ¹H NMR (300 MHz,CDCl₃) δ 7.53 (s, 1H), 7.40-7.33 (m, 4H), 7.07-7.03 (m, 1H), 6.91 (t,J=8.0 Hz, 1H), 5.16 (s, 2H), 4.12 (q, J=7.0 Hz, 2H), 1.45 (t, J=7.0 Hz,3H); MS (ES) m/z: 332 (M−H₂O).

Replacing A2b with I2 and following the same procedure as in thepreparation of compound A2c gave compound I3 (99%): ¹H NMR (300 MHz,CDCl₃) δ 7.29 (t, J=8.0 Hz, 1H), 6.98-6.84 (m, 4H), 6.67 (t, J=7.9 Hz,1H), 6.61 (d, J=7.9 Hz, 1H), 4.48 (bd, J=8.7 Hz, 1H), 4.43-4.39 (m, 1H),4.09-3.99 (m, 4H), 1.42 (t, J=7.0 Hz, 3H); MS (ES) m/z: 334 (M), 336(M+2).

Replacing A2c with I3 and following the same procedure as in thepreparation of compound A2d gave compound I4 (87%): ¹H NMR (300 MHz,CDCl₃) δ 7.51-7.38 (m, 3H), 7.28 (t, J=8.1 Hz, 1H), 7.15 (d, J=8.1 Hz,1H), 6.98-6.95 (m, 2H), 6.95-6.84 (m, 2H), 6.76-6.67 (m, 2H), 4.51 (dd,J=8.5, 2.5 Hz, 1H), 4.31 (d, J=10.5 Hz, 1H), 4.11-3.92 (m, 4H), 1.41 (t,J=7.0 Hz, 3H); MS (ES) m/z: 416 (M+H⁺).

Replacing A2d with I4 and following the same procedure as in thepreparation of compound 1 and 2 gave compound higher Rf compound 17(43%) and lower Rf compound 18 (solvent for column: 20% EtOAc inhexane). Spectrums of compound 17 are as following: ¹H NMR (300 MHz,CDCl₃) δ 7.47-7.36 (m, 3H), 7.29-7.22 (m, 1H), 7.15 (d, J=8.1 Hz, 1H),6.99 (t, J=7.9 Hz, 1H), 6.88-6.75 (m, 5H), 4.77 (dd, J=5.2, 3.3 Hz, 1H),4.34 (t, J=7.4 Hz, 1H), 4.26 (dd, J=10.9, 3.2 Hz, 1H), 4.15 (dd, J=10.9,5.4 Hz, 1H), 4.00 (q, J=7.0 Hz, 2H), 3.78 (d, J=5.7 Hz, 1H), 3.37 (dd,J=15.7, 9.7 Hz, 1H), 2.49 (s, 1H), 1.39 (t, J=7.0 Hz, 3H); MS (ES) m/z:528 (M+H⁺).

Example 18

Spectrums of compound 18 (43%) are as following: ¹H NMR (300 MHz, CDCl₃)δ 7.45-7.34 (m, 3H), 7.25 (t, J=7.9 Hz, 1H), 7.13 (d, J=7.9 Hz, 1H),7.00 (t, J=7.9 Hz, 1H), 6.90-6.75 (m, 5H), 4.47 (t, J=3.3 Hz, 1H),4.32-4.20 (m, 3H), 3.98 (q, J=7.0 Hz, 2H), 3.69-3.58 (m, 2H), 2.23 (brs,1H), 1.38 (t, J=7.0 Hz, 3H); MS (ES) m/z: 528 (M+H⁺).

Example 19

To a solution of compound 14 (25 mg, 0.044 mmol) in CH₂Cl₂ (1 mL) at 4°C. was added Dess-Martin periodinane (28 mg, 0.066 mmol). After stirringat 4° C. for 2 h, Na₂S₂O₃ and NaHCO₃ aqueous solution were added and thesolution was stirred vigorously for ˜15 min. The mixture was extractedwith CH₂Cl₂ and the combined organic extracts were dried (Na₂SO₄) andconcentrated to give compound 19 as an oil: ¹H NMR (300 MHz, CDCl₃) δ7.47-7.38 (m, 3H), 7.17 (d, J=7.9 Hz, 1H), 7.09-6.92 (m, 4H), 6.82 (d,J=7.7 Hz, 1H), 6.49 (d, J=8.1 Hz, 1H), 4.65 (d, J=19.6 Hz, 1H), 4.58 (d,J=5.9 Hz, 1H), 4.30 (dd, J=11.0, 3.2 Hz, 1H), 4.17-4.10 (m, 2H); MS (ES)m/z: 581 (M+K⁺).

Example 20

A mixture of A2d (40 mg, 0.082 mmol), pyridine (0.040 mL, 0.50 mmol) andmethyl chloroformate (0.026 mL, 0.34 mmol)) in CH₂Cl₂ (1 mL) was stirredat room temperature for 24 h. The mixture was concentrated and purifiedby column chromatography to afford 11 mg (25%) of compound 20 as an oil:¹H NMR (300 MHz, CDCl₃) δ 7.93 (t, J=3.9 Hz, 1H), 7.40-7.09 (m, 8H),7.01 (m, 2H), 5.86 (tt, J=53.1, 2.8 Hz, 1H), 5.72 (m, 1H), 4.62 (dd,J=11.4, 2.4 Hz, 1H), 4.39 (dd, J=11.4, 3.3 Hz, 1H), 3.85 (s, 3H); MS(ES) m/z: 546 (M+H⁺).

Example 21

Replacing methyl chloroformate with ethyl chloroformate and followingthe same procedure as in the preparation of compound 20 gave compound 21(76%): ¹H NMR (300 MHz, CDCl₃) δ 7.99 (t, J=4.9 Hz, 1H), 7.42-7.09 (m,8H), 7.02 (s, 1H), 7.00 (s, 1H), 5.86 (tt, J=53.1, 2.8 Hz, 1H), 5.71 (m,1H), 4.59 (dd, J=11.4, 2.5 Hz, 1H), 4.38 (dd, J=11.4, 3.4 Hz, 1H),4.37-4.24 (m, 2H), 1.30 (t, J=7.1 Hz, 3H); MS (ES) m/z: 560 (M+H⁺).

Example 22

A mixture of A2d (50 mg, 0.10 mmol), TBSOCH₂CHO (54 mg, 0.31 mmol),molecular sieves (3 Å, 0.62 g) in EtOH (1.2 mL) was heated at 65° C. for1 h and cooled to room temperature.

A mixture of NaBH₃CN (26 mg, 0.41 mmol), ZnCl₂ (0.5 M in THF, 0.41 mL,0.20 mmol) and EtOH (0.5 mL) was stirred at room temperature for 1 h andthen was added to the above mixture. The resulting reaction mixture wasstirred at room temperature overnight and filtered. The filtrate wasconcentrated and partitioned between CH₂Cl₂ and water. The organic layerwas dried (Na₂SO₄), concentrated and purified by column chromatographyto afford 22 mg (33%) of compound 22: ¹H NMR (400 MHz, CDCl₃) δ7.46-7.32 (m, 4H), 7.21-7.10 (m, 4H), 6.98 (t, J=7.9 Hz, 1H), 6.85 (d,J=8.2 Hz, 1H), 6.70 (d, J=7.6 Hz, 1H), 5.89 (bt, J=53.1 Hz, 1H), 4.73(t, J=3.7 Hz, 1H), 4.21 (dd, J=10.9, 3.2 Hz, 1H), 4.14 (dd, J=10.9, 4.4Hz, 1H), 3.93-3.85 (m, 1H), 3.70-3.51 (m, 2H), 3.32-3.23 (m, 1H), 0.87(s, 9H), 0.00 (s, 6H); MS (ES) m/z: 646 (M+H⁺).

Example 23

To a solution of compound 22 (160 mg, 0.248 mmol) in THF (2 mL) wasadded Bu₄NF (1.0 M in THF, 0.3 mL, 0.3 mmol). After stirring at roomtemperature for 30 min, the reaction mixture was concentrated andpurified by column chromatography to afford 87 mg (>66%) of compound 23:¹H NMR (400 MHz, CDCl₃) δ 7.45-7.32 (m, 4H), 7.21-7.10 (m, 4H), 6.98 (t,J=7.9 Hz, 1H), 6.88 (d, J=7.8 Hz, 1H), 6.73 (d, J=7.6 Hz, 1H), 5.88 (tt,J=53.1, 2.7 Hz, 1H), 4.67 (t, J=3.5 Hz, 1H), 4.26 (dd, J=10.9, 3.1 Hz,1H), 4.18 (dd, J=10.9, 4.1 Hz, 1H), 3.92-3.83 (m, 1H), 3.79-3.71 (m,1H), 3.60 (dt, J=15.2, 5.0 Hz, 1H), 3.41-3.31 (m, 1H), 1.26 (t, J=7.1Hz, 1H); MS (ES) m/z: 532 (M+H⁺).

Example 24

To a solution of compound 23 (11 mg, 0.021 mmol) in THF (0.6 mL) wasadded NaH (60% in mineral oil, much excess amount) followed by MeI (muchexcess amount). The reaction mixture was stirred at room temperature for5 h and then partitioned between CH₂Cl₂ and water. The organic layer wasdried (Na₂SO₄), concentrated and purified by column chromatography toafford 13 mg (100%) of compound 24 as a clear oil: ¹H NMR (400 MHz,CDCl₃) δ 7.44-7.31 (m, 4H), 7.20-7.10 (m, 4H), 6.98 (t, J=7.9 Hz, 1H),6.84 (d, J=8.2 Hz, 1H), 6.71 (d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1, 2.7Hz, 1H), 4.69 (t, J=3.5 Hz, 1H), 4.21 (dd, J=10.8, 3.1 Hz, 1H), 4.15(dd, J=10.8, 4.2 Hz, 1H), 3.70-3.56 (m, 2H), 3.49-3.41 (m, 1H),3.39-3.31 (m, 1H), 3.29 (s, 3H); MS (ES) m/z: 546 (M+H⁺).

Example 25

Replacing TBSOCH₂CHO with TBSOCH₂CH₂CHO and following the same procedureas in the preparation of compound 22 gave compound 25 (22%): ¹H NMR (300MHz, CDCl₃) δ 7.43-7.30 (m, 4H), 7.19-7.09 (m, 4H), 7.00-6.87 (m, 2H),6.67 (d, J=7.4 Hz, 1H), 6.70 (d, J=7.5 Hz, 1H), 5.86 (bt, J=53.1 Hz,1H), 4.54 (t, J=3.6 Hz, 1H), 4.23-4.10 (m, 2H), 3.60 (t, J=5.7 Hz, 2H),3.58-3.44 (m, 1H), 3.30-3.18 (m, 1H), 1.83-1.65 (m, 2H), 0.86 (s, 9H),0.00 (s, 6H); MS (ES) m/z: 660 (M+H⁺).

Example 26

Replacing 22 with 25 and following the same procedure as in thepreparation of compound 23 gave compound 26: ¹H NMR (300 MHz, CDCl₃) δ7.45-7.31 (m, 4H), 7.21-7.10 (m, 4H), 6.99 (t, J=7.8 Hz, 1H), 6.88 (d,J=7.6 Hz, 1H), 6.70 (d, J=7.5 Hz, 1H), 5.88 (tt, J=53.1, 2.8 Hz, 1H),4.56 (t, J=3.6 Hz, 1H), 4.22 (dd, J=10.8, 3.3 Hz, 1H), 4.16 (dd, J=11.0,4.2 Hz, 1H), 3.68 (t, J=5.9 Hz, 2H), 3.63-3.51 (m, 1H), 3.31-3.19 (m,1H), 1.95-1.72 (m, 2H), 1.36 (brs, 1H); MS (ES) m/z: 546 (M+H⁺).

Example 27

Replacing 23 with 26 and following the same procedure as in thepreparation of compound 24 gave compound 27: ¹H NMR (400 MHz, CDCl₃) δ7.46-7.31 (m, 4H), 7.21-7.10 (m, 4H), 6.99 (t, J=8.0 Hz, 1H), 6.86 (d,J=8.2 Hz, 1H), 6.69 (d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1, 2.6 Hz, 1H),4.52 (t, J=3.5 Hz, 1H), 4.21 (dd, J=10.9, 3.1 Hz, 1H), 4.16 (dd, J=10.8,4.1 Hz, 1H), 3.59-3.50 (m, 1H), 3.41-3.32 (m, 2H), 3.30 (s, 3H),3.28-3.18 (m, 1H), 1.89-1.79 (m, 2H); MS (ES) m/z: 560 (M+H⁺).

Example 28

To a solution of 23 (87 mg, 0.16 mmol) and Et₃N (0.046 mL, 0.33 mmol) inCH₂Cl₂ (2 mL) at 0° C. was added methanesulfonyl chloride (0.019 mL,0.25 mmol). The cooling bath was removed and the solution was stirred atroom temperature for 3 h. The reaction mixture was concentrated andpurified by column chromatography to give 97 mg (100%) of compound O1 asa clear oil: ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.33 (m, 4H), 7.22-7.11 (m,4H), 7.01 (t, J=7.9 Hz, 1H), 6.82 (d, J=8.1 Hz, 1H), 6.77 (d, J=7.6 Hz,1H), 5.89 (tt, J=53.1, 2.8 Hz, 1H), 4.64 (t, J=3.8 Hz, 1H), 4.48-4.38(m, 1H), 4.31-4.21 (m, 2H), 4.16 (dd, J=11.1, 4.6 Hz, 1H), 3.79 (dt,J=15.8, 5.2 Hz, 1H), 3.59-3.50 (m, 1H), 2.91 (s, 3H); MS (ES) m/z: 610(M+H⁺).

A mixture of O1 (20 mg, 0.033 mmol), HNMe₂.HCl (67 mg, 0.82 mmol),Cs₂CO₃ (24 mg, 0.074 mmol) and Et₃N (0.14 mL, 1.01 mmol) in CH₃CN (1 mL)was heated in a sealed tube at 70° C. for 2 days. After cooling to roomtemperature, the reaction mixture was concentrated and partitionedbetween CH₂Cl₂ and water. The organic layer was dried (Na₂SO₄),concentrated and purified by column chromatography to give 7 mg (38%) ofcompound 28 as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.48-7.31 (m,4H), 7.22-7.10 (m, 4H), 6.99 (t, J=7.9 Hz, 1H), 6.84 (d, J=7.7 Hz, 1H),6.71 (d, J=7.5 Hz, 1H), 5.88 (bt, J=53.1 Hz, 1H), 4.62 (t, J=3.8 Hz,1H), 4.20 (dd, J=10.8, 3.2 Hz, 1H), 4.14 (dd, J=10.9, 4.6 Hz, 1H),3.59-3.45 (m, 1H), 3.30-3.18 (m, 1H), 2.62-2.50 (m, 1H), 2.45-2.32 (m,1H), 2.20 (s, 6H); MS (ES) m/z: 559 (M+H⁺).

Example 29

A mixture of O1 (17 mg, 0.028 mmol), morpholine (0.07 mL, 0.080 mmol)and Cs₂CO₃ (11 mg, 0.034 mmol) in CH₃CN (1 mL) was heated in a sealedtube at 65° C. overnight. After cooling to room temperature, thereaction mixture was concentrated and partitioned between CH₂Cl₂ andwater. The organic layer was dried (Na₂SO₄), concentrated and purifiedby column chromatography to give 3 mg (18%) of compound 29: ¹H NMR (400MHz, CDCl₃) δ 7.46-7.35 (m, 4H), 7.21-7.11 (m, 4H), 6.99 (t, J=7.9 Hz,1H), 6.84 (d, J=8.0 Hz, 1H), 6.71 (d, J=7.6 Hz, 1H), 5.89 (tt, J=53.1,2.7 Hz, 1H), 4.66 (t, J=3.9 Hz, 1H), 4.21 (dd, J=10.8, 3.3 Hz, 1H), 4.14(dd, J=10.9, 4.8 Hz, 1H), 3.67 (t, J=4.6 Hz, 4H), 3.59-3.49 (m, 1 H),3.31-3.21 (m, 1H), 2.18-2.58 (m, 1H), 2.50-2.35 (m, 5H); MS (ES) m/z:601 (M+H⁺).

Example 30

Replacing morpholine with piperazine and following the same procedure asin the preparation of compound 29 gave compound 30 (oil, 41%): ¹H NMR(300 MHz, CDCl₃) δ 7.47-7.31 (m, 4H), 7.21-7.10 (m, 4H), 6.98 (t, J=7.9Hz, 1H), 6.84 (d, J=8.2 Hz, 1H), 6.70 (d, J=7.6 Hz, 1 H), 5.89 (tt,J=53.1, 2.7 Hz, 1H), 4.65 (t, J=3.7 Hz, 1H), 4.25-4.09 (m, 2H),3.60-3.49 (m, 1H), 3.32-3.20 (m, 1H), 2.69-2.58 (m, 1H), 2.51-2.29 (m,5H), 1.44-1.21 (m, 4H); MS (ES) m/z: 600 (M+H⁺).

Example 31

A mixture of 30 (8 mg, 0.013 mmol) and HCHO (37% in water, 13 mg, 0.13mmol) in CH₂Cl₂ was stirred at room temperature for 30 min. NaB(OAc)₃H(14 mg, 0.066 mmol) was added and the reaction mixture was stirred atroom temperature for 1 h. NaHCO₃ saturated solution was added and theaqueous layer was extracted with CH₂Cl₂. The combined organic phaseswere dried (Na₂SO₄), concentrated and purified by column chromatographyto get 3 mg (37%) of compound 31 as a yellow oil: ¹H NMR (300 MHz,CDCl₃) δ 7.48-7.22 (m, 4H), 7.22-7.10 (m, 4H), 6.98 (t, J=7.8 Hz, 1H),6.84 (d, J=8.0 Hz, 1H), 6.70 (d, J=7.0 Hz, 1H), 5.89 (tt, J=53.1, 2.6Hz, 1H), 4.65 (t, J=3.6 Hz, 1H), 4.20 (dd, J=10.9, 3.2 Hz, 1H), 4.13(dd, J=10.9, 4.6 Hz, 1H), 3.60-3.48 (m, 1H), 3.31-3.19 (m, 1H),2.20-2.59 (m, 1H), 2.44 (m, 5H), 2.28 (s, 3H), 1.82 (s, 4H); MS (ES)m/z: 614 (M+H⁺).

Example 32

Replacing TBSOCH₂CHO with HCHO and following the same procedure as inthe preparation of compound 22 gave compound 32 (55%): ¹H NMR (300 MHz,CDCl₃) δ 7.48-7.32 (m, 4H), 7.23-7.11 (m, 4H), 7.00 (t, J=7.9 Hz, 1H),6.83 (d, J=8.1 Hz, 1H), 6.74 (d, J=7.6 Hz, 1H), 5.89 (tt, J=53.1, 2.8Hz, 1H), 4.39 (dd, J=5.7, 3.1 Hz, 1H), 4.26 (dd, J=11.0, 3.2 Hz, 1H),4.10 (dd, J=10.9, 5.8 Hz, 1H), 2.85 (s, 3H); MS (ES) m/z: 502 (M+H⁺).

Example 33

Replacing A2b with A2d, adding CH₃CHO and following the same procedureas in the preparation of compound A2c gave compound 33 (clear oil, 79%):¹H NMR (300 MHz, CDCl₃) δ 7.46-7.33 (m, 4H), 7.25-7.11 (m, 4H), 6.99 (t,J=7.9 Hz, 1H), 6.85 (d, J=7.4 Hz, 1H), 6.70 (d, J=7.6 Hz, 1H), 5.88 (tt,J=53.1, 2.8 Hz, 1H), 4.51 (t, J=4.1 Hz, 1H), 4.21-4.11 (m, 2H),3.59-3.48 (m, 1H), 3.20-3.10 (m, 1H), 1.11 (t, J=7.1 Hz, 3 H); MS (ES)m/z: 516 (M+H⁺).

Example 34

Replacing CH₃CHO with CH₃CH₂CHO and following the same procedure as inthe preparation of compound 33 gave compound 34 (clear oil, 92%): ¹H NMR(300 MHz, CDCl₃) δ 7.45-7.31 (m, 4H), 7.21-7.09 (m, 4H), 6.98 (t, J=7.9Hz, 1H), 6.80 (d, J=8.2 Hz, 1H), 6.68 (d, J=7.6 Hz, 1H), 5.88 (tt,J=53.1, 2.8 Hz, 1H), 4.53 (t, J=3.7 Hz, 1H), 4.20 (dd, J=10.9, 3.3 Hz,1H), 4.15 (dd, J=10.8, 4.3 Hz, 1H), 3.46-3.33 (m, 1H), 3.08-2.93 (m,1H), 1.70-1.52 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ES) m/z: 530 (M+H⁺).

Example 35

Replacing 2-trifluoromethyl-oxirane with 2-methyl-oxirane and followingthe same procedure as in the preparation of compound 3 and 4 gavecompound 35 and 36. The spectrums of compound 35 are as following: ¹HNMR (400 MHz, CDCl₃) δ 7.44-7.32 (m, 4H), 7.19-7.09 (m, 4H), 6.98 (t,J=7.9 Hz, 1H), 6.82 (d, J=7.4 Hz, 1H), 6.73 (d, J=7.6 Hz, 1H), 5.88 (tt,J=53.1, 2.7 Hz, 1H), 4.77 (t, J=3.1 Hz, 1H), 4.30 (dd, J=10.9, 3.0 Hz,1H), 4.32-4.17 (m, 2H), 3.46 (dd, J=15.2, 2.4 Hz, 1H), 3.05 (dd, J=15.2,9.7 Hz, 1H), 1.82 (brs, 1H), 1.18 (d, J=6.3 Hz, 3H); MS (ES) m/z: 546(M+H⁺).

Example 36

The spectrums of compound 36 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.42-7.30 (m, 4H), 7.19-7.08 (m, 4H), 7.01-6.91 (m, 2H), 6.73 (d, J=7.3Hz, 1H), 5.87 (tt, J=53.1, 2.6 Hz, 1H), 4.61 (d, J=2.4 Hz, 1H), 4.29(dd, J=10.8, 2.8 Hz, 1H), 4.24 (dd, J=10.8, 2.7 Hz, 1H), 4.20-4.12 (m,1H), 3.49 (dd, J=15.0, 7.6 Hz, 1H), 3.15 (dd, J=15.1, 4.8 Hz, 1 H), 1.67(brs, 1H), 1.24 (d, J=6.2 Hz, 3H); MS (ES) m/z: 546 (M+H⁺).

Example 37

To a solution of compound 3 (27 mg, 0.045 mmol) in CH₂Cl₂ (1.5 mL) at 4°C. was added Dess-Martin periodinane (30 mg, 0.071 mmol). After stirringat 4° C. for 30 min and then room temperature for another 30 min,Na₂S₂O₃ and NaHCO₃ aqueous solution were added and the solution wasstirred vigorously for ˜5 min. The solution was extracted with CH₂Cl₂and the combined organic extracts were dried (Na₂SO₄), concentrated andpurified by column chromatography to give a mixture of 39 and hydrate.The mixture was treated with 2 M HCl/Et₂O in CH₂Cl₂ (2 mL) for 3 h,washed with water, dried (Na₂SO₄) and concentrated to afford purecompound 37 (19 mg, 71%): ¹H NMR (300 MHz, CDCl₃) δ 7.49-7.37 (m, 4H),7.29-7.09 (m, 4H), 6.95 (t, J=7.9 Hz, 1H), 6.81 (d, J=7.6 Hz, 1H), 6.49(d, J=7.9 Hz, 1H), 5.89 (bt, J=53.0 Hz, 1H), 4.70-4.59 (m, 2H), 4.32(dd, J=11.1, 3.1 Hz, 1H), 4.20-4.08 (m, 2H); MS (ES) m/z: 616(M+H₂O+H⁺).

Example 38

To a solution of compound 35 (36 mg, 0.066 mmol) in CH₂Cl₂ (1.5 mL) at4° C. was added Dess-Martin periodinane (56 mg, 0.13 mmol). Afterstirring at 4° C. for 45 min, Na₂S₂O₃ and NaHCO₃ aqueous solution wereadded and the solution was stirred vigorously for ˜10 min. The solutionwas extracted with CH₂Cl₂ and the combined organic extracts were dried(Na₂SO₄), concentrated and purified by column chromatography to givecompound 38 (10 mg, 28%): ¹H NMR (400 MHz, CDCl₃) δ 7.47-7.36 (m, 4H),7.23-7.12 (m, 4H), 6.93 (t, J=7.9 Hz, 1H), 6.75 (d, J=7.7 Hz, 1H), 6.48(d, J=8.1 Hz, 1H), 5.89 (tt, J=53.1, 2.8 Hz, 1H), 4.61 (dd, J=5.3, 3.3Hz, 1H), 4.31 (dd, J=11.0, 3.3 Hz, 1H), 4.21 (d, J=18.7 Hz, 1H), 4.17(dd, J=11.0, 5.5 Hz, 1H), 3.74 (d, J=8.7 Hz, 1H), 2.13 (s, 3H); MS (ES)m/z: 544 (M+H⁺).

Example 39

A mixture of O1 (33 mg, 0.054 mmol) and NH₃ (2 M in MeOH, 2 mL, 4 mmol)in a sealed tube was heated at 70° C. for 23 h. After cooling to roomtemperature, the reaction mixture was concentrated and partitionedbetween CH₂Cl₂ and saturated NaHCO₃ solution. The organic layer wasdried (Na₂SO₄) and concentrated to give 30 mg (100%) of compound 39: ¹HNMR (300 MHz, CDCl₃) δ 7.46-7.32 (m, 4H), 7.21-7.10 (m, 4H), 6.98 (t,J=7.9 Hz, 1H), 6.87 (d, J=7.3 Hz, 1H), 6.71 (d, J=7.5 Hz, 1H), 5.88 (tt,J=53.1, 2.8 Hz, 1H), 4.61 (t, J=3.3 Hz, 1H), 4.24 (dd, J=10.8, 3.1 Hz,1H), 4.17 (dd, J=10.8, 4.1 Hz, 1H), 3.57-3.42 (m, 1H), 3.29-3.15 (m,1H), 3.05-2.80 (m, 2H); MS (ES) m/z: 531 (M+H⁺).

Example 40

A mixture of compound 39 (11 mg, 0.021 mmol), acetyl chloride (1 drop)and Et₃N (0.016 mL, 0.11 mmol) in CH₂Cl₂ (1 mL) was heated for 24 h andconcentrated. The residue was purified by column chromatography to give7 mg (59%) of compound 40: ¹H NMR (300 MHz, CDCl₃) δ 7.45-7.32 (m, 4H),7.21-7.10 (m, 4H), 7.05-6.95 (m, 2H), 6.73 (dd, J=6.9, 2.2 Hz, 1H), 5.89(tt, J=53.1, 2.8 Hz, 1H), 5.46 (brs, 1H), 4.54 (t, J=3.6 Hz, 1H),4.23-4.11 (m, 2H), 3.58-3.35 (m, 4H), 1.86 (m, 3H); MS (ES) m/z: 573(M+H⁺).

Example 41

Replacing acetyl chloride with methyl chloroformate and following thesame procedure as in the preparation of compound 40 gave compound 41: ¹HNMR (400 MHz, CDCl₃) δ 7.44-7.31 (m, 4H), 7.20-7.10 (m, 4H), 7.04-6.93(m, 2H), 6.73 (d, J=7.7 Hz, 1H), 5.89 (tt, J=53.0, 2.6 Hz, 1H), 4.71(brs, 1H), 4.55 (t, J=3.6 Hz, 1H), 4.22 (dd, J=11.0, 3.1 Hz, 1H), 4.16(dd, J=11.0, 4.0 Hz, 1H), 3.65 (s, 3H), 3.59-3.49 (m, 1H), 3.34 (m, 3H);MS (ES) m/z: 589 (M+H⁺).

Example 42

Replacing 23 with 41 and following the same procedure as in thepreparation of compound 24 gave compound 42: ¹H NMR (400 MHz, CDCl₃) δ7.46-7.32 (m, 4H), 7.23-7.11 (m, 4H), 7.05-6.99 (m, 2H), 6.73 (m, 1H),5.92 (bt, J=52.9 Hz, 1H), 4.56 (d, J=25.0 Hz, 1H), 4.24-4.10 (m, 2H),3.65 (s, 3H), 3.55-3.20 (m, 4H), 2.88 (s, 3H); MS (ES) m/z: 603 (M+H⁺).

Example 43

Replacing 23 with 39 and following the same procedure as in thepreparation of compound O1 gave compound 43: ¹H NMR (400 MHz, CDCl₃) δ7.42-7.35 (m, 4H), 7.21-7.10 (m, 4H), 7.01 (t, J=7.9 Hz, 1H), 6.88 (d,J=8.2 Hz, 1H), 6.76 (d, J=7.6 Hz, 1H), 5.89 (tt, J=53.1, 2.8 Hz, 1H),4.59 (t, J=3.6 Hz, 1H), 4.35 (t, J=6.4 Hz, 1H), 4.26 (dd, J=11.0, 3.2Hz, 1H), 4.17 (dd, J=11.0, 4.3 Hz, 1H), 3.66-3.57 (m, 1H), 3.49-3.19 (m,3H), 2.89 (s, 3H); MS (ES) m/z: 609 (M+H⁺).

Example 44

Replacing 23 with 39 and following the same procedure as in thepreparation of compound 24 gave compound 44: ¹H NMR (400 MHz, CDCl₃) δ7.45-7.35 (m, 4H), 7.26-7.11 (m, 4H), 7.01 (t, J=8.0 Hz, 1H), 6.88 (d,J=7.0 Hz, 1H), 6.74 (d, J=7.6 Hz, 1H), 5.90 (tt, J=53.1, 2.8 Hz, 1H),4.62 (t, J=3.9 Hz, 1H), 4.24 (dd, J=11.0, 3.2 Hz, 1H), 4.16 (dd, J=11.0,4.7 Hz, 1H), 3.68-3.58 (m, 1H), 3.44-3.32 (m, 2H), 3.19-3.09 (m, 1H),2.80 (s, 3H), 2.76 (s, 3H); MS (ES) m/z: 623 (M+H⁺).

Example 45

Replacing CH₃CHO with (R)-(+)-2,2-dimethyl-[1,3]dioxolane-4-carbaldehydeand following the same procedure as in the preparation of compound 33gave compound 45 and 46. The spectrums of compound 45 are as following:¹H NMR (300 MHz, CDCl₃) δ 7.47-7.31 (m, 4H), 7.21-7.11 (m, 4H), 6.98 (t,J=7.9 Hz, 1H), 6.81 (d, J=7.6 Hz, 1H), 6.72 (d, J=7.6 Hz, 1H), 5.88 (tt,J=53.2, 2.8 Hz, 1H), 4.83 (t, J=3.8 Hz, 1H), 4.50-4.41 (m, 1H), 4.24(dd, J=10.8, 3.2 Hz, 1H), 4.14 (dd, J=10.9, 4.5 Hz, 1H), 3.97 (dd,J=8.3, 6.4 Hz, 1H), 3.58 (dd, J=15.5, 3.1 Hz, 1H), 3.47 (dd, J=8.3, 6.6Hz, 1H), 3.22 (dd, J=15.5, 8.1 Hz, 1H), 1.38 (s, 3H), 1.31 (s, 3H); MS(ES) m/z: 602 (M+H⁺).

Example 46

The spectrums of compound 46 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.42-7.31 (m, 4H), 7.19-7.10 (m, 3H), 7.07 (s, 1H), 6.99 (t, J=7.9 Hz,1H), 6.84 (d, J=7.7 Hz, 1H), 6.72 (d, J=7.3 Hz, 1H), 5.87 (bt, J=53.1Hz, 1H), 4.65 (t, J=2.9 Hz, 1H), 4.38-4.27 (m, 2H), 4.21 (dd, J=10.9,3.1 Hz, 1H), 4.06 (dd, J=8.1, 6.1 Hz, 1H), 3.70 (t, J=7.5 Hz, 1H), 3.62(dd, J=15.3, 4.6 Hz, 1H), 3.31 (dd, J=15.4, 5.9 Hz, 1H), 1.40 (s, 3H),1.33 (s, 3H); MS (ES) m/z: 602 (M+H⁺).

Example 47

A mixture of compound 45 (5 mg) and PTSA (11 mg) in MeOH (1 mL) wasstirred for 1 h and concentrated. The residue was purified by PLC (50%EtOAc in hexane) to give compound 47: ¹H NMR (400 MHz, CDCl₃) δ7.44-7.32 (m, 4H), 7.20-7.10 (m, 4H), 6.98 (t, J=7.9 Hz, 1H), 6.85 (d,J=8.2 Hz, 1H), 6.74 (d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1, 2.8 Hz, 1H),4.77 (t, J=3.4 Hz, 1H), 4.29 (dd, J=10.9, 3.1 Hz, 1H), 4.20 (dd, J=10.9,4.0 Hz, 1H), 4.10 (m, 1H), 3.70 (d, J=10.8 Hz, 1H), 3.56-3.48 (m, 2H),3.22 (dd, J=15.3, 9.1 Hz, 1H), 2.27 (brs, 1H), 1.78 (brs, 1H); MS (ES)m/z: 562 (M+H⁺).

Example 48

Replacing 45 with 46 and following the same procedure as in thepreparation of compound 47 gave compound 48: ¹H NMR (400 MHz, CDCl₃) δ7.42-7.31 (m, 4H), 7.19-7.08 (m, 4H), 7.00 (t, J=7.9 Hz, 1 H), 6.92 (d,J=7.2 Hz, 1H), 6.73 (d, J=6.1 Hz, 1H), 5.88 (bt, J=53.2 Hz, 1H), 4.63(t, J=3.0 Hz, 1H), 4.28 (dd, J=10.7, 3.0 Hz, 1H), 4.23 (dd, J=10.8, 3.1Hz, 1H), 4.08 (m, 1H), 3.79 (d, J=14.4 Hz, 1H), 3.63-3.53 (m, 2H), 3.30(dd, J=15.1, 6.8 Hz, 1H), 2.08 (brs, 1H), 1.84 (brs, 1H); MS (ES) m/z:562 (M+H⁺).

Example 49

A mixture of compound A2d (23 mg, 0.047 mmol) and 2,2-dimethyl-oxirane(0.1 mL, 1.13 mmol) in EtOH (0.2 mL) in a sealed tube was heated at 110°C. for 5 d. After cooling to room temperature, the mixture wasconcentrated and purified by column chromatography to give 5 mg (19%) ofcompound 49 as an oil: ¹H NMR (300 MHz, CDCl₃) δ 7.40-7.29 (m, 4H),7.15-6.92 (m, 6H), 6.71 (d, J=7.2 Hz, 1H), 5.86 (bt, J=53.1 Hz, 1H),4.82 (m, 1H), 4.38 (dd, J=10.7, 2.5 Hz, 1H), 4.32 (d, J=19.0, 2.4 Hz,1H), 3.52 (d, J=15.3 Hz, 1H), 3.16 (d, J=15.4 Hz, 1H), 1.32 (s, 3H),1.30 (s, 3H); MS (ES) m/z: 560 (M+H⁺).

Example 50

To a solution of A1a (1.30 g, 6.91 mmol) in 2-butanone (35 mL) was addeda solution of K₂CO₃ (3.34 g, 24.2 mmol) in water (5 mL) followed bychloro acetyl chloride (0.8 mL, 10 mmol). After stirring at roomtemperature for 2 h and then 80° C. for another 2 h, the mixture wascooled down and was let standing at room temperature overnight. Theprecipitated crystals were filtered, washed with Et₂O and dried undervacuum to give 1.58 g (100%) of compound FF1 as a pink crystal: ¹H NMR(400 MHz, CDCl₃) δ 8.21 (brs, 1H), 7.22 (m, 1H), 6.85 (t, J=8.0 Hz, 1H),6.76 (d, J=7.9 Hz, 1H), 4.73 (s, 2H).

Replacing A2c with FF1 and following the same procedure as in thepreparation of A2d gave compound FF1 (92%): ¹H NMR (300 MHz, CDCl₃) δ8.91 (brs, 1H), 7.49-7.39 (m, 3H), 7.09-7.03 (m, 2H), 6.87 (dd, J=5.8,3.6 Hz, 1H), 4.63 (s, 2H); MS (ES) m/z: 332 (M+Na⁺).

To a solution of FF2 (3.27 g, 10.6 mmol) and Boc₂O (3.50 g, 16.1 mmol)in CH₂Cl₂ (60 mL) was added DMAP (0.25 g, 2.05 mmol) and Et₃N (2.3 mL,16.5 mmol). After stirring for 1 h, the mixture was concentrated andpurified by column chromatography to give 4.05 g (94%) of compound FF3as a yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.45-7.43 (m, 2H), 7.37 (s,3H), 7.26-7.11 (m, 4H), 4.53 (s, 2H), 1.63 (s, 9H); MS (ES) m/z: 432(M+Na⁺).

To a solution of FF3 (3.20 g, 7.8 mmol) in THF (35 mL) at −78° C. wasadded DIBAL (1.0 M in hexane, 14 mL, 14 mmol). After stirring at −78° C.for 30 min, the reaction was quenched with saturated NH₄Cl followed bypotassium sodium tartrate (aq). The reaction mixture was allowed to warmto room temperature, the organic layer was separated, and the aqueouslayer was extracted with CH₂Cl₂. The combined organic extracts weredried (Na₂SO₄) and concentrated to give 2.96 g (92%) of compound FF4 asa yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.91-7.88 (m, 1H), 7.44-7.38 (m,3H), 7.18 (d, J=7.5 Hz, 1H), 7.04-7.01 (m, 2H), 5.93 (m, 1H), 4.11-4.09(m, 2H), 3.45 (d, J=4.9 Hz, 1H), 1.59 (s, 9H); MS (ES) m/z: 434 (M+Na⁺).

A mixture of compound FF4 (2.95 g, 7.18 mmol) and PTSA (0.71 g, 3.2mmol) in EtOH (40 mL) was stirred for 22 h and concentrated. The residuewas purified by column chromatography to give 2.97 g (94%) of compoundFF5 as an oil: ¹H NMR (300 MHz, CDCl₃) δ 7.73 (m, 1H), 7.49-7.36 (m,3H), 7.16 (m, 1H), 7.04 (d, J=7.6 Hz, 1H), 6.96 (t, J=7.9 Hz, 1 H), 5.78(s, 1H), 4.41 (d, J=11.2 Hz, 1H), 4.14 (dd, J=11.2, 2.2 Hz, 1H), 3.63(q, J=7.2 Hz, 2H), 1.57 (s, 9H), 1.17 (t, J=7.1 Hz, 3H); MS (ES) m/z:462 (M+Na⁺).

To a solution of FF5 (86 mg, 0.20 mmol) and allyltrimethylsilane (156mL, 0.98 mmol) in CH₂Cl₂ (2.5 mL) at 4° C. was added BF₃.OEt₂ (0.075 mL,0.59 mmol). The reaction mixture was allowed to warm to room temperatureand stirred for 2.5 h. More allyltrimethylsilane (0.080 mL, 0.49 mmol)and BF₃.OEt₂ (0.050 mL, 0.39 mmol) were added and the reaction mixturewas stirred for another 1 h. Saturated NaHCO₃ was added to quench thereaction and the resulting mixture was extracted with CH₂Cl₂. Thecombined organic extracts were dried (Na₂SO₄), concentrated and purifiedto give 47 mg (72%) of compound FF6 as a clear oil: ¹H NMR (300 MHz,CDCl₃) δ 7.50-7.35 (m, 3H), 7.15 (d, J=8.2 Hz, 1H), 6.83 (t, J=7.7 Hz,1H), 6.69 (d, J=7.6 Hz, 1H), 6.61 (d, J=7.6 Hz, 1H), 5.91-5.75 (m, 1H),5.20 (d, J=12.2 Hz, 2H), 4.25 (dd, J=10.5, 2.8 Hz, 1H), 3.91 (brs, 1H),3.87 (dd, J=10.5, 7.6 Hz, 1H), 3.49-3.43 (m, 1H), 2.40-2.28 (m, 1H),2.26-2.11 (m, 1H); MS (ES) m/z: 336 (M+H⁺).

Replacing A2d with FF6 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 50 (41%) andlower Rf compound 51 (solvent for column: 20% EtOAc in hexane).Spectrums of compound 50 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.49-7.38 (m, 3H), 7.17 (d, J=7.8 Hz, 1H), 6.94 (t, J=7.9 Hz, 1H), 6.76(d, J=7.6 Hz, 1H), 6.70 (d, J=8.1 Hz, 1H), 5.92-5.78 (m, 1H), 5.17 (s,1H), 5.12 (d, J=5.3 Hz, 1H), 4.36 (m, 1H), 4.22 (dd, J=10.7, 1.7 Hz, 1H), 3.99 (dd, J=10.7, 2.4 Hz, 1H), 3.75 (dd, J=15.1, 2.0 Hz, 1H),3.49-3.36 (m, 2H), 2.62 (d, J=3.2 Hz, 1H), 2.36 (m, 2H); MS (ES) m/z:448 (M+H⁺).

Example 51

Spectrums of compound 51 (48%) are as following: ¹H NMR (300 MHz, CDCl₃)δ 7.49-7.38 (m, 3H), 7.16 (d, J=7.8 Hz, 1H), 6.94 (t, J=7.9 Hz, 1H),6.80-6.71 (m, 2H), 5.91-5.78 (m, 1H), 5.14 (d, J=12.1 Hz, 2H), 4.29 (m,1H), 4.23 (dd, J=10.7, 1.6 Hz, 1H), 3.94 (dd, J=10.6, 2.2 Hz, 1H),3.70-3.53 (m, 2H), 3.31 (dd, J=10.6, 8.2 Hz, 1H), 2.64 (d, J=4.2 Hz,1H), 2.50-2.31 (m, 2H); MS (ES) m/z: 448 (M+H⁺).

Example 52

To a solution of 50 (18 mg, 0.040 mmol) in THF (1 mL) at 4° C. was addedBH₃.SMe₂ (2 M in THF, 0.050 mL, 0.10 mmol). The reaction mixture wasstirred at 4° C. for 10 min and then at room temperature for 2 h. MeOHwere added to quench the reaction and then 1.0 M NaOH (0.3 mL) and 30%H₂O₂ (0.1 mL) were added. After stirring for 1 h, the mixture waspartitioned between CH₂Cl₂ and brine. The organic layer was dried(Na₂SO₄), concentrated and purified by column chromatography to give 13mg (69%) of compound 52 as a clear oil: ¹H NMR (300 MHz, CDCl₃) δ7.49-7.38 (m, 3H), 7.16 (d, J=7.7 Hz, 1H), 6.93 (t, J=7.9 Hz, 1H), 6.73(bt, J=8.2 Hz, 2H), 4.36 (m, 1H), 4.20 (d, J=10.7 Hz, 1H), 4.02 (dd,J=10.7, 2.4 Hz, 1H), 3.78 (d, J=15.1 Hz, 1H), 3.66 (m, 2H), 3.44-3.35(m, 2H), 3.02 (m, 1H), 1.71-1.62 (m, 5H); MS (ES) m/z: 466 (M+H⁺).

Example 53

Replacing compound 26 with 52 and following the same procedure as in thepreparation of compound 27 gave compound 53 (94%): ¹H NMR (400 MHz,CDCl₃) δ 7.47 (d, J=7.7 Hz, 1H), 7.43-7.38 (m, 2H), 7.16 (d, J=8.0 Hz,1H), 6.93 (t, J=7.9 Hz, 1H), 6.69 (d, J=7.6 Hz, 1H), 6.61 (d, J=7.8 Hz,1H), 4.21 (d, J=10.6 Hz, 1H), 3.97-3.89 (m, 2H), 3.80 (d, J=15.5 Hz,1H), 3.54 (s, 3H), 3.39-3.32 (m, 6H), 1.68-1.56 (m, 5H); MS (ES) m/z:494 (M+H⁺).

Example 54

Replacing compound 50 with 51 and following the same procedure as in thepreparation of compound 52 gave compound 54 (64%): ¹H NMR (300 MHz,CDCl₃) δ 7.49-7.38 (m, 3H), 7.16 (d, J=7.6 Hz, 1H), 6.93 (t, J=7.9 Hz,1H), 6.74 (bt, J=7.4 Hz, 2H), 4.30 (m, 1H), 4.20 (d, J=9.7 Hz, 1H), 3.95(dd, J=10.8, 2.3 Hz, 1H), 3.78-3.44 (m, 5H), 3.34 (m, 1H), 1.89-1.59 (m,5H); MS (ES) m/z: 466 (M+H⁺).

Example 55

Replacing compound 26 with 54 and following the same procedure as in thepreparation of compound 27 gave compound 55 (63%): ¹H NMR (400 MHz,CDCl₃) δ 7.47-7.45 (m, 1H), 7.42-7.38 (m, 2H), 7.16 (d, J=8.0 Hz, 1H),6.93 (t, J=7.9 Hz, 1H), 6.71-6.66 (m, 2H), 4.20 (d, J=10.7 Hz, 1H), 3.93(d, J=10.7 Hz, 1H), 3.79 (m, 1H), 3.61-3.57 (m, 5H), 3.39 (m, 2H), 3.32(s, 3H), 1.73-1.58 (m, 5H); MS (ES) m/z: 494 (M+H⁺).

Example 56

Replacing allyl trimethylsilane with(1-tert-butyl-vinyloxy)-trimethyl-silane and following the sameprocedure as in the preparation of FF6 gave compound HH1 (50%): ¹H NMR(300 MHz, CDCl₃) δ 7.41-7.30 (m, 3H), 7.08 (d, J=7.9 Hz, 1H), 6.76 (t,J=7.7 Hz, 1H), 6.61 (d, J=7.6 Hz, 1H), 6.52 (d, J=7.8 Hz, 1H), 4.47(brs, 1H), 4.11 (dd, J=10.5, 2.4 Hz, 1H), 3.92-3.79 (m, 2H), 2.66 (d,J=6.1 Hz, 2H), 1.08 (s, 9H); MS (ES) m/z: 394 (M+H⁺).

Replacing A2d with HH1 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 56 (43%, eluentfor column: 20% EtOAc in hexane) and lower Rf compound 57 (48%).Spectrums of compound 56 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.45-7.40 (m, 3H), 7.19 (m, 1H), 6.96 (t, J=7.8 Hz, 1H), 6.84-6.77 (m,2H), 4.42 (m, 1H), 4.12 (d, J=10.6 Hz, 1H), 4.05-3.91 (m, 2H), 3.61 (dd,J=15.1, 2.5 Hz, 1H), 3.43 (dd, J=15.0, 9.5 Hz, 1H), 3.12 (brs, 1H), 2.84(dd, J=17.7, 7.4 Hz, 1H), 2.68 (dd, J=17.7, 5.8 Hz, 1H), 1.09 (s, 9H);MS (ES) m/z: 506 (M+H⁺).

Example 57

Spectrums of compound 57 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.47-7.39 (m, 3H), 7.19 (d, J=6.8 Hz, 1H), 6.97 (t, J=7.8 Hz, 1H), 6.85(d, J=7.6 Hz, 1H), 6.78 (d, J=8.2 Hz, 1H), 4.36 (brs, 1H), 4.14-4.02 (m,2H), 4.00-3.88 (m, 2H), 3.66 (dd, J=15.1, 3.7 Hz, 1H), 3.40 (dd, J=15.3,7.6 Hz, 1H), 2.93 (dd, J=17.9, 7.2 Hz, 1H), 2.75 (dd, J=18.0, 6.0 Hz,1H), 1.11 (s, 9H); MS (ES) m/z: 506 (M+H⁺).

Example 58

To a solution of FF5 (75 mg, 0.17 mmol) and 2-ethyl-thiophene (100 mg,0.89 mmol) in CH₂Cl₂ (2 mL) at 4° C. was added BF₃.OEt₂ (0.026 mL, 0.21mmol). The reaction mixture was stirred at 4° C. for 40 min and quenchedwith saturated NaHCO₃. The solution was extracted with CH₂Cl₂ and thecombined organic extracts were dried (Na₂SO₄), concentrated and purifiedby column chromatography to give 75 mg (87%) of compound II1 as a clearoil: ¹H NMR (300 MHz, CDCl₃) δ 7.89 (d, J=7.0 Hz, 1H), 7.50-7.37 (m,3H), 7.16 (d, J=7.4 Hz, 1H), 7.01-6.95 (m, 2H), 6.83 (d, J=3.5 Hz, 1H),6.57 (t, J=3.5 Hz, 1H), 5.85 (s, 1H), 4.57 (dd, J=11.1, 1.7 Hz, 1H),4.35 (dd, J=11.1, 3.2 Hz, 1H), 2.74 (q, J=7.4 Hz, 2H), 1.57 (s, 9H),1.24 (t, J=7.5 Hz, 3H); MS (ES) m/z: 528 (M+H⁺).

A mixture of II1 (70 mg, 0.14 mmol) and TFA (0.25 mL) in CH₂Cl₂ (1 mL)was stirred at room temperature for 1 h and concentrated. The residuewas partitioned between NaHCO₃ and CH₂Cl₂. The organic layer was dried(Na₂SO₄), concentrated and purified by column chromatography to give 45mg (80%) of compound II2 as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ7.51-7.38 (m, 3H), 7.16 (d, J=8.1 Hz, 1H), 6.88-6.73 (m, 2H), 6.74 (d,J=7.6 Hz, 1H), 6.68-6.65 (m, 2H), 4.79 (dd, J=8.1, 2.9 Hz, 1H), 4.34(dd, J=10.6, 3.0 Hz, 1H), 4.19 (brs, 1H), 4.06 (dd, J=10.5, 8.2 Hz, 1H),2.82 (q, J=7.5 Hz, 2H), 1.30 (t, J=7.5 Hz, 3H); MS (ES) m/z: 406 (M+H⁺).

Replacing A2d with II2 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 58 (39%, solventfor column: 20% EtOAc in hexane) and lower Rf compound 59 (49%).Spectrums of compound 58 are as following: ¹H NMR (400 MHz, CDCl₃)δ7.50-7.38 (m, 3H), 7.16 (d, J=8.1 Hz, 1H), 6.97 (t, J=7.9 Hz, 1H), 6.84(d, J=3.4 Hz, 1H), 6.78-6.74 (m, 2H), 6.65 (d, J=3.4 Hz, 1 H), 4.92 (m,1H), 4.34-4.21 (m, 3H), 3.70 (d, J=15.6 Hz, 1H), 3.50 (dd, J=15.6, 9.5Hz, 1H), 2.80 (q, J=7.5 Hz, 2H), 2.50 (brs, 1H), 1.28 (t, J=7.6 Hz, 3H);MS (ES) m/z: 518 (M+H⁺).

Example 59

Spectrums of compound 59 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.51-7.38 (m, 3H), 7.16 (d, J=8.2 Hz, 1H), 6.98 (t, J=8.0 Hz, 1H),6.84-6.77 (m, 3H), 6.65 (d, J=3.4 Hz, 1H), 4.67 (t, J=2.9 Hz, 1 H),4.34-4.23 (m, 3H), 3.69 (dd, J=15.6, 4.8 Hz, 1H), 3.57 (dd, J=15.5, 7.0Hz, 1H), 2.78 (q, J=7.5 Hz, 2H), 2.34 (brs, 1H), 1.27 (t, J=7.5 Hz, 3H); MS (ES) m/z: 518 (M+H⁺).

Example 60

Replacing 2-ethyl-thiophene with 3-methoxythiophene and following thesame procedure as in the preparation of compound II1 gave compound JJ1(50%): ¹H NMR (300 MHz, CDCl₃) δ 7.88 (d, J=7.9 Hz, 1H), 7.47-7.36 (m,3H), 7.15 (d, J=8.0 Hz, 1H), 7.03-6.98 (m, 3H), 6.79 (d, J=5.4 Hz, 1H),6.13 (t, J=2.5 Hz, 1H), 4.46 (dd, J=10.8, 2.0 Hz, 1H), 4.31 (dd, J=10.8,2.2 Hz, 1H), 3.86 (s, 3H), 1.54 (s, 9H); MS (ES) m/z: 530 (M+Na⁺).

Replacing II1 with JJ1 and following the same procedure as in thepreparation of compound II2 gave compound JJ2 (81%): ¹H NMR (400 MHz,CDCl₃) δ 7.52-7.38 (m, 3H), 7.19-7.12 (m, 2H), 6.89-6.81 (m, 2H), 6.74(d, J=7.6 Hz, 1H), 6.66 (d, J=7.8 Hz, 1H), 4.98 (dd, J=7.7, 3.0 Hz, 1H),4.35 (dd, J=10.5, 3.0 Hz, 1H), 4.18 (brs, 1H), 4.06 (dd, J=10.5, 7.8 Hz,1H), 3.86 (s, 3H); MS (ES) m/z: 408 (M+H⁺).

Replacing A2d with JJ2 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 60 (28%) andlower Rf compound 61 (35%, solvent for column: 20% EtOAc in hexane).Spectrums of compound 60 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.52-7.38 (m, 3H), 7.21-7.12 (m, 2H), 6.96 (t, J=7.9 Hz, 1H), 6.87 (d,J=5.5 Hz, 1H), 6.76 (d, J=8.0 Hz, 2H), 5.12 (t, J=3.9 Hz, 1H), 4.29 (d,J=3.9 Hz, 2H), 4.24 (m, 1H), 3.90 (s, 3H), 3.67 (dd, J=15.6, 2.6 Hz,1H), 3.47 (dd, J=15.6, 9.6 Hz, 1H), 2.84 (brs, 1H); MS (ES) m/z: 520(M+H⁺).

Example 61

Spectrums of compound 61 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.53-7.38 (m, 3H), 7.20-7.12 (m, 2H), 6.95 (t, J=7.5 Hz, 1H), 6.86 (d,J=5.5 Hz, 1H), 6.78 (d, J=7.6 Hz, 2H), 4.93 (t, J=2.9 Hz, 1H), 4.41-4.26(m, 3H), 3.88 (s, 3H), 3.65-3.49 (m, 2H), 2.60 (brs, 1H); MS (ES) m/z:520 (M+H⁺).

Example 62

Replacing 3-methoxy-thiophene with 2-methoxythiophene and following thesame procedure as in the preparation of compound JJ1 gave low yield ofBoc-protected intermediate (not pure).

Replacing JJ1 with the above intermediate and following the sameprocedure as in the preparation of compound JJ2 gave compound KK1: ¹HNMR (300 MHz, CDCl₃) δ 7.52-7.38 (m, 3H), 7.17 (d, J=7.5 Hz, 1H),6.89-6.80 (m, 2H), 6.74 (d, J=7.5 Hz, 1H), 6.66 (d, J=7.7 Hz, 1H), 6.62(d, J=5.8 Hz, 1H), 4.75 (dd, J=8.2, 3.0 Hz, 1H), 4.31 (dd, J=10.5, 3.1Hz, 1H), 4.11-4.03 (m, 2H), 3.95 (s, 3H); MS (ES) m/z: 408 (M+H⁺).

Replacing A2d with KK1 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 62 and lower Rfcompound 63 (solvent for column: 20% EtOAc in hexane). Spectrums ofcompound 62 are as following: ¹H NMR (400 MHz, CDCl₃) δ 7.49-7.38 (m,3H), 7.15 (d, J=7.9 Hz, 1H), 6.96 (t, J=7.9 Hz, 1H), 6.79-6.74 (m, 2H),6.67 (d, J=5.9 Hz, 1H), 6.59 (d, J=5.9 Hz, 1H), 4.85 (t, J=4.3 Hz, 1 H),4.25-4.15 (m, 3H), 3.95 (s, 3H), 3.66 (dd, J=15.6, 2.4 Hz, 1H), 3.41(dd, J=15.6, 9.6 Hz, 1H), 2.60 (brs, 1H); MS (ES) m/z: 520 (M+H⁺).

Example 63

Spectrums of compound 63 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.49-7.38 (m, 3H), 7.16 (d, J=8.2 Hz, 1H), 6.97 (t, J=7.9 Hz, 1H),6.81-6.75 (m, 2H), 6.70 (d, J=6.0 Hz, 1H), 6.60 (d, J=5.7 Hz, 1 H), 4.66(t, J=3.5 Hz, 1H), 4.34-4.22 (m, 3H), 3.96 (s, 3H), 3.57-3.55 (M, 2H),2.37 (brs, 1H); MS (ES) m/z: 520 (M+H⁺).

Example 64

Replacing 3-trifluoromethoxy-benzene-boronic acid with3,5-difluoro-benzene-boronic acid and following the same procedure as inthe preparation of compound A2d gave compound LL1: ¹H NMR (300 MHz,CDCl₃) δ 7.41 (t, J=7.9 Hz, 1H), 7.35-7.19 (m, 3H), 7.09 (d, J=2.2 Hz,1H), 7.06 (d, J=2.1 Hz, 1H), 6.88 (t, J=7.7 Hz, 1H), 6.29-6.69 (m, 3 H),5.90 (tt, J=53.1, 2.7 Hz, 1H), 4.56 (dd, J=7.2, 2.5 Hz, 1H), 4.32 (d,J=8.3 Hz, 1H), 4.14 (brs, 1H), 3.98 (dd, J=10.6, 8.3 Hz, 1H); MS (ES)m/z: 440 (M+H⁺).

Replacing A2d with LL1 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 64 and lower Rfcompound 65 (solvent for column: 20% EtOAc in hexane). Spectrums ofcompound 64 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.39 (t, J=7.9Hz, 1H), 7.19 (s, 1H), 7.17 (s, 1H), 7.11 (s, 1H), 7.08-6.97 (m, 3H),6.83-6.69 (m, 3H), 5.89 (tt, J=53.1, 2.8 Hz, 1H), 4.86 (t, J=3.8 Hz,1H), 4.39 (m, 1H), 4.27 (dd, J=10.9, 3.2 Hz, 1H), 4.18 (dd, J=11.0, 5.7Hz, 1H), 3.82 (t, J=15.5 Hz, 1H), 3.33 (dd, J=15.7, 9.6 Hz, 1H), 2.44(d, J=3.7 Hz, 1H); MS (ES) m/z: 552 (M+H⁺).

Example 65

Spectrums of compound 65 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.37 (t, J=7.9 Hz, 1H), 7.21-6.99 (m, 6H), 6.90 (d, J=7.3 Hz, 1H),6.79-6.69 (m, 2H), 5.88 (tt, J=53.1, 2.8 Hz, 1H), 4.55 (t, J=2.8 Hz,1H), 4.37-4.21 (m, 3H), 3.70 (dd, J=15.7, 6.4 Hz, 1H), 3.56 (dd, J=15.7,5.1 Hz, 1H), 2.28 (d, J=4.5 Hz, 1H); MS (ES) m/z: 552 (M+H⁺).

Example 66

Replacing 3-trifluoromethoxy-benzene-boronic acid with3-fluoro-benzene-boronic acid and following the same procedure as in thepreparation of compound A2d gave compound MM1: ¹H NMR (400 MHz, CDCl₃) δ7.43-7.23 (m, 6H), 7.20 (d, J=8.0 Hz, 1H), 7.00 (bt, J=8.0 Hz, 1H), 6.89(t, J=7.7 Hz, 1H), 6.77 (d, J=7.6 Hz, 1H), 6.72 (d, J=7.8 Hz, 1H), 5.91(tt, J=53.1, 2.7 Hz, 1H), 4.58 (d, J=8.1 Hz, 1H), 4.31 (dt, J=10.7, 2.3Hz, 1H), 4.13 (brs, 1H), 3.98 (dd, J=10.6, 8.4 Hz, 1H).

Replacing A2d with MM1 and following the same procedure as in thepreparation of compound 1 and 2 gave compound higher Rf compound 66 andlower Rf compound 67 (solvent for column: 20% EtOAc in hexane).Spectrums of compound 66 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.41-7.23 (m, 6H), 7.12 (s, 1H), 7.02-6.95 (m, 2H), 6.81-6.76 (m, 2 H),5.88 (tt, J=53.1, 2.8 Hz, 1H), 4.85 (t, J=3.8 Hz, 1H), 4.46-4.32 (m,1H), 4.26 (dd, J=10.9, 3.2 Hz, 1H), 4.16 (dd, J=10.9, 4.7 Hz, 1H), 3.82(d, J=15.7 Hz, 1H), 3.32 (dd, J=15.7, 9.6 Hz, 1H); MS (ES) m/z: 534(M+H⁺).

Example 67

Spectrums of compound 67 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.40-7.12 (m, 6H), 7.08 (s, 1H), 7.05-6.94 (m, 2H), 6.88 (d, J=8.0 Hz,1H), 6.78 (d, J=7.5 Hz, 1H), 5.88 (tt, J=53.1, 2.7 Hz, 1H), 4.54 (t,J=2.8 Hz, 1H), 4.31 (dd, J=12.3, 6.4 Hz, 1H), 4.24 (d, J=3.0 Hz, 2H),3.69 (dd, J=15.7, 6.5 Hz, 1H), 3.56 (dd, J=15.7, 5.2 Hz, 1H), 2.31 (brs,1H); MS (ES) m/z: 534 (M+H⁺).

Example 68

Replacing 2-trifluoromethyl-oxirane with 2-fluoromethyl-oxirane andfollowing the same procedure as in the preparation of compound 1 and 2gave higher Rf compound 68 and lower Rf compound 69 (solvent for column:20% EtOAc in hexane). Spectrums of compound 68 are as following: ¹H NMR(400 MHz, CDCl₃) δ 7.43-7.22 (m, 4H), 7.20-7.09 (m, 4H), 6.99 (t, J=7.9Hz, 1H), 6.83 (d, J=8.2 Hz, 1H), 6.75 (d, J=7.6 Hz, 1H), 5.88 (tt,J=53.1, 2.7 Hz, 1H), 4.79 (t, J=3.3 Hz, 1H), 4.51-4.18 (m, 5H), 3.60(dd, J=15.4, 3.0 Hz, 1H), 3.22 (dd, J=15.4, 8.8 Hz, 1H), 2.17 (brs, 1H);MS (ES) m/z: 564 (M+H⁺).

Example 69

Spectrums of compound 69 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.43-7.32 (m, 4H), 7.14 (m, 3H), 7.08 (s, 1H), 7.00 (t, J=7.9 Hz, 1H),6.90 (d, J=8.1 Hz, 1H), 6.75 (d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1, 2.6Hz, 1H), 4.61-4.39 (m, 3H), 4.29 (dd, J=10.9, 2.9 Hz, 1H), 4.22 (dd,J=11.0, 3.2 Hz, 1H), 4.13 (m, 1H), 3.61 (dd, J=15.2, 5.8 Hz, 1H), 3.32(dd, J=15.2, 7.3 Hz, 1H), 2.04 (brs, 1H); MS (ES) m/z: 564 (M+H⁺).

Example 70

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with3-trifluoro-benzaldehyde and following the same procedure as in thepreparation of compound A2a gave compound PP1 (42%): ¹H NMR (300 MHz,CDCl₃) δ 8.22 (s, 1H), 8.16 (d, J=7.8 Hz, 1H), 7.89 (d, J=7.8 Hz, 1H),7.67 (t, J=7.9 Hz, 1H), 4.71 (s, 2H).

Replacing D2 with PP1 and following the same procedure as in thepreparation of compound D3 gave compound PP2 (28%): ¹H NMR (300 MHz,CDCl₃) δ 8.25 (s, 1H), 8.09 (d, J=8.0 Hz, 1H), 7.76 (d, J=7.8 Hz, 1H),7.62 (t, J=7.8 Hz, 1H), 7.51-7.41 (m, 3H), 7.30-7.20 (m, 3H), 7.14 (t,J=7.7 Hz, 1H), 5.07 (s, 2H); MS (ES) m/z: 438 (M−H₂O+H⁺).

Replacing D3 with PP2 and following the same procedure as in thepreparation of compound D4 gave compound PP3 (91%): ¹H NMR (300 MHz,CDCl₃) δ 7.69 (s, 1H), 7.62 (m, 2H), 7.53-7.38 (m, 4H), 7.16 (d, J=8.1Hz, 1H), 6.90 (t, J=7.8 Hz, 1H), 6.79-6.70 (m, 2H), 4.63 (bd, J=8.2 Hz,1H), 4.34-4.30 (m, 1H), 4.14 (brs, 1H), 4.00 (dd, J=10.3, 8.6 Hz, 1H);MS (ES) m/z: 440 (M+H⁺).

Replacing A2d with PP3 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 70 (34%) andlower Rf compound 71 (39%, solvent for column: 20% EtOAc in hexane).Spectrums of compound 70 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.51-7.33 (m, 7H), 7.13 (d, J=7.3 Hz, 1H), 7.02 (t, J=7.9 Hz, 1H), 6.78(m, 2H), 4.94 (t, J=3.8 Hz, 1H), 4.44 (m, 1H), 4.28 (dd, J=11.0, 3.2 Hz,1H), 4.17 (dd, J=11.0, 4.7 Hz, 1H), 3.85 (d, J=15.7 Hz, 1H), 3.28 (dd,J=15.7, 9.6 Hz, 1H), 2.45 (d, J=3.8 Hz, 1H); MS (ES) m/z: 552 (M+H⁺).

Example 71

Spectrums of compound 71 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.60-7.31 (m, 7H), 7.13 (m, 1H), 7.03 (t, J=7.8 Hz, 1H), 6.90 (d, J=8.2Hz, 1H), 6.79 (d, J=7.6 Hz, 1H), 4.60 (t, J=3.0 Hz, 1H), 4.37-4.19 (m,3H), 3.71 (dd, J=15.7, 6.5 Hz, 1H), 3.52 (dd, J=15.7, 5.2 Hz, 1H), 2.30(brs, 1H); MS (ES) m/z: 552 (M+H⁺).

Example 72

Replacing C2b with A2c and following the same procedure as in thepreparation of compound LL1 gave compound QQ1: ¹H NMR (300 MHz, CDCl₃) δ7.41 (t, J=7.9 Hz, 1H), 7.35-7.19 (m, 3H), 7.09 (d, J=2.2 Hz, 1H), 7.06(d, J=2.1 Hz, 1H), 6.88 (t, J=7.7 Hz, 1H), 6.29-6.69 (m, 3 H), 5.90 (tt,J=53.1, 2.7 Hz, 1H), 4.56 (dd, J=7.2, 2.5 Hz, 1H), 4.32 (d, J=8.3 Hz,1H), 4.14 (brs, 1H), 3.98 (dd, J=10.6, 8.3 Hz, 1H); MS (ES) m/z: 440(M+H⁺).

Replacing A2d with QQ1 and following the same procedure as in thepreparation of compound 1 and 2 gave compound 72 and 73. Spectrums ofcompound 72 are as following: [α]²⁰ _(D) −88.8° (c=1, CHCl₃); ¹H NMR(300 MHz, CDCl₃) δ 7.39 (t, J=7.9 Hz, 1H), 7.19 (s, 1H), 7.17 (s, 1H),7.11 (s, 1H), 7.08-6.97 (m, 3H), 6.83-6.69 (m, 3H), 5.89 (tt, J=53.1,2.8 Hz, 1 H), 4.86 (t, J=3.8 Hz, 1H), 4.39 (m, 1H), 4.27 (dd, J=10.9,3.2 Hz, 1H), 4.18 (dd, J=11.0, 5.7 Hz, 1H), 3.82 (t, J=15.5 Hz, 1H),3.33 (dd, J=15.7, 9.6 Hz, 1H), 2.44 (d, J=3.7 Hz, 1H); MS (ES) m/z: 552(M+H⁺).

Example 73

Spectrums of compound 73 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.37 (t, J=7.9 Hz, 1H), 7.21-6.99 (m, 6H), 6.90 (d, J=7.3 Hz, 1H),6.79-6.69 (m, 2H), 5.88 (tt, J=53.1, 2.8 Hz, 1H), 4.55 (t, J=2.8 Hz,1H), 4.37-4.21 (m, 3H), 3.70 (dd, J=15.7, 6.4 Hz, 1H), 3.56 (dd, J=15.7,5.1 Hz, 1H), 2.28 (d, J=4.5 Hz, 1H); MS (ES) m/z: 552 (M+H⁺).

Example 74

Replacing A2d with C1a and following the same procedure as in thepreparation of compound 68 and 69 gave compound 74 (30%) and 75 (22%)(solvent for column: 25% EtOAc in hexane). Spectrums of compound 74 areas following: [α]²⁰ _(D) −63.4° (c=1, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ7.43-7.22 (m, 4H), 7.20-7.09 (m, 4H), 6.99 (t, J=7.9 Hz, 1H), 6.83 (d,J=8.2 Hz, 1H), 6.75 (d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1, 2.7 Hz, 1H),4.79 (t, J=3.3 Hz, 1H), 4.51-4.18 (m, 5H), 3.60 (dd, J=15.4, 3.0 Hz,1H), 3.22 (dd, J=15.4, 8.8 Hz, 1H), 2.17 (brs, 1H); MS (ES) m/z: 564(M+H⁺).

Example 75

Spectrums of compound 75 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.43-7.32 (m, 4H), 7.14 (m, 3H), 7.08 (s, 1H), 7.00 (t, J=7.9 Hz, 1H),6.90 (d, J=8.1 Hz, 1H), 6.75 (d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1, 2.6Hz, 1H), 4.61-4.39 (m, 3H), 4.29 (dd, J=10.9, 2.9 Hz, 1H), 4.22 (dd,J=11.0, 3.2 Hz, 1H), 4.13 (m, 1H), 3.61 (dd, J=15.2, 5.8 Hz, 1H), 3.32(dd, J=15.2, 7.3 Hz, 1H), 2.04 (brs, 1H); MS (ES) m/z: 564 (M+H⁺).

Example 76

Replacing 3,5-difluoro-benzene-boronic acid with3,4,5-trifluoro-benzene-boronic acid and following the same procedure asin the preparation of compound QQ1 gave compound SS1: ¹H NMR (400 MHz,CDCl₃) δ 7.41 (t, J=7.9 Hz, 1H), 7.37-7.12 (m, 5H), 6.88 (t, J=7.8 Hz, 1H), 6.74-6.68 (m, 2H), 5.91 (tt, J=53.1, 2.8 Hz, 1H), 4.57 (d, J=8.2 Hz,1H), 4.34-4.30 (m, 1H), 4.16 (s, 1H), 3.98 (dd, J=10.7, 8.3 Hz, 1H); MS(ES) m/z: 458 (M+H⁺).

Replacing A2d with SS1 and following the same procedure as in thepreparation of compound 1 and 2 gave compound 76 and 77. Spectrums ofcompound 76 are as following: [α]²⁰ _(D) −79.0° (c=1, CHCl₃); ¹H NMR(400 MHz, CDCl₃) δ 7.38 (t, J=7.9 Hz, 1H), 7.27-7.08 (m, 5H), 7.00 (t,J=7.9 Hz, 1H), 6.79 (d, J=8.2 Hz, 1H), 6.71 (d, J=7.7 Hz, 1H), 5.89 (tt,J=53.1, 2.7 Hz, 1H), 4.86 (t, J=3.8 Hz, 1H), 4.42-4.35 (m, 1H), 4.26(dd, J=10.9, 3.2 Hz, 1H), 4.18 (dd, J=10.9, 4.6 Hz, 1H), 3.82 (d, J=15.7Hz, 1H), 3.33 (dd, J=15.7, 9.6 Hz, 1H), 2.37(d, J=4.6 Hz, 1H); MS (ES)m/z: 570 (M+H⁺).

Example 77

Spectrums of compound 77 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.37 (t, J=7.9 Hz, 1H), 7.20-6.90 (m, 6H), 6.89 (d, J=8.2 Hz, 1H), 6.72(d, J=7.6 Hz, 1H), 5.88 (tt, J=53.1, 2.8 Hz, 1H), 4.55 (t, J=3.0 Hz,1H), 4.38-4.19 (m, 3H), 3.69 (dd, J=15.8, 6.5 Hz, 1H), 3.55 (dd, J=15.8,5.2 Hz, 1H), 2.21 (d, J=5.0 Hz, 1H); MS (ES) m/z: 570 (M+H⁺).

Example 78

Replacing 3,5-difluoro-benzene-boronic acid with3,5-bis-trifluoromethyl-benzene-boronic acid and following the sameprocedure as in the preparation of compound QQ1 gave compound TT1: ¹HNMR (300 MHz, CDCl₃) δ 8.00 (s, 2H), 7.81 (s, 1H), 7.42 (t, J=7.8 Hz,1H), 7.38-7.19 (m, 3H), 6.93 (t, J=8.3 Hz, 1H), 6.77 (d, J=7.7 Hz, 2H),5.91 (tt, J=53.1, 2.8 Hz, 1H), 4.60 (d, J=8.4 Hz, 1H), 4.36-4.30 (m,1H), 4.19 (s, 1H), 3.99 (dd, J=10.7, 8.4 Hz, 1H); MS (ES) m/z: 540(M+H⁺).

Replacing A2d with SS1 and following the same procedure as in thepreparation of compound 1 and 2 gave compound 78 and 79. Spectrums ofcompound 78 are as following: ¹H NMR (400 MHz, CDCl₃) δ 7.93 (s, 2H),7.80 (s, 1H), 7.39 (t, J=8.0 Hz, 1H), 7.21-7.18 (m, 2H), 7.13 (s, 1H),7.04 (t, J=8.0 Hz, 1H), 6.84 (d, J=7.8 Hz, 1H), 6.78 (d, J=7.6 Hz, 1H),5.89 (tt, J=53.1, 2.7 Hz, 1H), 4.88 (t, J=4.0 Hz, 1H), 4.43-4.36 (m, 1H), 4.29 (dd, J=11.0, 3.2 Hz, 1H), 4.18 (dd, J=11.0, 4.9 Hz, 1H), 3.83(d, J=15.7 Hz, 1H), 3.34 (dd, J=15.7, 9.6 Hz, 1H), 2.46 (brs, 1H); MS(ES) m/z: 652 (M+H⁺).

Example 79

Spectrums of compound 79 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.91 (s, 2H), 7.79 (s, 1H), 7.38 (t, J=7.9 Hz, 1H), 7.19-7.13 (m, 2H),7.09-7.02 (m, 2H), 6.94 (d, J=8.2 Hz, 1H), 6.78 (d, J=7.6 Hz, 1H), 5.88(tt, J=53.1, 2.7 Hz, 1H), 4.57 (t, J=3.0 Hz, 1H), 4.34-4.21 (m, 3H),3.71 (dd, J=15.7, 6.5 Hz, 1H), 3.56 (dd, J=15.8, 5.2 Hz, 1H), 2.27 (brs,1H); MS (ES) m/z: 652 (M+H⁺).

Example 80

Replacing A2a with 2-bromo-1-(3-trifluoromethoxy-phenyl)-ethanone andfollowing the same procedure as in the preparation of compound A2b gavecompound UU1: ¹H NMR (300 MHz, CDCl₃) δ 7.86 (s, 1H), 7.77 (d, J=7.9 Hz,1H), 7.52 (t, J=8.0 Hz, 1H), 7.41-7.35 (m, 3H), 6.93 (t, J=8.0 Hz, 1H),5.17 (s, 2H).

Replacing A2b with UU1 and following the same procedure as in thepreparation of compound C2b gave compound UU2: ¹H NMR (300 MHz, CDCl₃) δ7.42 (t, J=7.7 Hz, 1H), 7.38 (d, J=7.6 Hz, 1H), 7.31-7.25 (m, 2H),7.03-7.00 (m, 1H), 6.78-6.67 (m, 2H), 4.61 (d, J=8.2 Hz, 1H), 4.50-4.44(m, 1H), 4.17 (brs, 1H), 4.10 (dd, J=10.7, 8.2 Hz, 1H); MS ®(ES) m/z:374 (M).

Replacing C2b with UU2 and following the same procedure as in thepreparation of compound C1a gave compound UU3: ¹H NMR (400 MHz, CDCl₃) δ7.42 (t, J=7.9 Hz, 1H), 7.34 (d, J=7.8 Hz, 1H), 7.28 (s, 1H), 7.20 (d,J=8.0 Hz, 1H), 7.11-7.07 (m, 2H), 6.89 (t, J=7.7 Hz, 1H), 6.78-6.68 (m,3H), 4.58 (d, J=8.1 Hz, 1H), 4.34-4.30 (m, 1H), 4.15 (brs, 1H), 3.98(dd, J=10.6, 8.3 Hz, 1H); MS (ES) m/z: 408 (M+H⁺).

Replacing A2d with UU3 and following the same procedure as in thepreparation of compound 1 and 2 gave compound 80 and 81. Spectrums ofcompound 80 are as following: [α]²⁰ _(D) −95.4° (c=1, CHCl₃); ¹H NMR(300 MHz, CDCl₃) δ 7.39 (t, J=7.9 Hz, 1H), 7.23-7.15 (m, 2H), 7.11 (s,1H), 7.07-6.98 (m, 3H), 6.82-6.69 (m, 3H), 4.87 (t, J=3.8 Hz, 1H),4.48-4.32 (m, 1H), 4.27 (dd, J=10.9, 3.2 Hz, 1H), 4.17 (dd, J=10.9, 4.4Hz, 1H), 3.83 (d, J=15.7 Hz, 1H), 3.31 (dd, J=15.7, 9.6 Hz, 1H), 2.42(d, J=3.5 Hz, 1H); MS (ES) m/z: 520 (M+H⁺). Anal. Calcd. ForC₂₄H₁₇F₈NO₃.0.1H₂O: C, 55.31; H, 3.33; N, 2.69. Found: C, 55.07; H,3.05; N, 2.60.

Example 81

Spectrums of compound 81 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.38 (t, J=8.0 Hz, 1H), 7.16 (bt, J=6.7 Hz, 2H), 7.07 (s, 1H), 7.03-6.99(m, 3H), 6.90 (d, J=8.2 Hz, 1H), 6.77-6.70 (m, 2H), 4.56 (s, 1H),4.37-4.20 (m, 3H), 3.69 (dd, J=15.8, 6.5 Hz, 1H), 3.55 (dd, J=15.7, 5.2Hz, 1H), 2.36 (brs, 1H); MS (ES) m/z: 520 (M+H⁺).

Example 82

Replacing 3,5-difluoro-benzene-boronic acid with3,4,5-trifluoro-benzene-boronic acid and following the same procedure asin the preparation of compound UU3 gave compound VV1: ¹H NMR (400 MHz,CDCl₃) δ 7.43 (t, J=7.9 Hz, 1H), 7.34 (d, J=7.7 Hz, 1H), 7.26 (d, J=8.4Hz, 1H), 7.22-7.11 (m, 3H), 6.88 (t, J=7.8 Hz, 1H), 6.74-6.69 (m, 2H),4.58 (dd, J=8.1, 2.8 Hz, 1H), 4.32 (d, J=10.6 Hz, 1H), 4.16 (s, 1H),3.98 (dd, J=10.6, 8.2 Hz, 1H); MS (ES) m/z: 426 (M+H⁺).

Replacing A2d with VV1 and following the same procedure as in thepreparation of compound 1 and 2 gave compound 82 and 83. Spectrums ofcompound 82 are as following: [α]²⁰ _(D) −87.6° (c=1, CHCl₃); ¹H NMR(400 MHz, CDCl₃) δ 7.40 (t, J=7.9 Hz, 1H), 7.19 (d, J=7.7 Hz, 1H),7.14-7.07 (m, 3H), 7.00 (t, J=7.9 Hz, 1H), 4.87 (t, J=7.9 Hz, 1H), 6.79(d, J=8.2 Hz, 1H), 6.71 (d, J=7.7 Hz, 1H), 4.87 (t, J=3.7 Hz, 1H),4.45-4.36 (m, 1H), 4.26 (dd, J=10.9, 3.2 Hz, 1H), 4.17 (dd, J=10.9, 4.4Hz, 1H), 3.83 (d, J=15.7 Hz, 1H), 3.31 (dd, J=15.7, 9.6 Hz, 1H), 2.37(d, J=4.6 Hz, 1H); MS (ES) m/z: 538 (M+H⁺).

Example 83

Spectrums of compound 83 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.38 (t, J=8.0 Hz, 1H), 7.19-6.98 (m, 6H), 6.90 (d, J=8.2 Hz, 1H), 6.73(d, J=7.7 Hz, 1H), 4.56 (t, J=2.9 Hz, 1H), 4.34-4.26 (m, 1 H), 4.24 (d,J=3.0 Hz, 2H), 3.70 (dd, J=15.8, 6.5 Hz, 1H), 3.55 (dd, J=15.8, 5.2 Hz,1H), 2.22 (d, J=5.7 Hz, 1H); MS (ES) m/z: 538 (M+H⁺).

Example 84

Replacing 2-trifluoromethyl-oxirane with 2-isopropyl-oxirane andfollowing the same procedure as in the preparation of compound 1 and 2gave an un-separable mixture compound 84: MS (ES) m/z: 574 (M+H⁺).

Example 85

Replacing 2-methoxy-thiophene with 3-methyl-thiophene and following thesame procedure as in the preparation of compound KK1 gave compound XX1:¹H NMR (300 MHz, CDCl₃) δ 7.52-7.38 (m, 3H), 7.25-7.12 (m, 2H),6.92-6.82 (m, 2H), 6.76 (d, J=7.6 Hz, 1H), 6.69 (d, J=7.8 Hz, 1H), 4.90(dd, J=8.6, 3.0 Hz, 1H), 4.31 (dd, J=10.5, 2.9 Hz, 1H), 4.18 (brs, 1H),4.03 (dd, J=10.6, 8.6 Hz, 1H), 2.27 (s, 3H); MS (ES) m/z: 392 (M+H⁺).

Replacing A2d with VV1 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 85 and lower Rfcompound 86 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 85 are as following: ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, J=7.7Hz, 1H), 7.42-7.38 (m, 2H), 7.21-7.14 (m, 2H), 7.01-6.96 (m, 1H), 6.84(d, J=5.0 Hz, 1H), 6.78 (d, J=7.9 Hz, 2H), 5.17-5.14 (m, 1H), 4.31-4.22(m, 2H), 4.18 (dd, J=11.0, 6.1 Hz, 1H), 3.68 (d, J=15.7 Hz, 1H), 3.42(dd, J=15.7, 9.6 Hz, 1H), 2.41 (d, J=3.8 Hz, 1H), 2.29 (s, 3H); MS (ES)m/z: 504 (M+H⁺).

Example 86

Spectrums of compound 86 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.48 (d, J=7.6 Hz, 1H), 7.43-7.37 (m, 2H), 7.19-7.14 (m, 2H), 6.99 (t,J=7.9 Hz, 1H), 6.85-6.78 (m, 3H), 4.85 (t, J=3.4 Hz, 1H), 4.33-4.20 (m,3H), 3.63 (dd, J=15.7, 4.7 Hz, 1H), 3.54 (dd, J=15.7, 7.1 Hz, 1H),2.32-2.21 (m, 4H); MS (ES) m/z: 504 (M+H⁺).

Example 87

Replacing 2-methoxy-thiophene with 3-ethyl-thiophene and following thesame procedure as in the preparation of compound KK1 gave compound YY1:¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, J=7.8 Hz, 1H), 7.44-7.39 (m, 2H),7.24 (d, J=5.1 Hz, 1H), 7.17 (d, J=8.1 Hz, 1H), 6.92 (d, J=5.1 Hz, 1H),6.88 (t, J=7.7 Hz, 1H), 6.76 (d, J=7.6 Hz, 1H), 6.69 (d, J=7.8 Hz, 1H),4.93 (dd, J=8.7, 2.7 Hz, 1H), 4.31 (bd, J=10.5 Hz, 1H), 4.18 (brs, 1H),4.05 (dd, J=10.6, 8.8 Hz, 1H), 2.76-2.59 (m, 2H), 1.23 (t, J=7.6 Hz,3H); MS (ES) m/z: 406 (M+H⁺).

Replacing A2d with YY1 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 87 and lower Rfcompound 88 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 87 are as following: ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, J=7.8Hz, 1H), 7.43-7.38 (m, 2H), 7.22 (d, J=5.2 Hz, 1H), 7.18-7.15 (m, 1H),6.98 (t, J=8.1 Hz, 1H), 6.91 (d, J=5.2 Hz, 1H), 6.78 (d, J=7.8 Hz, 2H),5.18 (dd, J=6.1, 3.4 Hz, 1H), 4.32-4.26 (m, 2H), 4.18 (dd, J=11.0, 6.2Hz, 1H), 3.67 (d, J=15.7 Hz, 1H), 3.42 (dd, J=15.7, 9.7 Hz, 1H),2.74-2.62 (m, 2H), 2.43 (d, J=4.0 Hz, 1H), 1.23 (t, J=7.6 Hz, 3H); MS(ES) m/z: 518 (M+H⁺).

Example 88

Spectrums of compound 88 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.52-7.38 (m, 3H), 7.21 (d, J=5.2 Hz, 1H), 7.19-7.14 (m, 1H), 7.02-6.92(m, 1H), 6.91 (d, J=5.2 Hz, 1H), 6.85-6.29 (m, 2H), 4.87 (t, J=3.4 Hz,1H), 4.35-4.20 (m, 3H), 3.69-3.49 (m, 2H), 2.72-2.58 (m, 2H), 2.27 (d,J=4.6 Hz, 1H), 1.29-1.19 (m, 3H); MS (ES) m/z: 518 (M+H⁺).

Example 89

A mixture of FF5 (29 mg, 0.066 mmol) and PTSA (25 mg, 0.13 mmol) infurane (1 mL) was stirred at room temperature for 2 d. The mixture waspartitioned between CH₂Cl₂ and NaHCO₃ aqueous solution. The organiclayer was dried (Na₂SO₄), concentrated and purified by columnchromatography to afford 5 mg (21%) of ZZ1 as a yellow oil: ¹H NMR (400MHz, CDCl₃) δ 7.47 (d, J=7.8 Hz, 1H), 7.43-7.38 (m, 3H), 7.16 (d, J=8.1Hz, 1H), 6.87 (t, J=7.7 Hz, 1H), 6.74 (d, J=7.6 Hz, 1H), 6.69 (d, J=7.8Hz, 1H), 6.38-6.29 (m, 2H), 4.68 (dd, J=7.0, 2.9 Hz, 1 H), 4.41 (dd,J=10.6, 3.0 Hz, 1H), 4.24-4.15 (m, 2H); MS (ES) m/z: 362 (M+H⁺).

Replacing A2d with ZZ1 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 89 and lower Rfcompound 90 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 89 are as following: ¹H NMR (400 MHz, CDCl₃) δ 7.47-7.36 (m,4H), 7.16 (d, J=7.5 Hz, 1H), 6.96 (t, J=7.9 Hz, 1H), 6.80-6.74 (m, 2H),6.35-6.33 (m, 1H), 6.27 (d, J=4.3 Hz, 1H), 4.75 (t, J=3.6 Hz, 1H), 4.46(dd, J=10.9, 4.2 Hz, 1H), 4.30-4.21 (m, 2H), 3.76 (d, J=15.5 Hz, 1H),3.52 (dd, J=15.5, 9.7 Hz, 1H), 2.54 (d, J=3.7 Hz, 1H); MS (ES) m/z: 474(M+H⁺).

Example 90

Spectrums of compound 90 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.47-7.36 (m, 4H), 7.17 (d, J=7.7 Hz, 1H), 6.98 (t, J=7.7 Hz, 1H),6.82-6.78 (m, 2H), 6.37-6.35 (m, 1H), 6.28 (d, J=3.1 Hz, 1H), 4.58 (t,J=3.2 Hz, 1H), 4.50 (dd, J=11.0, 3.8 Hz, 1H), 4.39-4.30 (m, 1 H), 4.26(dd, J=10.6, 2.8 Hz, 1H), 3.69 (dd, J=15.6, 4.8 Hz, 1H), 3.61 (dd,J=15.3, 7.5 Hz, 1H), 2.60 (d, J=4.9 Hz, 1H); MS (ES) m/z: 474 (M+H⁺).

Example 91

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with2-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde and following the sameprocedure as in the preparation of compound A2a gave compound aa1 (47%):¹H NMR (300 MHz, CDCl₃) δ 7.78 (d, J=8.0 Hz, 1H), 6.60 (bt, J=7.9 Hz,1H), 7.43-7.33 (m, 2H), 6.01 (tt, J=52.9, 2.3 Hz, 1H), 4.62 (s, 2H); MS(ES) m/z: 271 (M+H⁺).

Replacing A2a with aa1 and following the same procedure as in thepreparation of compound A2b gave compound aa2 (39%): ¹H NMR (300 MHz,CDCl₃) δ 7.89 (d, J=7.6 Hz, 1H), 7.52 (bt, J=7.9 Hz, 1H), 7.43-7.34 (m,4H), 6.94 (d, J=8.0 Hz, 1H), 5.93 (tt, J=52.9, 1.9 Hz, 1H), 4.97 (s,2H); MS (ES) m/z: 404 (M−H₂O).

Replacing A2b with aa2 and following the same procedure as in thepreparation of compound A2c gave compound aa3 (74%): ¹H NMR (300 MHz,CDCl₃) δ 7.90 (d, J=8.1 Hz, 1H), 7.38-7.28 (m, 3H), 6.95 (d, J=7.8 Hz,1H), 6.72-6.60 (m, 2H), 5.96 (tt, J=53.0, 2.3 Hz, 1H), 4.88 (d, J=7.2Hz, 1H), 4.44-4.39 (m, 1H), 4.19-4.02 (m, 2H); MS (ES) m/z: 408 (M+2).

Replacing A2c with aa3 and following the same procedure as in thepreparation of compound A2d gave compound aa4 (59%): ¹H NMR (300 MHz,CDCl₃) δ 7.57 (dd, J=7.7, 2.2 Hz, 1H), 7.50-7.29 (m, 6H), 7.15 (d, J=8.2Hz, 1H), 6.89 (t, J=7.7 Hz, 1H), 6.77-6.69 (m, 2H), 5.95 (tt, J=53.0,2.4 Hz, 1H), 4.93-4.84 (m, 1H), 4.33 (dd, J=10.6, 3.0 Hz, 1H), 4.06-3.99(m, 2H); MS (ES) m/z: 488 (M+H⁺).

Replacing A2d with aa4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 91 and lower Rfcompound 92 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 91 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.45-7.20 (m,7H), 7.14 (d, J=7.7 Hz, 1H), 7.01 (t, J=7.9 Hz, 1H), 6.80-6.75 (m, 2H),5.95 (tt, J=53.0, 2.2 Hz, 1H), 5.17 (t, J=3.0 Hz, 1H), 4.45-4.20 (m,3H), 3.81 (dd, J=15.6, 3.2 Hz, 1H), 3.31 (dd, J=15.7, 9.5 Hz, 1H), 2.38(brs, 1H); MS (ES) m/z: 600 (M+H⁺).

Example 92

Spectrums of compound 92 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.45-7.30 (m, 5H), 7.25-7.19 (m, 2H), 7.13 (d, J=7.7 Hz, 1H), 7.02 (t,J=7.9 Hz, 1H), 6.90 (d, J=8.2 Hz, 1H), 6.77 (d, J=7.6 Hz, 1H), 5.95 (bt,J=53.0 Hz, 1H), 4.92 (t, J=2.3 Hz, 1H), 4.45-4.20 (m, 3H), 3.69 (dd,J=15.7, 6.7 Hz, 1H), 3.50 (dd, J=15.7, 5.2 Hz, 1H), 2.23 (brs, 1H); MS(ES) m/z: 600 (M+H⁺).

Example 93

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with4-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde and following the sameprocedure as in the preparation of compound A2a gave compound bbl (39%):¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, J=8.7 Hz, 2H), 7.34 (d, J=8.3 Hz,2H), 5.94 (tt, J=53.0, 2.7 Hz, 1H), 4.67 (s, 2H).

Replacing A2a with bbl and following the same procedure as in thepreparation of compound A2b gave compound bb2 (48%): ¹H NMR (300 MHz,CDCl₃) δ 7.96 (d, J=8.8 Hz, 2H), 7.45-7.31 (m, 4H), 6.92 (t, J=8.0 Hz,1H), 5.94 (tt, J=53.0, 2.8 Hz, 1H), 5.17 (s, 2H).

Replacing A2b with bb2 and following the same procedure as in thepreparation of compound A2c gave compound bb3 (50%): ¹H NMR (300 MHz,CDCl₃) δ 7.53-7.39 (m, 3H), 7.28-7.18 (m, 1H), 6.95 (d, J=7.8 Hz, 1H),6.72-6.60 (m, 2H), 5.92 (tt, J=53.1, 2.8 Hz, 1H), 4.54 (dd, J=8.4, 2.1Hz, 1H), 4.44-4.38 (m, 1H), 4.22-4.00 (m, 2H); MS (ES) m/z: 408 (M+H⁺).

Replacing A2c with bb3 and following the same procedure as in thepreparation of compound A2d gave compound bb4 (52%): ¹H NMR (300 MHz,CDCl₃) δ 7.52-7.39 (m, 6H), 7.33-7.11 (m, 2H), 6.89 (t, J=7.7 Hz, 1H),6.76 (d, J=7.6 Hz, 1H), 6.71 (d, J=7.7 Hz, 1H), 5.91 (bt, J=53.0 Hz,1H), 4.62-4.54 (m, 1H), 4.36-4.26 (m, 1H), 4.12 (s, 1H), 3.98 (dd,J=10.6, 8.4 Hz, 1H); MS (ES) m/z: 488 (M+H⁺).

Replacing A2d with bb4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 96 and lower Rfcompound 97 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 96 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.50-7.11 (m,8H), 7.01 (t, J=7.9 Hz, 1H), 6.77 (t, J=7.5 Hz, 2H), 5.90 (tt, J=53.1,2.8 Hz, 1H), 4.86 (t, J=3.9 Hz, 1H), 4.45-4.33 (m, 1H), 4.27 (dd,J=11.0, 3.2 Hz, 1H), 4.15 (dd, J=10.8, 4.7 Hz, 1H), 3.81 (d, J=15.6 Hz,1H), 3.31 (dd, J=15.7, 9.6 Hz, 1H), 2.45 (brs, 1H); MS (ES) m/z: 600(M+H⁺).

Example 94

Spectrums of compound 94 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.97 (d, J=8.8 Hz, 1H), 7.47-7.11 (m, 7H), 7.02 (t, J=7.7 Hz, 1H), 6.90(d, J=7.7 Hz, 1H), 6.78 (d, J=7.6 Hz, 1H), 5.90 (tt, J=53.0, 2.7 Hz,1H), 3.55 (t, J=3.0 Hz, 1H), 4.36-4.19 (m, 3H), 3.70 (dd, J=15.5, 6.7Hz, 1H), 3.54 (dd, J=15.7, 5.3 Hz, 1H), 2.28 (brs, 1H); MS (ES) m/z: 600(M+H⁺).

Example 95

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with benzaldehydeand following the same procedure as in the preparation of compound A2agave compound cc1 (23%): ¹H NMR (300 MHz, CDCl₃) δ 7.97 (d, J=7.5 Hz,2H), 7.65-7.60 (m, 1H), 7.53-7.46 (m, 1H), 7.41-7.37 (m, 1H), 4.72 (s,2H).

Replacing A2a with cc1 and following the same procedure as in thepreparation of compound A2b gave compound cc2 (44%): ¹H NMR (300 MHz,CDCl₃) δ 7.93 (dd, J=7.5, 2.5 Hz, 2H), 7.52-7.45 (m, 3H), 7.40-7.30 (m,2H), 6.92 (t, J=8.0 Hz, 1H), 5.19 (s, 2H).

Replacing A2b with cc2 and following the same procedure as in thepreparation of compound A2c gave compound cc3 (44%): ¹H NMR (300 MHz,CDCl₃) δ 7.47-7.32 (m, 5H), 6.94 (d, J=7.7 Hz, 1H), 6.70-6.59 (m, 2H),4.52 (d, J=8.5 Hz, 1H), 4.44-4.39 (m, 1H), 4.12-4.00 (m, 2H).

Replacing A2c with cc3 and following the same procedure as in thepreparation of compound A2d gave compound cc4 (69%): ¹H NMR (300 MHz,CDCl₃) δ 7.51-7.14 (m, 9H), 6.88 (d, J=7.8 Hz, 1H), 6.76-6.69 (m, 2H),4.55 (dd, J=8.5, 2.9 Hz, 1H), 4.32 (d, J=10.4 Hz, 1H), 4.12 (s, 1H),4.00 (dd, J=10.5, 8.8 Hz, 1H); MS (ES) m/z: 372 (M+H⁺).

Replacing A2d with cc4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 95 and lower Rfcompound 96 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 95 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.50-7.22 (m,8H), 7.16-7.10 (m, 1H), 7.00 (t, J=7.9 Hz, 1H), 6.82-6.69 (m, 2H), 4.80(t, J=5.2 Hz, 1H), 4.40-4.23 (m, 2H), 4.17 (dd, J=11.0, 5.3 Hz, 1 H),3.78 (d, J=15.7 Hz, 1H), 3.36 (dd, J=15.7, 9.6 Hz, 1H), 2.40 (d, J=4.4Hz, 1H); MS (ES) m/z: 484 (M+H⁺).

Example 96

Spectrums of compound 96 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.48-7.20 (m, 8H), 7.11 (d, J=7.8 Hz, 1H), 7.01 (t, J=7.9 Hz, 1H), 6.88(d, J=8.2 Hz, 1H), 6.99 (d, J=7.6 Hz, 1H), 4.52 (t, J=3.3 Hz, 1H),4.33-4.21 (m, 3H), 3.66-3.60 (m, 2H), 2.15 (brs, 1H); MS (ES) m/z: 484(M+H⁺).

Example 97

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with4-trifluoromethoxy-benzaldehyde and following the same procedure as inthe preparation of compound A2a gave compound ddI (29%): ¹H NMR (300MHz, CDCl₃) δ 8.03 (d, J=8.8 Hz, 2H), 7.33 (d, J=8.5 Hz, 2H), 4.67 (s,2H).

Replacing A2a with ddI and following the same procedure as in thepreparation of compound A2b gave compound dd2 (31%): ¹H NMR (300 MHz,CDCl₃) δ 7.97 (d, J=8.6 Hz, 2H), 7.39-7.31 (m, 4H), 6.93 (t, J=7.9 Hz,1H), 5.17 (s, 2H); MS (ES) m/z: 372 (M−H₂O).

Replacing A2b with dd2 and following the same procedure as in thepreparation of compound A2c gave compound dd3 (50%): ¹H NMR (300 MHz,CDCl₃) δ 7.42 (d, J=8.7 Hz, 2H), 7.24 (d, J=7.9 Hz, 2H), 6.95 (d, J=7.8Hz, 1H), 6.72-6.60 (m, 2H), 4.54 (d, J=8.3 Hz, 1H), 4.43-4.37 (m, 1H),4.14-4.00 (m, 2H).

Replacing A2c with dd3 and following the same procedure as in thepreparation of compound A2d gave compound dd4 (74%): ¹H NMR (300 MHz,CDCl₃) δ 7.51-7.38 (m, 5H), 7.29-7.12 (m, 3H), 6.89 (t, J=7.7 Hz, 1H),6.78-6.69 (m, 2H), 4.58 (d, J=8.1 Hz, 1H), 4.33-4.27 (m, 1H), 4.11 (brs,1H), 3.98 (dd, J=10.6, 8.4 Hz, 1H); MS (ES) m/z: 456 (M+H⁺).

Replacing A2d with dd4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 97 and lower Rfcompound 98 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 97 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.47-7.11 (m,8H), 7.01 (t, J=7.9 Hz, 1H), 6.77 (d, J=7.9 Hz, 2H), 4.87 (d, J=3.8 Hz,1H), 4.45-4.35 (m, 1H), 4.27 (dd, J=10.9, 3.1 Hz, 1H), 4.15 (dd, J=10.7,4.3 Hz, 1H), 3.82 (d, J=14.5 Hz, 1H), 3.30 (dd, J=15.7, 9.6 Hz, 1H),2.40 (brs, 1H); MS (ES) m/z: 568 (M+H⁺).

Example 98

Spectrums of compound 98 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.45-7.32 (m, 3H), 7.28-7.10 (m, 5H), 7.02 (t, J=7.9 Hz, 1H), 6.89 (d,J=8.1 Hz, 1H), 6.78 (d, J=7.5 Hz, 1H), 4.55 (m, 1H), 4.37-4.18 (m, 3H),3.70 (dd, J=15.7, 6.5 Hz, 1H), 3.53 (dd, J=15.7, 5.4 Hz, 1H), 2.23 (brs,1H); MS (ES) m/z: 568 (M+H⁺).

Example 99

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with3-methoxy-benzaldehyde and following the same procedure as in thepreparation of compound A2a gave compound eel (38%): ¹H NMR (300 MHz,CDCl₃) δ 7.55-7.48 (m, 2H), 7.40 (d, J=7.9 Hz, 1H), 7.19-7.14 (m, 1H),4.70 (s, 2H), 3.87 (s, 3H).

Replacing A2a with eel and following the same procedure as in thepreparation of compound A2b gave compound ee2 (22%): ¹H NMR (300 MHz,CDCl₃) δ 7.55 (m, 1H), 7.45-7.32 (m, 4H), 7.10-7.02 (m, 1H), 6.91 (t,J=7.9 Hz, 1H), 5.17 (s, 2H), 3.90 (s, 3H).

Replacing A2b with ee2 and following the same procedure as in thepreparation of compound A2c gave compound ee3 (72%): ¹H NMR (300 MHz,CDCl₃) δ 7.35-7.28 (m, 1H), 7.02-6.91 (m, 4H), 6.71-6.59 (m, 2H), 4.49(dd, J=8.6, 3.0 Hz, 1H), 4.42 (dd, J=10.6, 3.0 Hz, 1H), 4.12-4.00 (m,2H), 3.82 (s, 3H); MS (ES) m/z: 320 (M).

Replacing A2c with ee3 and following the same procedure as in thepreparation of compound A2d gave compound ee4 (57%): ¹H NMR (300 MHz,CDCl₃) δ 7.52-7.38 (m, 3H), 7.35-7.26 (m, 1H), 7.16 (d, J=7.9 Hz, 1H),7.02-6.95 (m, 2H), 6.91-6.85 (m, 2H), 6.79-6.68 (m, 2H), 4.53 (dd,J=8.4, 2.7 Hz, 1H), 4.32 (bd, J=10.4 Hz, 1H), 4.11 (brs, 1H), 3.99 (dd,J=10.5, 8.7 Hz, 1H), 3.82 (s, 3H); MS (ES) m/z: 402 (M+H⁺).

Replacing A2d with ee4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 99 and lower Rfcompound 100 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 99 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.49-7.28 (m,4H), 7.14 (d, J=8.0 Hz, 1H), 6.99 (t, J=7.8 Hz, 1H), 6.90-6.72 (m, 5H),4.77 (dd, J=5.2, 3.4 Hz, 1H), 4.40-4.21 (m, 2H), 4.16 (dd, J=11.3, 5.6Hz, 1H), 3.83-3.75 (m, 4H), 3.37 (dd, J=15.6, 9.7 Hz, 1H), 2.37 (brs,1H); MS (ES) m/z: 514 (M+H⁺).

Example 100

Spectrums of compound 100 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.47-7.28 (m, 4H), 7.15 (d, J=7.8 Hz, 1H), 7.00 (t, J=7.9 Hz, 1H),6.90-6.72 (m, 5H), 4.48 (t, J=3.4 Hz, 1H), 4.35-4.21 (m, 3H), 3.80-3.75(m, 4H), 3.63 (t, J=5.3 Hz, 1H), 2.17 (brs, 1H); MS (ES) m/z: 514(M+H⁺).

Example 101

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde with3-chloro-benzaldehyde and following the same procedure as in thepreparation of compound A2a gave compound ff1 (30%): ¹H NMR (300 MHz,CDCl₃) δ 7.94 (s, 1H), 7.84 (d, J=7.8 Hz, 1H), 7.62-7.58 (m, 1H), 7.45(t, J=7.9 Hz, 1H), 4.67 (s, 2H).

Replacing A2a with ff1 and following the same procedure as in thepreparation of compound A2b gave compound ff2 (46%): ¹H NMR (300 MHz,CDCl₃) δ 7.97 (s, 1H), 7.73 (d, J=7.6 Hz, 1H), 7.50-7.35 (m, 4H), 6.93(t, J=7.9 Hz, 1H), 5.15 (s, 2H); MS (ES) m/z: 362 (M+Na⁺).

Replacing A2b with ff2 and following the same procedure as in thepreparation of compound A2c gave compound ff3 (64%): ¹H NMR (300 MHz,CDCl₃) δ 7.45-7.19 (m, 4H), 6.95 (d, J=7.7 Hz, 1H), 6.71-6.60 (m, 2H),4.50 (d, J=8.3, 2.5 Hz, 1H), 4.42-4.37 (m, 1H), 4.21-3.95 (m, 2H); MS(ES) m/z: 326 (M+H⁺).

Replacing A2c with ff3 and following the same procedure as in thepreparation of compound A2d gave compound ff4 (63%): ¹H NMR (300 MHz,CDCl₃) δ7.51-7.22 (s, 7H), 7.16 (d, J=8.0 Hz, 1H), 6.89 (t, J=7.7 Hz,1H), 6.78-6.69 (m, 2H), 4.54 (d, J=7.3 Hz, 1H), 4.33-4.27 (m, 1H), 4.11(brs, 1H), 3.97 (d, J=10.6, 8.4 Hz, 1H); MS (ES) m/z: 406 (M+H⁺).

Replacing A2d with ff4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 101 and lower Rfcompound 102 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 101 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.48-7.33 (m,4H), 7.32-7.25 (m, 2H), 7.19-7.11 (m, 2H), 7.01 (t, J=7.9 Hz, 1H), 6.77(t, J=7.9 Hz, 2H), 4.83 (t, J=3.9 Hz, 1H), 4.46-4.35 (m, 1H), 4.25 (dd,J=10.9, 3.2 Hz, 1H), 4.14 (dd, J=10.7, 4.8 Hz, 1H), 3.83 (d, J=15.7 Hz,1H), 3.31 (dd, J=15.7, 9.6 Hz, 1H), 2.40 (d, J=4.2 Hz, 1H); MS (ES) m/z:518 (M+H⁺).

Example 102

Spectrums of compound 102 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.45-7.20 (m, 6H), 7.19-7.09 (m, 2H), 7.02 (t, J=7.8 Hz, 1H), 6.89 (d,J=8.0 Hz, 1H), 6.78 (d, J=7.5 Hz, 1H), 4.51 (t, J=2.9 Hz, 1 H),4.36-4.18 (m, 3H), 3.70 (dd, J=15.7, 6.6 Hz, 1H), 3.54 (dd, J=15.7, 5.1Hz, 1H), 2.23 (d, J=5.1 Hz, 1H); MS (ES) m/z: 518 (M+H⁺).

Example 103

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde withthiophene-2-carbaldehyde and following the same procedure as in thepreparation of compound A2a gave compound gg1 (26%): ¹H NMR (300 MHz,CDCl₃) δ 7.79 (d, J=3.7 Hz, 1H), 7.73 (d, J=4.9 Hz, 1H), 7.17 (t, J=4.5Hz, 1H), 4.59 (s, 2H).

Replacing A2a with gg1 and following the same procedure as in thepreparation of compound A2b gave compound gg2 (23%): ¹H NMR (300 MHz,CDCl₃) δ 7.58 (d, J=5.0 Hz, 1H), 7.44 (d, J=3.8 Hz, 1H), 7.34 (d, J=8.0Hz, 2H), 7.15 (t, J=4.4 Hz, 1H), 6.90 (t, J=7.9 Hz, 1H), 5.11 (s, 2H).

Replacing A2b with gg2 and following the same procedure as in thepreparation of compound A2c gave compound gg3 (67%): ¹H NMR (300 MHz,CDCl₃) δ 7.31 (d, J=4.9 Hz, 1H), 7.09 (d, J=3.0 Hz, 1H), 7.02 (t, J=4.8Hz, 1H), 6.95 (d, J=7.9 Hz, 1H), 6.68 (t, J=7.9 Hz, 1H), 6.60 (d, J=7.9Hz, 1H), 4.86 (d, J=6.5 Hz, 1H), 4.47 (bd, J=10.5 Hz, 1H), 4.21 (brs,1H), 4.15 (dd, J=10.6, 8.2 Hz, 1H); MS (ES) m/z: 298 (M+2).

Replacing A2c with gg3 and following the same procedure as in thepreparation of compound A2d gave compound gg4 (89%): ¹H NMR (300 MHz,CDCl₃) δ 7.51-7.38 (m, 3H), 7.30 (d, J=5.0 Hz, 1H), 7.18-7.14 (m, 1H),7.09 (d, J=3.4 Hz, 1H), 7.03-6.90 (m, 1H), 6.88 (t, J=7.5 Hz, 1H), 6.76(d, J=7.6 Hz, 1H), 6.69 (d, J=7.8 Hz, 1H), 4.89 (d, J=6.3 Hz, 1H), 4.36(bd, J=10.6 Hz, 1H), 4.24 (brs, 1H), 4.10 (dd, J=10.5, 8.1 Hz, 1H); MS(ES) m/z: 378 (M+H⁺).

Replacing A2d with gg4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 103 and lower Rfcompound 104 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 103 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.50-7.36 (m,3H), 7.31-7.25 (m, 1H), 7.16 (d, J=8.0 Hz, 1H), 7.08-6.93 (m, 3H), 6.77(t, J=8.1 Hz, 2H), 5.03 (t, J=3.7 Hz, 1H), 4.38-4.25 (m, 3H), 3.72 (d,J=15.7, 2.1 Hz, 1H), 3.48 (dd, J=15.7, 9.5 Hz, 1H), 2.47 (brs, 1H); MS(ES) m/z: 490 (M+H⁺).

Example 104

Spectrums of compound 104 are as following: ¹H NMR (300 MHz, CDCl₃) δ7.51-7.37 (m, 3H), 7.30-7.23 (m, 1H), 7.16 (d, J=8.1 Hz, 1H), 7.04-6.95(m, 3H), 6.84-6.78 (m, 2H), 4.77 (t, J=2.7 Hz, 1H), 4.39-4.25 (m, 3H),3.71-3.52 (m, 2H), 2.31 (brs, 1H); MS (ES) m/z: 490 (M+H⁺).

Example 105

Replacing 3-(1,1,2,2-tetrafluoro-ethoxy)-benzaldehyde withfuran-3-carbaldehyde and following the same procedure as in thepreparation of compound A2a gave compound hh1 (25%): ¹H NMR (300 MHz,CDCl₃) δ 8.15 (s, 1H), 7.48 (m, 1H), 6.81 (s, 1H), 4.42 (s, 2H).

Replacing A2a with hh1 and following the same procedure as in thepreparation of compound A2b gave compound hh2 (31%): ¹H NMR (300 MHz,CDCl₃) δ 7.87 (s, 1H), 7.53 (t, J=2.0 Hz, 1H), 7.35-7.31 (m, 2H), 6.97(s, 1H), 6.90 (t, J=8.0 Hz, 1H), 4.93 (s, 2H).

Replacing A2b with hh2 and following the same procedure as in thepreparation of compound A2c gave compound hh3 (80%): ¹H NMR (300 MHz,CDCl₃) δ 7.48 (s, 1H), 7.43 (s, 1H), 6.93 (d, J=7.8 Hz, 1H), 6.66 (t,J=7.9 Hz, 1H), 6.57 (d, J=7.9 Hz, 1H), 6.40 (s, 1H), 4.52 (d, J=8.1 Hz,1H), 4.41 (bd, J=10.6 Hz, 1H), 4.09 (dd, J=10.6, 8.2 Hz, 1H), 4.00 (brs,1H); MS (ES) m/z: 282 (M+2).

Replacing A2c with hh3 and following the same procedure as in thepreparation of compound A2d gave compound hh4 (63%): ¹H NMR (300 MHz,CDCl₃) δ 7.50-7.36 (m, 5H), 7.16 (d, J=7.4 Hz, 1H), 6.86 (t, J=7.7 Hz,1H), 6.74 (d, J=7.7 Hz, 1H), 6.66 (d, J=7.8 Hz, 1H), 6.41 (s, 1H), 4.55(dd, J=8.2, 2.8 Hz, 1H), 4.31 (dd, J=10.5, 2.9 Hz, 1H), 4.06-3.99 (m,2H); MS (ES) m/z: 262 (M+H⁺).

Replacing A2d with hh4 and following the same procedure as in thepreparation of compound 1 and 2 gave higher Rf compound 105 and lower Rfcompound 106 (solvent for PLC: 15% EtOAc in hexane). Spectrums ofcompound 105 are as following: ¹H NMR (300 MHz, CDCl₃) δ 7.49-7.38 (m,5H), 7.16 (d, J=7.7 Hz, 1H), 6.96 (t, J=7.9 Hz, 1H), 6.74 (bt, J=7.6 Hz,2H), 6.34 (s, 1H), 4.68 (t, J=3.9 Hz, 1H), 4.38-4.18 (m, 3H), 3.71 (d,J=15.5 Hz, 1H), 3.46 (dd, J=15.6, 9.4 Hz, 1H), 2.46 (d, J=4.4 Hz, 1H);MS (ES) m/z: 474 (M+H⁺).

Example 106

Spectrums of compound 106 are as following: ¹H NMR (400 MHz, CDCl₃) δ7.48-7.37 (m, 5H), 7.17-7.14 (m, 1H), 6.96 (t, J=7.9 Hz, 1H), 6.82-6.74(m, 2H), 6.34 (s, 1H), 4.43 (t, J=3.1 Hz, 1H), 4.32-4.22 (m, 3H),3.65-3.52 (m, 2H), 2.36 (d, J=4.8 Hz, 1H); MS (ES) m/z: 474 (M+H⁺).

Compounds 1 through 108 of Formula (I), (Ia), (Ib) or (Ic) in Table 1were prepared according to the methods described by the Schemes andExamples described herein.

TABLE 1 Representative Compounds Cpd No. Structure Rf 1

Higher 2

Lower 3

NotApplicable 4

NotApplicable 5

NotApplicable 6

NotApplicable 7

Higher 8

Lower 9

NotApplicable 10

NotApplicable 11

Higher 12

Lower 13

Higher 14

Lower 15

Higher 16

Lower 17

Higher 18

Lower 19

NotApplicable 20

NotApplicable 21

NotApplicable 22

NotApplicable 23

NotApplicable 24

NotApplicable 25

NotApplicable 26

NotApplicable 27

NotApplicable 28

NotApplicable 29

NotApplicable 30

NotApplicable 31

NotApplicable 32

NotApplicable 33

NotApplicable 34

NotApplicable 35

NotApplicable 36

NotApplicable 37

NotApplicable 38

NotApplicable 39

NotApplicable 40

NotApplicable 41

NotApplicable 42

NotApplicable 43

NotApplicable 44

NotApplicable 45

NotApplicable 46

NotApplicable 47

NotApplicable 48

NotApplicable 49

NotApplicable 50

Higher 51

Lower 52

NotApplicable 53

NotApplicable 54

NotApplicable 55

NotApplicable 56

Higher 57

Lower 58

Higher 59

Lower 60

Higher 61

Lower 62

Higher 63

Lower 64

Higher 65

Lower 66

Higher 67

Lower 68

Higher 69

Lower 70

Higher 71

Lower 72

NotApplicable 73

NotApplicable 74

NotApplicable 75

NotApplicable 76

NotApplicable 77

NotApplicable 78

NotApplicable 79

NotApplicable 80

NotApplicable 81

NotApplicable 82

NotApplicable 83

NotApplicable 84

NotApplicable 85

Higher 86

Lower 87

Higher 88

Lower 89

Higher 90

Lower 91

Higher 92

Lower 93

Higher 94

Lower 95

Higher 96

Lower 97

Higher 98

Lower 99

Higher 100

Lower 101

Higher 102

Lower 103

Higher 104

Lower 105

Higher 106

Lower 107

108

BIOLOGICAL EXAMPLES CETP In Vitro Assay

The CETP inhibitory activity of the compounds was determined using acommercially available kit from Amersham Biosciences (Catalog#TRKQ7005).

For the measurement of inhibitory activity in human plasma, a modifiedprotocol (Connolly, D. T. et al., Biochemistry, 39, 13870-13879, 2000)was used. Briefly, 80 μl of human plasma (obtained from normalvolunteers), approximately 25 μg/ml (20 μl) of [³H]CE-HDL (AmershamBiosciences from kit TRKQ7005) and 1 μl of compound dissolved in DMSOwas incubated for at least 4 hrs at 37° C. and non-specific transfer wasdetermined by incubating a corresponding plate at 4° C. (blank). Afterthe incubation period, 10 μl of a solution of 1% Dextralip 50/0.5MMgCl₂, pH 7.4 was added, vortexed and incubated at room temperature for10 min. The plate was then centrifuged for 30 min at 10° C. at 3000 rpmin a Sorvall RT6000B centrifuge. Fifty microliters of the supernatantwas transferred to a Picoplate (Packard) containing 100 μl of Microscint40 (Perkin Elmer) and mixed for 30 min using a plate mixer. Theradioactivity was counted using a TopCount (Perkin Elmer) and the %control was determined in the samples using the following formula: %transfer relative to vehicle controls (% control)=[cpm blank-cpmtest]/cpm blank/cpm control]×100. IC₅₀s were calculated from plots ofthe % control versus compound concentration.

A variety of example compounds have been made and tested, with a rangeof in vitro results. Below, in Table 2, are representative compounds andthe corresponding data; in some cases, where multiple IC₅₀'s are shown,multiple measurements were taken. Naturally, different compounds inFormula (I), (Ia), (Ib) and (Ic) may have not activities identical toany one compound below.

TABLE 2 In vitro data of representative compounds of the invention %Inhibition Cpd No. @ 1 μM IC₅₀ (μM) 1 96 0.052, 0.038 2 73 0.276, 0.1313 91 0.026 4 26 Not Determined 5 23 Not Determined 6 14 Not Determined 764, 66 0.104, 0.11 8 21 Not Determined 9 68, 72, 67 0.071, 0.195 10 23Not Determined 13 48 0.104, 0.437 15 67, 69 0.36  16 20 Not Determined17 55, 56 0.49  18  8 Not Determined 19  0 Not Determined 20 16 NotDetermined 21  2 Not Determined 22 13 Not Determined 23 29 NotDetermined 24 25 Not Determined 25 13 Not Determined 26 10 NotDetermined 27 29 Not Determined 28  9 Not Determined 29  0 NotDetermined 30  0 Not Determined 31 17 Not Determined 32  0 NotDetermined 33 24 Not Determined 34 38, 39 0.190 35 47, 52 0.026, 0.117,0.121 36 28 Not Determined 37  5 Not Determined 38  5 Not Determined 39 2 Not Determined 40  0 Not Determined 41  2 Not Determined 42  8 NotDetermined 43  0 Not Determined 44  0 Not Determined 45 25 NotDetermined 46 20 Not Determined 47 27 Not Determined 48 13 NotDetermined 49 34, 24 0.560 50 10 Not Determined 51  0 Not Determined 5213 Not Determined 53  0 Not Determined 54  1 Not Determined 55  0 NotDetermined 56  9 Not Determined 57  0 Not Determined 58 60, 96 0.502 59 0 Not Determined 60  0 Not Determined 61  3 Not Determined 62 19 NotDetermined 63 17 Not Determined 64 121, 101, 119 0.1, 0.117 65 86, 760.99  66 104, 79, 107 0.001, 0.322 67 97, 83 0.78  68 79, 91 0.127 69 50Not Determined 70 37 Not Determined 71  2 Not Determined 72 100  0.05 73 76 0.46  74 77 0.014 75 55 0.147 76 106, 101 0.041 77 80, 82 0.22  7855, 62 0.58  79 43, 40 5.0  80 100  0.193 82 91, 96 0.094 83 29 NotDetermined 84 84, 87 0.1, 0.158 85 20 Not Determined 86  2 NotDetermined 87  8 Not Determined 88 12 Not Determined 89 17 NotDetermined 90 17 Not Determined 91  6 Not Determined 92  1 NotDetermined 93 33 Not Determined 94 11 Not Determined 95 43 NotDetermined 96  1 Not Determined 97 38 Not Determined 98 10 NotDetermined 99 29 Not Determined 100  6 Not Determined 101 61, 63 0.214102  0 Not Determined 103 20 Not Determined 104  0 Not Determined 105  2Not Determined 106  0 Not Determined 107 59, 87 0.134, 0.198 108 34, 39>2.925  

CETP In Vivo Assay

To determine the in vivo efficacy of a test compound, hamsters are firstfed a moderately high cholesterol diet (Research Diets, D5012801) fortwo weeks before commencing treatment. The animals are orally gavagedwith the vehicle (10% solutol, 5% ethanol, 85% D5W) and test compoundfor 5 days with the last dose being administered 2 hrs before sacrifice.Plasma is obtained and lipid parameters (HDL-C, LDL-C, TotalCholesterol, Triglycerides) are measured.

The results for compound 3 is shown in Table 3.

TABLE 3 Effect of Compound 3 on lipid parameters in cholesterol-fedhamsters Total HDL-C/ Dose HDL LDL Cholesterol Triglycerides LDL (mg/kg)(mg/dL) (mg/dL) (mg/dL) (mg/dL) Ratio Vehicle 145 ± 7 37 ± 2 218 ± 11228 ± 20 3.9 ± 0.3  3 mg/kg 136 ± 6 36 ± 3 207 ± 7  278 ± 21 3.7 ± 0.210 mg/kg  158 ± 10 30 ± 2 217 ± 12 282 ± 16 5.2 ± 0.4 30 mg/kg 167 ± 527 ± 2 226 ± 5  300 ± 36 6.2 ± 0.3 Data are expressed as the mean ± SEM

While the foregoing specification teaches the principles of the presentinvention, with examples provided for the purpose of illustration, itwill be understood that the practice of the invention encompasses all ofthe usual variations, adaptations and/or modifications as come withinthe scope of the following claims and their equivalents.

1. A compound of Formula (I):

wherein: L is a covalent bond or O; X is O or S; Q is C₆₋₁₀ aryl or 5-or 6-membered heteroaryl; n is 0 to 3; m is 0 to 3; R₁ is C₁₋₁₀ alkyl,C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀cycloalkyl, 5- or 6-memberedheteroaryl, wherein each of C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl,C₃₋₁₀cycloalkyl, 5- or 6-membered heteroaryl may be optionallysubstituted; or R₁ is phenyl optionally substituted with 1 or 2 membersselected from R_(a) and R_(b), wherein R_(a) and R_(b) are independentlyselected from the group consisting of optionally substituted C₁₋₄ alkyl,halogenated C₁₋₄alkyl, optionally substituted C₂₋₄ alkenyl, optionallysubstituted C₂₋₄ alkynyl, optionally substituted C₁₋₄ alkoxy,halogenatedC₁₋₄alkoxy, optionally substituted C₁₋₄ alkylthio, halo,cyano, and hydroxy, or R_(a) and R_(b) together with the carbon atoms ofthe phenyl ring to which they are attached form an optionallysubstituted 5- or 6-membered heterocyclyl fused to the phenyl ring; eachR₂ is independently selected from halo, hydroxy, cyano, C₁₋₄ alkoxy,halogenated C₁₋₄alkoxy, C₁₋₄ alkyl, halogenated C₁₋₄alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl and —C(O)H; each R₃ is independently selected from C₁₋₄alkyl, halogenated C₁₋₄alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, C₁₋₄ alkoxy,halo, cyano, and hydroxy; R₄ is C₁₋₁₀ alkyl optionally substituted with1-3 members independently selected from halo, oxo, hydroxy, halogenatedC₁₋₄alkyl, C₁₋₄ alkoxy, C₃₋₈ cycloalkyl, CN, tert-butyldimethylsilyloxy,optionally substituted heterocyclyl and —NR_(c)R_(d), wherein R_(c) andR_(d) are independently selected from H, optionally substituted C₁₋₃alkyl, —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl; or R₄ isC₁₋₆alkyl substituted with heteroaryl or phenyl substituted with 1 to 3members independently selected from halo, hydroxy, C₁₋₃alkyl,halogenated C₁₋₃alkyl, C₁₋₄alkoxy, or halogenated C₁₋₄alkoxy; andenantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.
 2. A compound according to claim 1 wherein mis
 0. 3. A compound according to claim 1 wherein n is 1 or
 2. 4. Acompound according to claim 1 wherein L is a covalent bond.
 5. Acompound according to claim 1 wherein Q is phenyl.
 6. A compoundaccording to claim 1 wherein X is O.
 7. A compound according to claim 1wherein R₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl,C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, halo, cyano, hydroxy, halogenatedC₁₋₄alkylthio, or an optionally substituted five membered heterocyclylring fused to the phenyl ring forming a bicyclic ring system.
 8. Acompound according to claim 1 wherein R₁ is phenyl substituted with C₁₋₄alkyl, halogenated C₁₋₄alkyl, C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, halo,cyano, or hydroxy.
 9. A compound according to claim 1 wherein R₁ isphenyl substituted with halogenated C₁₋₄alkyl or halogenated C₁₋₄alkoxy.10. A compound according to claim 9 wherein R₁ is phenyl substitutedwith —OCF₂CF₂H, —CF₃, or —OCF₃.
 11. A compound according to claim 1wherein R₁ is C₁₋₆ alkyl substituted with hydroxy, C₁₋₄alkoxy, oxo,halo, or cyano.
 12. A compound according to claim 1 wherein R₁ isfuranyl or thienyl optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy,hydroxy, or cyano.
 13. A compound according to claim 1 wherein n is 1,2, or 3 and each R₂ is independently selected from halo, halogenatedC₁₋₄alkyl, and halogenated C₁₋₄alkoxy.
 14. A compound according to claim13 wherein each R₂ is independently selected from —OCF₂CF₂H, —OCF₃ or F.15. A compound according to claim 1 wherein n is 1 and R₂ is halogenatedC₁₋₄alkoxy.
 16. A compound according to claim 15, wherein R2 is—OCF₂CF₂H.
 17. A compound according to claim 1, wherein R₄ is C₁₋₅ alkyloptionally substituted with 1 or 2 members each independently selectedfrom halo, oxo, hydroxy, halogenatedC₁₋₄alkyl, and optionallysubstituted heterocyclyl.
 18. A compound according to claim 17, whereinR₄ is C₁₋₃ alkyl substituted with 2 members each independently selectedfrom halo, hydroxy, and halogenatedC₁₋₃alkyl.
 19. A compound of Formula(Ia):

wherein: X is O or S; L is a covalent bond or 0; Q is phenyl,naphthalenyl, or a heteroaryl selected from the group consisting ofthienyl, oxazolyl, thiazolyl, isoxazolyl, pyridinyl, and pyridazinyl; nis 0 to 3; m is 0 to 3; R₁ is C₁₋₁₀ alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl,C₃₋₁₀cycloalkyl, or a 5- or 6-membered heteroaryl; wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, or 5- or 6-memberedheteroaryl is optionally substituted with 1 to 3 substituentsindependently selected from halo, cyano, hydroxy, oxo, C₁₋₃alkyl, andC₁₋₃alkoxy; or R₁ is phenyl optionally substituted with 1 to 2 membersselected from R_(a) and R_(b), wherein R_(a) and R_(b) are independentlyselected from the group consisting of C₁₋₄ alkyl, halogenatedC₁₋₄alkyl,phenylC₁₋₄alkyl, C₁₋₄ alkoxy, halogenated C₁₋₄ alkoxy, phenylC₁₋₄alkoxy, C₁₋₄ alkylthio, halogenatedC₁₋₄alkylthio, halo, cyano, andhydroxy, or R_(a) and R_(b) together with the carbon atoms of the phenylring to which they are attached form a 5- or 6-membered heterocyclylfused to the phenyl ring; said heterocyclyl optionally substituted with1 or 2 members independently selected from halo, C₁₋₃alkyl, cyano, andhydroxy; each R₂ is independently selected from the group consisting ofhalo, hydroxy, cyano, C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, C₁₋₄ alkyl,halogenatedC₁₋₄ alkyl, and —C(O)H; each R₃ is independently selectedfrom the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, halo, cyano, andhydroxy; R₄ is C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl,wherein said C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl isoptionally substituted with 1-3 members independently selected from thegroup consisting of oxo, hydroxy, C₁₋₄ alkoxy, halogenatedC₁₋₄ alkoxy,C₃₋₈ cycloalkyl, cyano, tert-butyldimethylsilyloxy, heterocyclyloptionally substituted with 1 or 2 C₁₋₃alkyl groups, and —NR_(c)R_(d),wherein R_(c) and R_(d) are independently selected from H, optionallysubstituted C₁₋₃ alkyl, —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and—SO₂C₁₋₃alkyl; and enantiomers, diastereomers, tautomers, solvates, orpharmaceutically acceptable salts thereof.
 20. A compound according toclaim 19 wherein X is O.
 21. A compound according to claim 19 wherein mis
 0. 22. A compound according to claim 19 wherein n is 1 or
 2. 23. Acompound according to claim 19, wherein L is a covalent bond.
 24. Acompound according to claim 19, wherein Q is phenyl.
 25. A compoundaccording to claim 19, wherein R₁ is


26. A compound according to claim 19, wherein R₁ is —CH₂CH₃,

or phenyl.
 27. A compound according to claim 19, wherein R₁ is—CH₂CH₂CH₂OH.
 28. A compound according to claim 19, wherein R₄ isC₁₋₅alkyl substituted with 1 or 2 members independently selected fromoxo, hydroxy, —O—CH₃, and —O—CH₂CH₃.
 29. A compound according to claim19, wherein R₄ is C₁₋₅alkyl substituted with


30. A compound according to claim 19, wherein R₄ is C₁₋₅alkylsubstituted with


31. A compound according to claim 19, wherein R₄ is halogenatedC₁₋₄alkyl substituted with oxo, hydroxy, or —O—CH₃.
 32. A compound accordingto claim 31, wherein R₄ is —CH₂CH(OH)CF₃.
 33. A compound according toclaim 19, wherein X is O; Q is phenyl; m is 0; n is 1 or 2; L is acovalent bond; R₁ is phenyl optionally substituted with C₁₋₄ alkyl,halogenatedC₁₋₄alkyl, C₁₋₄alkoxy, halogenatedC₁₋₄ alkoxy, halo, orcyano; Each R₂ is independently selected from halo, hydroxy, cyano, C₁₋₄alkoxy, halogenatedC₁₋₄ alkoxy, C₁₋₄alkyl, halogenatedC₁₋₄alkyl, and—C(O)H; and R₄ is C₁₋₅ alkyl substituted with 1 to 2 membersindependently selected from hydroxy, C₁₋₄alkoxy, oxo,halogenatedC₁₋₄alkoxy, heterocyclyl, C₃₋₈cycloalkyl, cyano; or R₄ ishalogenatedC₁₋₄ alkyl substituted with hydroxy, C₁₋₄alkoxy, oxo, orcyano.
 34. A compound according to claim 19, wherein X is O; m is 0; andL is a covalent bond.
 35. A compound according to claim 19, wherein (n)is 1; (m) is 0; and the Q-R₂ group is


36. A compound according to claim 19, wherein (m) is 0; and R₁ is


37. A compound according to claim 19, wherein (m) is 0, and R₄ is


38. A compound of Formula (Ib):

wherein: R₁ is C₁₋₁₀ alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl,or a 5- or 6-membered heteroaryl; wherein said C₁₋₁₀ alkyl,C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, or 5- or 6-memberedheteroaryl is optionally substituted with halo, cyano, or hydroxy, oxo,C₁₋₃alkyl, or C₁₋₃alkoxy; or R₁ is phenyl optionally substituted with 1to 2 members selected from R_(a) and R_(b), wherein R_(a) and R_(b) areindependently selected from the group consisting of C₁₋₄ alkyl,halogenatedC₁₋₄alkyl, phenylC₁₋₄alkyl, C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, phenylC₁₋₄ alkoxy, C₁₋₄ alkylthio, halogenatedC₁₋₄alkylthio,halo, cyano, and hydroxy, or R_(a) and R_(b) together with the carbonatoms of the phenyl ring to which they are attached form a 5- or6-membered heterocyclyl fused to the phenyl ring; said heterocyclyloptionally substituted with 1 or 2 members independently selected fromhalo, C₁₋₃alkyl, cyano, and hydroxy; each of R_(2a), R_(2b), R_(2c) isindependently absent or selected from the group consisting of halo,hydroxy, cyano, C₁₋₄ alkoxy, halogenated C₁₋₄alkoxy, C₁₋₄ alkyl,halogenatedC₁₋₄ alkyl, and —C(O)H; R₃ is absent or selected from thegroup consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, halo, cyano, and hydroxy;R₄ is C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl, whereinsaid C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl isoptionally substituted with 1-3 members independently selected from thegroup consisting of oxo, hydroxy, C₁₋₄ alkoxy, halogenatedC₁₋₄ alkoxy,C₃₋₈ cycloalkyl, cyano, heterocyclyl, and —NR_(c)R_(d), wherein R_(c)and R_(d) are independently selected from H, optionally substituted C₁₋₃alkyl, —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl, and —SO₂C₁₋₃alkyl; andenantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.
 39. A compound according to claim 38, whereinR₁ is phenyl substituted with C₁₋₄ alkyl, halogenated C₁₋₄alkyl, C₁₋₄alkoxy, halogenatedC₁₋₄alkoxy, halo, cyano, or hydroxy.
 40. A compoundaccording to claim 38, wherein R₁ is phenyl substituted with —OCF₂CF₂H,—CF₃, or —OCF₃.
 41. A compound according to claim 38, wherein R_(2a),R_(2b), R_(2c) are each independently selected from halo, halogenatedC₁₋₄alkyl, and halogenated C₁₋₄alkoxy.
 42. A compound according to claim38, wherein R_(2a) and R_(2b) are both absent and R_(2c) is selectedfrom halo, halogenated C₁₋₄alkyl, and halogenated C₁₋₄alkoxy.
 43. Acompound according to claim 42, wherein R_(2c) is —OCF₂CF₂H or —OCF₃.44. A compound according to claim 38, wherein R₄ is halogenatedC₁₋₄alkyl substituted with oxo, hydroxy, C₁₋₄alkoxy, or cyano.
 45. Acompound according to claim 38, wherein R₄ is fluorinatedC₁₋₃ alkylsubstituted with hydroxy.
 46. A compound according to claim 38, whereinR₃ is absent.
 47. A compound of Formula (Ic):

wherein: each R_(2a), R_(2b), R_(2c) is independently absent or selectedfrom the group consisting of halo, hydroxy, cyano, C₁₋₄ alkoxy,halogenated C₁₋₄alkoxy, C₁₋₄ alkyl, halogenatedC₁₋₄ alkyl, and —C(O)H;R₄ is C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl, whereinsaid C₁₋₁₀ alkyl, halogenated C₁₋₁₀alkyl, or phenylC₁₋₃alkyl isoptionally substituted with 1-3 members independently selected from thegroup consisting of halo, oxo, hydroxy, C₁₋₄ alkoxy, C₃₋₈ cycloalkyl,cyano, heterocyclyl, heteroaryl, tert-butyldimethylsilyloxy, and—NR_(c)R_(d), wherein R_(c) and R_(d) are independently selected from H,optionally substituted C₁₋₃ alkyl, —C(O)C₁₋₃alkyl, —C(O)O—C₁₋₃ alkyl,and SO₂C₁₋₃alkyl; R₅ is selected from the group consisting of C₁₋₄alkyl, halogenatedC₁₋₄alkyl, C₁₋₄ alkoxy, halogenated C₁₋₄ alkoxy, C₁₋₄alkylthio, halo, cyano, and hydroxy; and enantiomers, diastereomers,tautomers, solvates, or pharmaceutically acceptable salts thereof.
 48. Acompound selected from

enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.
 49. A compound selected from

or enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.
 50. A compound selected from the groupconsisting of1,1,1-Trifluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-,(3S,αR)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-,(3R,αS)—;3-[3,8-Bis-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3,8-bis[3-(trifluoromethoxy)phenyl]-a-(trifluoromethyl)-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3,8-bis[3-(trifluoromethoxy)phenyl]-a-(trifluoromethyl)-,(3S,αR)—;3-[3-(3-Benzyl-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;3-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;1,1,1-Trifluoro-3-[8-(3-trifluoromethoxy-phenyl)-3-(3-trifluoromethylsulfanylmethyl-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[8-(3-trifluoromethoxy-phenyl)-3-(3-trifluoromethylsulfanyl-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;3-[3-(3-Ethoxy-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;3-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-one;3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylicacid methyl ester;3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylicacid ethyl ester;4-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethanol;4-(2-Methoxy-ethyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;4-[3-(tert-Butyl-dimethyl-silanyloxy)-propyl]-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;3-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-1-ol;4-(3-Methoxy-propyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;Dimethyl-{2-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-amine;4-(2-piperazin-1-yl-ethyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;4-(2-Morpholin-4-yl-ethyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;4-[2-(4-Methyl-piperazin-1-yl)-ethyl]-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;4-Methyl-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;4-Ethyl-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;4-Propyl-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazine;4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-α-methyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,(3S,αR)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-a-methyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,(3S,αS)—; 2-Propanone,3-[(3S)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-1,1,1-trifluoro-;2-Propanone,1-[(3S)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-;2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethylamine;N-{2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-acetamide;{2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-carbamicacid methyl ester;Methyl-{2-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-carbamicacid methyl ester;N-{2-[3-[3-(1,1,2,2-Tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-methanesulfonamide;N-Methyl-N-{2-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-ethyl}-methanesulfonamide;2H-1,4-Benzoxazine,4-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-3,4-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,(3S)—; 2H-1,4-Benzoxazine,4-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-3,4-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,(3R)—; 1,2-Propanediol,3-[(3S)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-,(2S)—; 1,2-Propanediol,3-[(3R)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-4H-1,4-benzoxazin-4-yl]-,(2S)—;2-Methyl-1-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;3-[3-Allyl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;3-[4-(3,3,3-Trifluoro-2-hydroxy-propyl)-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazin-3-yl]-propan-1-ol;1,1,1-Trifluoro-3-[3-(3-methoxy-propyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-]propan-2-ol;3-[4-(3,3,3-Trifluoro-2-hydroxy-propyl)-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazin-3-yl]-propan-1-ol;1,1,1-Trifluoro-3-[3-(3-methoxy-propyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;3,3-Dimethyl-1-[4-(3,3,3-trifluoro-2-hydroxy-propyl)-8-(3-trifluoromethoxy-phenyl)-3,4-dihydro-2H-benzo[1,4]oxazin-3-yl]-butan-2-one;3-[3-(5-Ethyl-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;1,1,1-Trifluoro-3-[3-(3-methoxy-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[3-(5-methoxy-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;3-{8-(3,5-Difluoro-phenyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxazin-4-yl}-1,1,1-trifluoro-propan-2-ol;1,1,1-Trifluoro-3-{8-(3-fluoro-phenyl)-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-2,3-dihydro-benzo[1,4]oxazin-4-yl}-propan-2-ol;1-Fluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[8-(3-trifluoromethoxy-phenyl)-3-(3-trifluoromethyl-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;4H-1,4-Benzoxazine-4-ethanol,8-(3,5-difluorophenyl)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-α-(trifluoromethyl)-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,8-(3,5-difluorophenyl)-2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-α-(trifluoromethyl)-,(3S,αR)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-a-fluoromethyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,(3S,αR)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-a-fluoromethyl-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3-(trifluoromethoxy)phenyl]-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,4,5-trifluoro-phenyl]-α-(trifluoromethyl)-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,4,5-trifluoro-phenyl]-α-(trifluoromethyl)-,(3S,αR)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,5-bis(trifluoromethyl)phenyl]-a-(trifluoromethyl)-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-8-[3,5-bis(trifluoromethyl)phenyl]-α-(trifluoromethyl)-,(3S,αR)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,5-(difluoro)phenyl]-α-(trifluoromethyl)-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,5-(difluoro)phenyl]-α-(trifluoromethyl)-,(3S,αR)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,4,5-(trifluoro)phenyl]-α-(trifluoromethyl)-,(3S,αS)—; 4H-1,4-Benzoxazine-4-ethanol,2,3-dihydro-3-[3-(trifluoromethoxy)phenyl]-8-[3,4,5-(trifluoro)phenyl]-α-(trifluoromethyl)-,(3S,αR)—;3-Methyl-1-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-butan-2-ol;1,1,1-Trifluoro-3-[3-(3-methyl-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;3-[3-(3-Ethyl-thiophen-2-yl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;1,1,1-Trifluoro-3-[3-furan-2-yl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[3-[2-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[3-phenyl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[3-(4-trifluoromethoxy-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[3-(3-methoxy-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;3-[3-(3-Chloro-phenyl)-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-1,1,1-trifluoro-propan-2-ol;1,1,1-Trifluoro-3-[3-thiophen-2-yl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[3-furan-3-yl-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol;1,1,1-Trifluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]thiazin-4-yl]-propan-2-ol;and enantiomers, diastereomers, tautomers, solvates, or pharmaceuticallyacceptable salts thereof.
 51. A prodrug of a compound of claim
 1. 52. Apharmaceutical composition comprising a compound, salt or solvateaccording to claim 1 admixed with a pharmaceutically acceptable carrier,excipient or diluent.
 53. A method of treating or preventing a diseaseor condition in a mammal which disease or condition is affected by themodulation of CETP, which method comprises administering to a mammal inneed of such treatment or prevention a therapeutically effective amountof a compound, salt or solvate of claim
 1. 54. A method of increasingHDL-C in a subject, which method comprises administering to a subject inneed thereof a therapeutically effective amount of a compound, salt orsolvate according to claim
 1. 55. A method of increasing the ratio ofHDL-C/total cholesterol in a subject, which method comprisesadministering to a subject in need thereof a therapeutically effectiveamount of a compound, salt or solvate according to claim
 1. 56. A methodof increasing the ratio of HDL-C/LDL-C in a subject, which methodcomprises administering to a subject in need thereof a therapeuticallyeffective amount of a compound, salt or solvate according to claim 1.57. A method of lowering either or both of LDL-C and non-HDL-Ccholesterol in a subject, which method comprises administering to asubject in need thereof a therapeutically effective amount of acompound, salt or solvate according to claim
 1. 58. The method of claim53, wherein said therapeutically effective amount comprises a dose rangeof from about 0.01 mg to about 1,000 mg.
 59. The method of claim 53wherein said therapeutically effective amount comprises a dose range offrom about 10 mg to about 800 mg.
 60. The method of claim 53 whereinsaid therapeutically effective amount comprises a dose range of fromabout 50 mg to about 400 mg.
 61. A method for treating or preventing adisease or condition selected from the group consisting ofatherosclerosis, peripheral vascular disease, dyslipidemia (includinghypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, andhypo-HDL-cholesterolemia), hyper-LDL-cholesterolemia,hyperbetaliproteinemia, hypoalphalipoproteinemia,familial-hypercholesterolemia, cardiovascular disorders, angina,ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusioninjury, angioplastic restenosis, hypertension, vascular complications ofdiabetes, obesity and Metabolic Syndrome, said method comprising thestep of administering to a mammal in need of such treatment atherapeutically effective amount of a compound, salt or solvate ofclaim
 1. 62. A method for treating or preventing a disease or conditionselected from the group consisting of atherosclerosis,hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia,hypercholesterolemia, mixed hyperlipidemia, andhypo-HDL-cholesterolemia), cardiovascular diseases (CVD), diabetes, andobesity, said method comprising the step of administering to a mammal inneed of such treatment a therapeutically effective amount of a compound,salt or solvate of claim 1.